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GENERAL INTRODUCTION 
It is a well known clinical phenomenon that patients suffering from 
bronchial obstructive disorders, usually covered by the term chronic 
non-specific lung disease (CNSLD) tend to react with exacerbations of 
their disease in the course of respiratory infections, especially if a 
viral or mycoplasmal agent is involved. However, there is no uniform 
opinion about the relative importance of viral respiratory infections 
in this respect, and much of the background of the features observed in 
virus-induced exacerbations is still unknown. This is at least partly 
due to semantic uncertainty with regard to both respiratory infection 
and the various clinical entities encompassed by the spectrum of CNSLD. 
The term CNSLD covers conditions most commonly referred to as bronchial 
asthma, asthmatic bronchitis, chronic bronchitis, and pulmonary emphy-
sema. 
The Netherlands Asthma Centre in Davos, Switzerland, lS a clinic for 
treatment of Dutch CNSLD patients. It is situated 1560 m above sea leve~ 
where climatic conditions have been shown to affect the course of the 
bronchial obstructive disease in a favourable way. Patients are usually 
referred to the clinic for a period of at least several months. 
In 1975 the suggestion was put forward that the situation in theDavos 
clinic was highly suitable to investigate some aspects of the abovemen-
tioned relationship between respiratory viral infection and flare-ups of 
signs and symptoms of CNSLD. A 4-year study was designed in order to 
find an answer to the following questions: 
I. Which is the frequency of symptomatic respiratory infection (SRI) in 
a group of CNSLD patients during their stay in an alpine climate? 
2. In how many episodes of SRI can a viral or mycoplasmal agent be iden-
tified as a causative factor, doing systemically conducted serologi-
cal investigations? 
3. To which extent do respiratory infections of known and unknownorigin 
cause exacerbations of CNSLD? 
14 
4. Are there any differences in infection rate and/or reaction pattern 
to respiratory infection between various subpopulations of CNSLD 
patients? 
5. Are there any differences in reaction pattern with regard to causa-
tive agent and clinical severity of respiratory infection? 
6. How often does bacterial infection occur in the course of SRI? 
In the second part of this thesis the design of the study and the results 
are presented. The first part contains a number of chapters dealing 
wi~h general information with regard to CNSLD (chapter 1) and respira-
tory virology (chapter 2), as well as comments on the role Of viral 
respiratory infection in the cause (chapter 3) and course (chapter 4) 
of CNSLD. Furthermore, a short r~view on climatic factors in CNSLD 
(chapter 5) and treatment in the Netherlands Asthma Centre (chapter 6) 
is presented in this part. 
PART I 
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CHAPTER I 
CHRONIC NON-SPECIFIC LUNG DISEASE (CNSLD) 
A REVIEW ON TERMINOLOGY 
1-1 Introduction 
In 1965 a Lancet editoriai 152 commented that "few diseases have been 
surrounded by such diagnostic confusion as thos~ whose clinical features 
are cough, sputum and breathlessness with wheezing, which are variously 
described as asthma, chronic bronchitis or emphysema". 
Indeed, terms like bronchial asthma, asthmatic bronchitis, chronic 
bronchiti& and pulmonary emphysema have led to much confusion. A few 
decades ago the term chronic bronchitis was used in Britain to describe 
the same condition that was generally called emphysema in North America, 
as was pointed out in a study by Fletcher et aZ. 76 
The ambiguity that existed was a serious obstacle in understanding the 
conditions which are attended with chronic obstruction of airflow. It 
was primarily for this reason that a group of British physicians met at 
a CIBA Foundation Guest Symposium and produced a set of definitions in 
1959. 44 The committee coined the term Chronic Non-Specific Lung Disease 
(CNSLD) to encompass the conditions usually termed asthma, chronic bron-
chitis and emphysema. (In The Netherlands the term was introduced as 
CARA = "Chronische Aspecifieke Respiratoire Aandoeningen"). The conclu-
sions drawn at- the symposium were amended by the World Health Organiza-
tion297 and the American Thoracic Society. 4 The idea of using an all-
over term was also sustained at the International Bronchitis Symposia 
held in Groningen in 1961, 1964, and 1969. 60 74 205 
Sluiter241 summarized the various arguments for the use of a general 
term to cover the three conditions already mentioned: 
-There is no well defined separation between the syndromes, usually 
called asthma, chronic bronchitis, and emphysema, but a fluent transi-
tion. 
-Symptomatology ·of the different conditions is likely to change in the 
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course of life, thus enabl·ing the use of various diagnoses for the same 
underlying disease. 
-There is no possibility to describe the seriousness of the symptoms in 
a quantitative way, using terms like asthma, chronic bronchitis and 
emphysema only •. 
Furthermore, Doeleman59 suggested that-data regarding the family his-
tories of patients with -.these conditions are confusing and in no way 
helpful in differentiating between them. 
Patients suffering from chronic non-specific lung disease may be de-
fined as subjects with one or more of the following symptoms: chronic 
~r recurrent cough with expectoration and/or persistent excessive 
breathlessness, which are not solely attributable to other diseases: 
a. Localized lung disea·se of any kind (e.g. tuberculosis, pneumonia, 
bronchiectasis, cystic disease). 
b. Ge~eralized specific infective lung disease (e.g. miliary tuberculo-
sis). 
c. The p;aeumoconioses. 
d. Collag~n disease and the generalized pulmonary fibroses and granulo-
mata. 
e. Primary cardiovascular-renal disease. 
f. Disease of the chest-wall. 
g. Disease of the upper respiratory tract. 
h. Psychoneurosis. 
For epidemiological purposes the words chronic or recurrent may be 
defined as occurring on most days for a least three months in the year 
during at least two consecutive years. 
1-2 The Dutch point of view 
In The Netherlands the prevailing opinion is that the large majority of 
patients with CNSLD are characterized by an increased bronchial reacti-
vity to various stimuli, which results in a (partially) reversible dif-
fuse bronchial obstruction. This opinion was particularly put forward 
by the Groningen workgroup of Orie £nd associates who stated that there 
does not seem to be a fundamental difference between the clinical enti-
ties of CNSLD: asthma, bronchitis and emphysema. It was their point of 
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view that it is preferable to avoid the use of these names and to stress 
the necessity of an exact description of each individual patient. They 
suggested that in each case of CNSLD, apart from the clinical symptoms, 
the following characteristics should be established: 203 241 
-Bronchial hyperreactivity and its degree. 
-Allergy and its degree. 
-Bronchia1:" obstruction and its degree. 
-Degree of reversibility of bronchial obstruction. 
-Presence of complicating factors, especially bacterial bronchial in-
flammation. 
-Sputum eosinophilia and its degree. 
-Presence of additional pulmonary disease. 
-Supplementary data, like a 1-antitrypsin content of the serum. 
Generalized bron~hial obstruction is considered to be the major patho-
physiological sequence in patients with CNSLD. The clinical picture is 
determined by various endogenous and exogenous factors. Fig. 1-1 shows 
a summary of these factors according to Vander Lende et al. 157 The im-
portance of these various factors was discussed in detail by Van der 
Lende156 and Westermann. 292 It has been suggested that there is a rela-
tionship between CNSLD and endocrine dysfunction. 124 289 293 
ENDOGENOUS FACTORS 
Genetically determined 
basic f.Jctors 
(metabolic:?: hormonal?} 
EXOGENOUS FACTORS 
Provoking factors 
(allergens, temperature 
Fundamental factors changes, exercise, viral 
(specifJc lgE, lgC, infection, stress, smoking, 
bronchial hyperreactivity) atmospheric pollution) 
'~ / 
Symp<om> oodl >;go> of CNSLD Attendant factors 
[complicating disease; 
bronchiectasis, cor pulmonale; 
concomitant disease; 
M. Boeck, tuberculosis) 
CLIN-ICAL MANIFESTATION-- Other factors 
(circadian rhythm, menstrual 
cycle, pregnancy) 
Social factors 
(occupational halards) 
Fig. 1-1 The role of various factors in the development 
of CNSLD, according to the hypothesis of the Groningen 
Work Group 156 (slighly modified) 
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Bronchial hyperreactivity is an important factor in patients with 
CNSLD and can be defined as the symptom of an increased reactivity to 
exogenous non-allergic substances. The threshold to inhaled histamine 
reflects the responsiveness of the bronchial system284 285 , whereas the 
potency to develop reagins is often used to determine the activi~y of 
allergic factors. 139 
G0kemeijer91 suggested that different profiles in reactivity can be 
found in different groups of patients with CNSLD and that the degree of 
hyperreactivity is an important co-determinating factor in the quanti-
tative response during allergen provocation. This suggestion is strongly 
supported by data from several investigators. 46 198 200 There seems to 
be a small effect on the degree of hyperreactivity after allergen inha-
lation as well. 
I-3 The Anglo-Saxon point of view 
Although the proposals made at the CIBA Guest Symposium44 gained wide 
acceptance, some confusion remained. 73 Though the need for an encom-
passing term was generally accepted, some investigators denied the bene-
fit of grouping conditions lLke asthma, bronchitis, and emphysema~ 20 216 
Various reports on the subject appeared: Medical Research Council 
Committee177 , CIBA Foundation Study Group43 , ACCP-ATS Joint Committee 
on Pulmonary Nomenclature. 223 
Except for The Netherlands, where the term CARA is widely accepted, 
the originally proposed term CNSLD has somewhat fallen into disuse. The 
main reasons for this are that the term is cumbersome in ~nglish, refers 
only to symptomatic patients and excludes bronchiectasis. 270 It has been 
progressively replaced in Anglo-Saxon literature by terms such as 
chronic obstructive lung disease (COLD), chronic obstructive pulmonary 
disease (COPD), chronic obstructive airway disease (COAD), and chronic 
airflow obstruction (CAO). These terms, however, have prgblems of their 
own and semantic uncertainty still remains. 
The proposal to avoid the terms asthma, chronic bronchitis, and emphy-
sema, whenever possible, has never been generally accepted, probably 
because of disagreement with regard to the hypothetical common funda-
mental aetiology of these conditions. Throughout the literature these 
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diagnoses are widely used and therefore a short review of the most 
frequently used definitions is necessary. A concise comment on bron-
chiectasis will be given as well. 
1-3-1 Bronchial asthma 
Asthma is usually described as a disease characterized by an increased 
responsiveness of the trachea and bronchi to various stimuli and mani-
fested by a widespread narrowing of the airways that changes in severity 
either spontaneously or as a result of therapy. 4 
Scadding236 gave the following definition: "Asthma is a disease, cha-
racterized by wide variations over short periods of time in resistance 
to flow in the airways of the lungs" and proceeded with some explana-
tory comments. 
Antigen-antibody reactions play an important role in a proportional 
part of asthmatic patients. The external source of the causal factor is 
usually indicated by the word extrinsic. Those allergic patients who 
produce IgE antibodies can be categorized as having extrinsic atopic 
asthma, whereas subjects who are not atopic and in whom asthma can be 
shown to be caused by reactions between environmental antigens and 
antibodies of other types than IgE 214 , are usually classified as suffe-
ring from extrinsic nonatopic asthma. 
Allergic asthmatic reactions can be divided into three main groups: 
immediate, nonimmediate, and late, and dual or combined reactions in 
which both immediate and late reactions occur. There are at least two 
forms of immediate and three forms of late asthmatic reactions, accor-
ding to Pepys. 215 
Immediate reactions usually result from type I (IgE mediated) allergic 
mechanisms, leading to mast cell degranulation and release of mediators, 
thus causing bronchial obstruction. It is now known that these chemical 
mediators of immediate hypersensitivity can be divided into preformed 
(primary) substances like histamine, serotonin, eosinophil chemotactic 
factor of anaphylaxis (ECF-A), intermediate molecular weight ECF(s), 
neutrophil chemotactic factor, heparin, chymase, N-acetyl-S -glucosa-
minidase and ary_lsulfatase A, and unstored (secondary) mediators like 
slow reacting substance of anaphylaxis (SRS-A), platelet activating 
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factors (PAFs), and lipid chemotactic and chemokinetic factor. 9 
The mechanisms of late reactions are still incompletely understood. 
Type III precipitating antibodies are supposed to play a role in the 
reaction which is maximal at about 5-8 hours after allergen provoca-
tion.161 162 Pepys 217 suggested that the immediate reaction, even if it 
remains clinically undetected, induces increased vascular permeability, 
so that immune complexes can precipitate on endothelial membranes. 
To those patients who have well marked asthma, though none of the 
immunological reactions can be detected, the term "intrinsic" asthma is 
usually applied. Some authors prefer the word "cryptogenic" asthma278 
because it implies that provocative agents are unknown at the present 
time. Typically, this type of asthma starts in middle or later adult 
life, shows marked eosinophilia of blood and sputum and tends to respond 
poorly to bronchodilating drugs~ but promptly to corticosteroids. The 
family histories of these patients seem to show fewer members with hay-
fever and eczema, but almost identical figures with regard to asthma 
as compared to patients with extrinsic asthma. 277 
A disturbance in the regulation of bronchial smooth muscle tone seems 
to be a basic defect in bronchial asthma. Szentivanyi264 presented a 
hypothesis that a partial S-adrenergic blockade constitutes the funda-
mental factor for this dysregulation. On the other hand, it has been 
shown that parasympathetic mechanisms also play an important role in 
controlling bronchial smooth muscle tone 92 93 196 and that some anti-
cholinergic drugs, like thiazinamium, have potent bronchodilating pro-
perties. 18 
1-3-2 Chronic bronchitis 
The term chronic bronchitis is most commonly defined as the condition of 
subjects with chronic or recurrent excessive mucous secretion in the 
bronchial tree. 44 This description is based on clinical criteria, in 
contrast to the definition of asthma, in which functional characteris-
tics (resistance to flow) are often used. 
Chronic bronchitis often occurs in combination with pulmonary emphy-
sema. It is estimated that about 30% of chronic bronchitics have no 
emphysema, whereas 80% of patients with emphysema have chronic bronchi-
23 
tis as well.l87 272 273 300 
For generations, British physicians have used the term chronic bron-
chitis synonymously with the syndrome of chronic airflow obstruction 
and, unfortunately, some still do. So the term was used without quali-
fication to indicate, at one extreme, regular production of small 
quantities of sputum without any functional abnormality and, at the 
other extreme, severe chronic airflow obstruction. 
The use of a single term to cover such a wide range of abnormalities 
was justified by the hypothesis that they embraced the natural course 
of a single disease and that a mere productive cough was regarded as 
its earliest stage. 75 186 Epidemiological investigations by Fletcher 
and associates 73 , commented in The Lancet 22 , suggest that mucous hyper-
secretion, bronchial infection, and airflow obstruction consist of two 
largely distinct processes, caused by two linked susceptibilities to 
smoking and other forms of air pollution. On the one hand, there is 
mucous hypersecretion, which increases liability to recurrent bronchial 
infection and, on the other hand, there is the development of bronchial 
obstruction. 
The first, the hypersecretory disorder, consists of hypersecretion of 
bronchial mucus, derived from enlarged bronchial mucus glands and hyper-
plastic goblet cells, producing a productive cough. It is considered as 
reaction of susceptible individuals to smoking and to other forms of 
air pollution. 
The latter, the obstructive disorder, is due to disease of the airways 
and to emphysema. Its main cause is also cigarette smoking with general 
and industrial air pollution as contributory causes. 
Because of the common causes and because these disorders develop only 
in subjects with constitutional susceptibilities, which are often linked 
with each other, they commonly occur together, but they may develop in-
dependently of each other. 
The obstruction to airflow found in patients with the obstructive 
disorder is thought to be distinct from asthma and to have a largely 
irreversible character. Whether the patients secrete too much mucus or 
not and whether or not they have repeated bronchopulmonary infections 
does not affect the outcome. The prognosis of these patients is deter-
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mined mainly by the degree to which expiratory flow is impaired. 135 
Besides, the degree of reversibility after administration of thiazina-
mium, a bronchodilator, and the rate of decrease in initial FEV1 per 
year have been shown to have important prognostic significance. 221 
On the base of their findings Fletcher et aZ. proposed to abandon the 
term chronic bronchitis and replace it by chronic mucous hypersecretion 
and chronic airflow obstruction to describe the above mentioned dis-
orders. The suggestion was adopted by Thurlbeck. 271 
1-3-3 Pulmonary emphysema 
Pulmonary emphysema is usually defined as an increase in the size of 
air spaces, distal to the terminal bronchioles either from dilatation 
or from destruction of their walls. 44 This definition is cvuched in 
anatomic terms and therefore it is inaccurate to use the term emphysema 
in living subjects, although clinical and pathological correlative 
studies by ThurlbecketaZ~ 73 suggest an association of the clinical and 
functional syndrome or syndromes with the disordered anatomy. 
Much of the disability occurring in advanced emphysema is probably 
due to associated airway lesions, causing progressive chronic airflow 
obstruction, which is the functional characteristic of the disease. 
Dornhorst 61 is generally credited with the observation that patients 
with chronic airflow obstruction may present with one or two very 
different clinical syndromes. One syndrome is characterized by hypoxe-
mia and hypercapnia accompanied by oedema, thought to be due to marked 
right ventricular failure (type B =blue bloater). In the other syndrome 
right ventricular failure is absent, blood gases are relatively well 
maintained, and minute ventilation is greatly increased (type A = pink 
puffer). The blue bloater is often referred to as chronic bronchitis 
and the pink puffer as emphysema, which is at best an oversimplifica-
tion. Although all agree that the syndromes exist, the exact definitions 
of the conditions and their underlying pathology are in dispute. For 
practical purposes the classification is of little use, as themajority 
of patients with chronic airflow obstruction cannot be categorized in 
one of the two syndromes. 5 5 
Emphysema has been classified on the basis of the location of the 
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lesions in the secondary lung l~bule into: 
a. Centrilobular emphysema, involving initially the first-order respira-
tory bronchioles. 
b. Panlobular emphysema, with diffuse involvement of the respiratory air 
spaces. 
c. Paraseptal or subpleural emphysema, in which the respiratory air 
spaces adjacent to fibrous septa are first involved. 
Centrilobular emphysema frequently gives rise to increased thickening 
and frequency of bronchovascular markings on the chest rOntgenogram 
(increased marking emphysema), whereas the panlobular type is often 
associated with peripheral vascular deficiency (arterial deficiency em-
physema).273 
The pathogenesis of emphysema is not completely understood. The sub-
ject has recently been discussed in detail by Hugh-Jones and Whimster120 
and by Franken. 78 Since there are several forms of emphysema, avariety 
of aetiologic and pathogenetic factors may be involved rather than just 
one. Endogenous factors leading to increased susceptibility certainly 
play a role in the development of pulmonary emphysema. Hyperreactivity 
is a feature not only found in asthmatics but also in patients with 
largely irreversible airflow obstruction. 91 145 240 Allergy also seems 
to be important in this respect. 129 230 303 It is an interesting issue 
that the obstructive changes have a progressive character, although 
hyperreactive and allergic features tend to diminish, according to 
Orie. 202 204 
The occurrence of severe pulmonary emphysema in association with ~ 1 -
antitrypsin deficiency, described by Laurell and Eriksson 151, togetherwith 
the observation that papain and elastase 99 132 137 produce emphysema in 
experimental animals, stressed the importance of proteolysis in human 
emphysema. 
Cigarette smoking is considered to be the most important factor in the 
development of emphysema. 8 73 Current theories hold proteinases from 
polymorphonuclear leucocytes sequestered in the pulmonary capillaires 
or from alveolar macrophages responsible for the damage to the connect-
ive tissue in the lung212 , but the literature does not provide conclu-
sive evidence. 78 
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1-3-4 Bronchiectasis 
Bronchiectasis refers to a condition of the lung in which there is per-
manent, abnormal dilatation of the bronchi. 273 It may be classified on 
anatomic grounds into cylindrical, varicose or saccular bronchiectasis, 
depending on the appearance of the dilated bronchi. 229 
Many patients characteristically date symptoms from an acute infective 
episode, usually in infancy or childhood. 83 260 251 These patients are 
often referred as having postinfective bronchiectasis. Bronchiectasis 
will often be associated with symptoms similar to those found inpatients 
with CNSLD, but is by definition not comprised in the spectrum of CNSLD, 
unless symptoms are not solely attributable to the bronchiectatic 
lesions. Nevertheless, it seems worthwhile to pay attention to this 
condition, because it is often ignored as a cause of chronic obstruct-
ive lung disease. Moreover, it is important to stress that bronchiec-
tasis may complicate asthma62 , bronchitis and emphysema63 273 and is 
often related to allergy. 288 
I-4 Conclusions 
On reviewing the literature one must conclude that international uni-
formity of nomenclature has not yet been achieved and probably will not 
be realised for some time. Therefore, it seems necessary to describe 
patients with clinical features like cough, phlegm, and breathlessness 
with wheezing as precisely as possible, using the characteristics 
listed in chapter I-2. The use of an encompassing term is recommendable, 
provided that this does not inhibit attempts to search for fundamental 
factors, distinguishing between the various conditions, described in 
this chapter. 
In this thesis the following guiding principles will be employed in 
the classification of patients: 
a. Preference is given to the omnibus-term chronic non-specific lung 
disease(CNSLD), mainly because its synonym CARA is generallyaccepted 
in The Netherlands and the term includes asthma. 
b. The term chronic airflow obstruction (CAO), which haS much tore-
commend for, will be used to describe the patients suffering from 
progressive, largely irreversible obstructive disease, due to 
27 
conditions like emphysema. 
c. On account of the data presented in chapter 1-3-2, the use of the 
name chronic bronchitis will be avoided. This term will only be em-
ployed with reference to the literature on the role of infections 
in CNSLD, where its use is inevitable. 
d. The condition of those persons merely suffering from the hypersecre-
tory disorder -only very rarely seen in a clinic for CNSLD- will be 
called chronic mucous hypersecretion. 
e. The presence of suspected or proven bronchiectatic lesions will be 
mentioned seperately. 
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CHAPTER 2 
RESPIRATORY VIRAI INFECTIONS IN MAN 
2-1 Introduction 
Within the past decades many new viruses have been isolated and asso-
ciated with respiratory illness in humans. In this chapter a short out-
line of the respiratory viruses which have been studied in the survey, 
described in this thesis, will be presented. Short comments on the non-
viral agents Mycoplasma pneumoniae and Chlamydia psittaei will be given 
as well. 
2-2 Adenovirus 
2-2-I Introduction 
Adenoviruses derive their name from the fact that they were first iso-
lated from adenoid tissues (tonsils) and have a certain affinity for 
lymph glands. They also invade the respiratory tract, the gastrointes-
tinal tract, and the conjunctiva. In the respiratory tract they may 
cause a variety of clinical manifestations, ranging from pharyngitis to 
bronchitis, croup, and pneumonia. Adenovirus infections are widely dis-
tributed and common. Most infections occur in childhood and remain sub-
clinical. About adenoviruses much detailed structure and biochemistry 
are known. Inactivated and live vaccines have been developed and found 
effective. 
2-2-2 Characteristics 
Adenoviruses are double-stranded DNA viruses lacking an envelope.126 201 
The diameter of the virion has been measured as 60-90 nm. 106 117 The 
capsid is made up of 252 hollow capsomeres arranged in an icosahedral 
symmetry. Adenoviruses are recognized by a common group antigen in a 
complement fixation test. By haemagglutination the 31 immunologically 
distinct types causing human infection can be determined. The replica-
tion cyclus requires at least 30 hours. 
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Adenoviruses are unusually stable to physical and chemical agents and 
adverse pH conditions resulting in prolonged survival outside the host 
cells and great potential for spread. 
2-2-3 Laboratory methods 
Adenoviruses are propagated most readily in continuous cell lines of 
human epithelial cells, such as HEK, Hep-2, and HeLa cells. 49 126 Pro-
perly interpreted virus isolation provides the most conclusive evidence 
of infection and offers the opportunity to determine the serotypesusing 
a neutralization test with type-specific rabbit antisera. The three co~ 
manly applied serological tests are the complement fixation (CF), neu-
tralization, and haemagglutination inhibitiontests.126 The CF test mea-
sures group-specific antibody, is the easiest to perform and is most 
useful in diagnosis of acute infections, since CF antibodies tend to 
disappear rather rapidly. Haemagglutination inhibition and neutraliza-
tion tests are used in serological epidemiology. 
2-2-4 Association with human illness 
Of the numerous clinical syndromes that have been associated with adeno-
virus infections, some have been proven to be causally related, whereas 
the evidence for specific aetiology for other syndromes remainsin ques-
tion. A few types of adenovirus are associated with a single clinical 
syndrome, but the majority cause different syndromes in diversified po-
pulations. The disease syndromes attributed to adenovirus include: 
-Undifferentiated acute respiratory disease. 
Types 4 and 7 are the major agents in military populations, whereas 
infections have also been observed in civilian adults. Clinical signs 
are sore throat, often with cervical lymphadenopathy, cough, chills, 
fever, malaise, headache, and sometimes rash. The incubation period is 
5-6 days, and the onset is usually gradual. 
-Pharyngoconjunctival fever. 
Types 3 and 7 are the main cause of this syndrome, characterized by 
the triad of conjunctivitis, pharyngitis, and fever. 
-Pharyngitis. 
Febrile pharyngitis without conjunctivitis, caused by types 3,4,7,14, 
and 21 has been reported. 
-Pneumonia. 
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Febrile interstitial pneumonia has been associated in infants and chil-
dren with types 3 and 7. 
-Keratoconjunctivitis. 
-Other diseases, such as common cold, croup, bronchitis, sometimes with 
subsequent development of bronchiectasis, acute haemorrhagic cystitis, 
and encephalitis. 
In healthy subjects adenovirus infection often passes without clinical 
symptoms. The incidence of adenovirus infection is estimated as 2-5% of the 
total respiratory illnesses each season. For children these figures vary 
from 2-24%. Two to 7% of all lower respiratory tract illnesses in young 
children seeking medical care can be attributed to adenoviruses: 1 77 
Adenovirus infections occur throughout the year, but incidence is higher 
in the cold season. 
2-3 Influenza viruses 
2-3-1 Introduction 
Influenza~ occurring epidemically, is the last great uncontrolled in-
fectious plague of mankind. The influenza viruses, especially influenza 
A virus, have a special position within the group of respiratory viral 
agents. One of the main characteristics is the appearance of periodic 
epidemic outbreaks. Epidemics of influenza A and B recur with monoto-
nous frequency. Type A and B viruses are antigenically distinct.However, 
within type, both surface antigens exhibit differences which confer 
identity and similarities which indicate lineage. Influenza C virus, 
isolated for the first time by Taylor in 1947269 , was found to be un-
related antigenically to type A or B viruses. 
Nomenclature of influenza viruses has evolved over time. In modern 
terminology strain designations identify serotype -A, B, or C- , host 
of origin, geographic origin, strain number, year of isolation, and in 
parentheses numerical indices of the antigenic character of viral hae-
magglutinin (H) and neuraminidase (N) subtype. 
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2-3-2 Characteristics 
The influenza viruses belong to the (ortho)myxovirus group, which are 
RNA containing viruses. Influenza virions are spherical particles 100 
nm in diameter. The serotypes A,B, and C are determined by a soluble 
antigen situated as an internal antigen in the virion. In addition, 
there are strain-specific viral antigens in the envelope of the virion, 
which include haemagglutinin and neuraminidase. These proteins are 
responsible for the overt biological activity of each strain. 
The pleomorphic influenza viruses are sensitive to inactivation by 
heat and aether. They are stable between pH 5.2 and pH 7.8 and more 
sensitive to acid than to alkaline pH. 
A major characteristic of influenza A virus is its antigenic varia-
tion, presenting as minor gradual changes occurring every 2-3 years 
(antigenic drift) and abrupt changes at 8-12-year intervals (antigenic 
shift). After 30-40 years complete alterations in the surface antigens 
haemagglutinin and neuraminidase give rise to pandemics. 174 175 Anti-
genic drift has also been recognized in type B influenza virus, but the 
degree of change is not great enough to permit recognition and designa-
tion of distinct subtypes. 5 3 
2-3-3 Laboratory methods 
It is important to isolate influenza virus early in the course of an 
epidemic in order to identify and characterize the antigenic composition 
of the prevailing strain. Rhesus monkey kidney cell cultures as well as 
embryonated eggs are used for propagation of the influenza viruses. 
Rapid identification of influenza A or B virus is possible within 16 
hours by immunofluorescence in cell cultures. Identification of isolates 
as type A or B strains is readily accomplished by the haemagglutination 
inhibition (HI) test. In epidemiological surveys serodiagnosis is 
usually employed. CF and HI tests are most commonly used, whereas neu-
tralization and immunofluorescence are techniques not employed for 
routine purposes. The CF and HI tests are about equally sensitive, but 
use of either technique alone may miss as much as 15% of infections. 
Therefore, paired negative sera should be tested by the other tech-
nique. Before applying the HI test, the serum is treated with receptor 
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destroying enzyme, and heated at 56° C, in order to remove non-specific 
inhibitors. 
2-3-4 Association with human illness 
The clinical spectrum of influenza shows a totally asymptomatic state 
at one and severe illness with fatal outcome at the other extreme. 
Estimates of subclinical infection rates indicate that for every febrile 
patient there is another subject who denies illness or has slight com-
plaints of common cold only. 109 
Uncomplicated influenza in adults appears as a febrile respiratory 
disease with sudden onset after an incubation period of 24-48 hours. 
The most frequent symptoms are fever with no~productive coughing, nasal 
obstruction, headache, myalgia, malaise, chills, sore throat, conjunc-
tivitis, and hoarseness. Anorexia, nausea, vomiting, dizziness, and in-
somnia may accompany fever, but diarrhoea is not characteristic. Acute 
symptoms last for 5-7 days. Fever usually persists for 3 days and may 
exhibit a diphasic course. Physical signs are few and not pathognomonic. 
Most patients are fully recovered within 10 days, but many experience 
prolonged lassitude or sense of debility and presistent cough. 
The clinical picture in children tends to be milder and more diffi-
cult to recognize. Pneumonia is the most frequent complication of 
influenza. It should be suspected if fever persists beyond the 4th or 
5th day or recurs suddenly after convalescence seems to have begun. 
Viral pneumonia may account for about 20% of influenza-associated 
pneumonias, whereas secondary bacterial infection is more frequent 111 
2 s 7 and is most commonly caused by Streptococc~s pneumoniae~ Haemo-
philus inj1uenzae~ and Staphylococcus aureus. Bacterial pneumonias are 
more frequently seen in patients with CNSLD, chronic cardiac disease, 
or pregnancy. 
Pathologically, there is a degeneration and desquamation of the cili-
ated epithelium of trachea and bronchi. Among fatal cases in 1957, the 
dominant feature was destruction of the alveolar cell lining, with or 
without bacterial superinfection. From 1960 to 1970 60-70% of fatal 
influenza cases were caused by a superinfection due to Staphylococcus 
aureus. Data accumulated by household surveys indicate that an incidence 
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of 20-40% can be expected during the wave of a new pandemic. The rate 
of decline of intensity of epidemics is somewhat variable and irregular. 
Influenza B epidemics are less frequent and it therefore seems that 
influenza B is less lethal than influenza A. In the last decade influ-
enza-associated death, as judged by monthly pneumonia-influenza death 
rates and excess mortality rates, appears to have declined gradually. 
Estimations of death rates extending from 1887 through 1956 are given 
by Collins 48 and from 1934 through 1973 in a report by the Center for 
Disease Control. 34 
The possibility of prevention or reduction of severity of disease by 
means of vaccination is well established and beyond question. 209 How-
ever, vaccine is not always effective. 2 ~ 3 If the strains used for 
vaccination are antigenically identical with or closely related to the 
epidemic virus, protection can be obtained in 60-80% as compared to 
non-vaccinated subjects. Other more recently developed protection mea-
sures include the use of amantadine hydrochloride, but this method is 
not suitable for widespread application. 
2-4 Parainfluenza viruses 
2-4-I Introduction 
The parainfluenza viruses are species of the paramyxovirus family. In 
1956 the first isolated strain was originally designated as croup-
associated orCA virus 36 , whereas two additional strains were characte-
rized as HA(haemadsorption)-1 and HA-2 in 1958. ~ 0 As these viruses had 
many biological properties in common, they were reclassified as para-
influenza viruses: type I (HA-2), type 2 (CA), and type 3 (HA-l). Type4 
was added after its first isolation in 1960. 13 ~ During the same period, 
these viruses were compared with isolates obtained from animals. 
The parainfluenza viruses are common causes of lower respiratory tract 
disease in young children and they frequently reinfect older children 
and adults to produce upper respiratory illnesses. 
2-4-2 Characteristics 
The pleomorphic parainfluenza viruses are RNA containing agents consis-
ting of a nucleocapside surrounded by a lipoprotein envelope with 
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haemagglutinin, neuraminidase, and haemolysin activity. The diameter of 
parainfluenza 1, 2, and 3 viruses is approximately 110 nm, whereas type 
4 measures 200 nm. The viruses are aether sensitive and acid labile. Out-
side the host there is a low temperature stability. Biologically, one 
of the main characteristics of the parainfluenza viruses is their abi-
lity to replicate in the respiratory epithelium. Excretion of virus may 
be prolonged up to one month or longer, even with the second or third 
infection 10 0 , which can oc.cur despite the preSence of circulating anti-
bodies. 41 
2-4-3 Laboratory methods 
The 4 types of parainfluenza viruses are most readily propagated in 
primary-monkey kidney tissue cultures, although human embryonic tissues 
may be used as well. Only type 2 is able to cause a characteristic cyto-
pathogenic effect. Haemadsorption techniques are most commonly used for 
virus detection and identification of isolates is accomplished by inhi-
bition of haemadsorption by specific antisera or by immunofluorescence 
in tissue cultures. Rapid identification can be realized by use of 
immunofluorescent-tagged antisera. 84 Serological tests include CF, 
neutralization and HI techniques. Serological methods, however, should 
be interpreted with care because of the occurrence of cross-reactions 
within members of the paramyxovirus group, which includes mumps virus 
as well as the parainfluenza viruses. 
2-4-4 Association with human illness 
Available evidence supports the view that parainfluenza viruses are 
ubiquitous viruses that infect most individuals during childhood. Para-
influenza viruses 1 and 2 show high isolation rates between 4 months 
and 5 years of age in the course of lower respiratorydisease88 , whereas 
type 3 has been detected in all studies of hospitalized children with 
acute lower respiratory symptoms 20 and is recognized to be second to 
RS virus as a cause of bronchiolitis and pneumonia in infants. 87 88 
Parainfluenza 4 infection may be common, but many of these infections 
are considered to be asymptomatic. 
Primary infections with parainfluenza viruses are usuallysymptomatic 
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(parainfluenza 1 : SO%; parainfluenza 2 : 70%; parainfluenza 3 : 80%) but 
the clinical manifestations may vary strongly. The most characteristic 
syndrome associated with types 1 and 2 is croup or laryngotracheobronchitis. 
Mortality has been reported with both agents, but is rare. 69 84 Rein-
fection with types 1 and 2 are associated with upper respiratory symp-
toms not distinguishable from those due to other viruses. 9 0 The clinical 
manifestations of infections with parainfluenza 3 virus are varied. 
Primary infection with this type is often mild, but lower respiratory 
tract involvement resulting in bronchiolitis and bronchopneumonia is not 
UUCOiiliD.OU. 
Reinfections with parainfluenza viruses are common, but usually do not 
cause severe respiratory symptoms. 
Efforts have been made to develop effective vaccines, especially to be 
used in younger children. However, all studies failed to show protection 
by parenterally administered vaccines despite good serum antibody res-
ponses. It would appear that attenuated strains given intranasally are 
more effective. Better understanding of immune response to parainfluenza 
virus infections is needed in order to develop effective vaccines suit-
able for large-scale use. 
2-5 Respiratory syncytial virus 
2-5-I Introduction 
Respiratory syncytial virus (RSV) was first isolated from a chimpanzee 
with common-cold-like illness. 193 Since its initial isolation fromyoung 
children with severe lower respiratory tract disease shortly there-
after37 42 , it has become clear that RSV is the major cause of bron-
chiolitis and pneumonia in young infants and young children. Based on 
serological surveys, infection with RSV has been shown to be a common 
occurrence during the first few years of life. 
It has been found that approximately one-half of the infants who lived 
through one RSV epidemic were infected, whereas infection occurred in 
almost all children who had lived through 2 successive epidemics. 142 
Reinfection appears to be a relatively frequent event among school age 
children and adolescents, but not among adults. 
RSV is the only respiratory agent that produces a' considerable 
37 
epidemic every year in larger urban centres. 211 
2-5-2 Characteristics 
RSV is an RNA containing~ enveloped, pleomorphic virus with a size of 
120-200 nm; it is usually classified into the subgroup of metamyxo-
viruses. The inner ribonucleoprotein helix has a diameter of 13 nm, 
intermediate between the helix of influenza viruses (9 nm) and paramyxo-
viruses (18 nm). RSV possesses no haemagglutinin or neuraminidase acti-
vity. The virus is infectious outside the host only if it is quickly 
frozen to -70° C. The optimum pH for storage is 7.5 and the RSV is 
sensitive to diethyl aether. A soluble CF antigen, different from that 
of paramyxoviruses and orthomyxoviruses can be separated from infected 
tissue culture by centrifugation. 
2-5-3 Laboratory methods 
RSV is labile when frozen and thawed. Bedside tissue cultivation of 
patient material is the most optimal way to succeed in isolation of the 
virus. The most sensitive cell cultures are Hep-2, monkey kidney, human 
amnion and human kidney in decreasing order: 99 The use of immunofluo-
rescence to recognize viral antigens has been extensively studied~ 0 280 
A rise in titre of serum antibody can be shown by CF or neutralization. 
The CF test will detect 90% of infections among individuals older than 
6 months, whereas below this age only 20% can be traced by this method. 
Therefore, in young infants, demonstration of infection by virus isola-
tion is more reliable than the use of serological tests, although rises 
in neutralization antibodies have been detected in half of the virus-
positive infections in this age group. 
2-5-4 Association with human illness 
The effect of RSV on the host ranges from inapparent infection to severe 
respiratory tract disease such as bronchiolitis or pneumonia. Illness 
may be gradual or abrupt after an incubation period of 3-5 days. In 
children the most frequent symptoms are cough, fever, rhinitis, and 
pharyngitis. Infection of adults often causes coryzal illness 133 , but it 
is also an important cause of pneumonia, bronchopneumonia and bronchitis? 8 
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In infants as many as 60% of cases of acute bronchiolitis have been 
caused by RSV. Bronchiolitis usually occurs during the first 6 months 
of life, when maternally derived serum antibodies are present. 
Several hypotheses have been proposed to explain the severity of RSV 
bronchiolitis in ·infancy: low maternal IgG antibodies 107 , low maternal 
IgG3 subclass
89
, a cell-mediated hypersensitivity reaction237 , diffe-
rences in inflammatory reactions in infant lungs 228 , degree of viral 
replication105 , and the presence of local immune complexes~ 71 A high 
incidence of immunolog\cal disorders was reported in children with fatal 
lower respiratory tract infection. 2 In spite of many investigations, the 
pathogenesis of RSV bronchiolitis remains to be elucidated. 
In the past the use of inactivated RSV vaccines has led to an exagge-
rated reactivity to infection136 , but nowadays encouraging attempts with 
attenuated, locally applicable vaccines are undertaken. 
2-6 MYcoplasma pneumoniae 
2-6-1 Introduction 
Mycoplasmas are the smallest of the cellular microorganisms with known 
pathogenic effects in animals and humans. At the turn of the century a 
unique microorganism from cattle suffering from a contagious form of 
pleuropneumonia, was isolated. Subsequently, a number of similar agents 
have been found. Because of their obvious relationship to the bovine 
pleuropneumonia organism, they were known for manY years as pleuro-
pneumonia like organisms, PPLO. Primary atypical pneumonia, studied in 
some detail by Eaton and associates 65 , was initially thought to be 
caused by a virus, known as the Eaton agent. In 1962, however, this 
agent was cultivated on artificial mediums and it was shown to be a 
Mycoplasma. The microorganism is immunologically homogeneous and has 
been designated Mycoplasma pneumoniae. 
2-6-2 Characteristics 
MYcoplasma pneumoniae has a diameter of about 250 nm. The cell size 
approaches the minimum for a free-living cell, being barely adequate to 
contain the genome and synthetic machinery necessary to carry out the 
metabolic and synthetic functions required of a minimal reproductive 
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unit. The pleomorphic Mycop~asma pneumoniae tends to be set apart from 
the other Mycoplasma species in that it grows relatively slowly~ for-
ming granular colonieS with translucent peripheral zones, and produces 
haemolysis of red blood cells. The agent is resistent to penicillin, 
but sensitive to tetracycline and erythromycine. 
2-6-3 Laboratory methods 
The diagnosis of Mycoplasma pneumoniae infection can be made by the iso-
lation of the agent in infusion or digest mediums enriched by the addi-
tion of serum in relatively large amounts, or by significant rises in 
specific antibody titre. Sputum or throat washings are inoculated in a 
complex medium and cultures are observed microscopically for typical 
Mycoplasma colonies for a period up to one month. Confirmation is 
achieved by demonstration of growth inhibition of isolates by specific 
antiserum. Furthermore, fluorescent antibody techniques are used, follo-
wing inoculation into the amniotic cavity of 13-day-old embryonated 
eggs. 
Serological diagnosis is usually achieved by CF, using a lipid antigen 
extracted from MYcoplasma pneumoniae cells. As this test reveals only 
70-80% of infections, more complex techniques like Dmmunofluorescence 
can be added in order to increase serological test sensitivity. 
2-6-4 Association with human illness 
MYcoplasma pneumoniae can be associated with pharyngitis, tracheobron-
chitis, pneumonia or a combination of these syndromes. Respiratory symp-
toms are often preceeded by general complaints such as malaise, fatigue-
ness, headache and moderate fever. In case of pharyngitis, sore throat, 
coughing and slight rhinitis are common complaints and diffuse erythema 
of pharynx and tonsils is usually found. Tracheobronchitis is associated 
with persistent coughing, most often in combination with substernal pain, 
and thorax X-rays frequently reveal pulmonary shadows. 
With the appearance of respiratory symptoms,malaise and headache in-
crease in severity and non-productive coughing in combination with fever 
and myalgia is a prominent feature. In relation to sometimes extensive 
radiographic changes, the clinical symptoms are scarce. There is a great 
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variety of radiologic patterns from interstitial, disseminated infil-
trates to total lobar consolidation38 and radiologic changes can be 
found for a period of several weeks. 23 
Reconvalescence is often prolonged, although fever usually subsides 
within 3-IO days. Mycoplasma pnewnoniae bears a low mortality. Other syn-
dromes that have been related to MYcoplasma pneumoniae comprise meningo-
encephalitis, myocarditis, pericarditis, Guillain-Barre syndrome, and 
Stevens-Johnson syndrome. 
2-7 Chlamydia psittaci 
2-7-1 Introduction 
Chlamydiae are non-viral microorganisms containing DNA as well as RNA 
and resembling rickettsiae in many respects. The genus is composed by 
2 groups: Chlamydia trachomatis and Chlamydia psittaei. Psittacosis 
occurs in psittacine birds and the closely related, if not substantially 
identical ornithosis occurs in wild birds as well as domestic fowl, such 
as pigeons and canaries. Human infection is most commonly acquired by 
such reservoirs of infection; transmission between humans has been des-
cribed, but is very rare. 
2-7-2 Characteristics 
Chlamydiae are characterized by an intracellular developmental cycle, 
which is not completely understood yet. 5 6 The mature particle, or ele-
mentary body is spherical or coccoidal in shape and relatively large, 
200-500 nm. Elementary bodies are capable of infecting new cells. The 
chlamydiae possess 2 types of antigens, group and specific, both present 
in the cell wall. The group antigen is heat-stable and glycolipid in 
nature and induces CF antibodies. The specific antigens are relatively 
labile and soluble in alkali; they are probably proteins. Specific anti-
gens are demonstrable by fluorescent antibody methods and strains are 
usually typed in this way. 
2-7-3 Laboratory methods 
Isolation of the infectious agent is very difficult in case of human 
infection, whereas material from birds more readily yields growth of 
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the organism. The agent is best grown in yolk sac of embryonated eggs. 
Serodiagnosis is used in practice and is dependent on the CF reaction, 
carried out with paired sera to demonstrate rise in titre. 5 6 97 
2-7-4 Association with human illness 
Human illness is produced by inhalation of infected material. The dis-
ease in man is a pneumonia with an incubation period of 1-2 weeks. The 
onset may be sudden or insidious. The symptoms include chills and fever, 
photophobia, usually severe headache, anorexia, sore throat, nausea,and 
vomiting. A dry cough develops, which persists and may become more 
severe; cyanosis and low blood pressure are frequent, and disorientation 
and occasional delirium indicate involvement of the central nervous 
system. Myocarditis can occur, occasionally with fatal outcome. X-ray 
examination of the thorax shows migrating patchy areas of consolidation 
in one or both lungs. Leucocytosis does not occur until late in the 
disease or early convalescence. Chlamydia psittaei usually causes a more 
severe clinical picture than Chlamydia ornithosis. Reinfections can 
occur. Tetracyclines are most frequently used for therapy of infections 
by chlamydiae. 
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CHAPTER 3 
THE ROLE OF RESPIRATORY INFECTION IN THE PATHOGENESIS OF CNSLD 
3-1 Introduction 
The role of respiratory infection in the pathogenesis of CNSLD has been 
discussed extensively in the past decades. Much work in this field, es-
pecially with regard to viral-bacterial interrelationships in the patho-
genesis of "chronic bronchitis" has been done by Stuart Harris and co-
workers.255 256 258 Nowadays it is generally believed that there is no 
support for a role of respiratory infections experienced in adult life 
in the progressive obstructive airway disease found in some patients. 73 
119 153 266 On the contrary, there is growing interest in the field of 
paediatric respiratory illness in relation to CNSLD. Over the past few 
years a number of epidemiological and pathophysiological studies have 
appeared, suggesting a close relationship between lower respiratory 
tract illnesses in infancy and early childhood and chronic respiratory 
disorders and pulmonary function abnormalities in later life. The back-
grounds of this relationship are not fully understood yet. The associa-
tion could reflect some inherent genetically determined defect of the 
airways, rendering them susceptible to infection and other adverse 
effects at all ages. It is also possible that subtle changes, induced 
by childhood infection in the growing airways, predispose them to risk 
effects by leading to bronchial hyperreactivity or by reducing the 
effectiveness of pulmonary defense mechanisms. Some studies indicate 
that both endogenous and exogenous factors are important, respiratory 
infection being a trigger mechanism for the appearance of symptoms in 
genetically predisposed persons. 71 81 
In this chapter a short review on the role of infection in the patho-
genesis of CNSLD will be given with special emphasis on the importance 
of paediatric illnesses. This is difficult because the exact nature of 
the childhood illness is often unknown. Moreover, semantic uncertainty 
with regard to the term respiratory infection96 206 and the different 
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diagnoses within the spectrum of CNSLD 233 (chapter 1) makes it arduous 
to ascertain the above-mentioned relationship. As many studies are li-
mited to asthma or chronic bronchitis-emphysemat the literature will be 
discussed for these categories separately, although this procedure 
brings some overlap of data along with it. 
3-2 Respiratory infection and asthma 
3-2-1 Terminology 
The term infectious asthma, still to be found in reference books on 
bronchial asthma233 263 underlines the role infection is supposed to 
play in the pathogenesis of the disease. This designation has been used 
widely, if respiratory infection was thought to be the main provoking 
factor of asthmatic attacks~ occurring in about 20% of the patients 
according to old studies~ 13 225 Nowadays, the term has been abolished 
by many authors because infections can cause exacerbations in patients 
with extrinsic as well as intrinsic asthma and other provoking factors 
are demonstrable in most instances. 236 276 
Similarly, the diagnosis "bacterial asthma", which has been used syno-
nymously, is not commonly used any more, as substantial evidence fo~ 
bacterial allergy in bronchial asthma is absent. 66 140 304 The benefi-
cial effects of bacterial vaccines in the treatment of asthma, reported 
by some authors 51 52 102 262 is probably due to the production of inter-
feron, according to Singer et aZ? 39 In children a distinction between 
wheezy bronchitis (bronchial obstruction in the course of respiratory 
infection) and astPma (other factors provoking obstruction as well) is 
sometimes made. Althou8h'slight differences are demonstrable between 
these clinical entities 116 the pathophysiological substrate is supposed 
to be identical. 294 
3-2-2 Childhood respiratory infection 
3-2-2-1 Subglottic laryngotracheobronchitis (croup) 
Croup has been considered a disease process of the larynx, trachea, and, 
possibly, larger bronchi. Therefore, it has never been regarded as a 
forerunner of bronchial obstructive disease. However, physiological 
changes indicating small airways involvement, were observed in the 
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course of the disease by Newth et az! 9 9 and Taussig and cO-workers. 26 8 
Subsequently, a high incidence of increased bronchial reactivity to 
exercise 163 and metacholine 103 was noticed in children with history of 
laryngotra.cheobronchitis. 
Hyperreactivity occurred irrespective of a positive history of allergy 
and a family background with regard to atopic disease. Although sympto-
matic asthma was not notified in the children studied, these findings 
suggest that subjects with a history of croup constitute a population 
susceptible to risk factors associated with bronchial obstructive dis-
ease. 
3-2-2-2 Bronchiolitis 
Acute bronchiolitis is a syndrome of inflammatory obstruction at the 
level of small airways, characterized pathologically by necrosis of 
bronchiolar epithelium followed by lymphocytic infiltration of the 
bronchial wall and narrowing of the lumen. 1 The majority of patients 
are children in the first two years of life and respiratory syncytial 
virus has been shown to be the most frequent aetiological agent. 11 39 142 
Freeman et al. 80 in a retrospective study found that 50% of children 
with lower respiratory tract infections continued to have wheezing 
episodes or allergic manifestations, whereas a percentage of only 17 
was noted in children with upper respiratory tract infections. 
Several studies have confirmed that there is a high incidence of 
recurrent wheezing subsequent to acute bronchiolitis. In Table 3-I 
a summary of these studies is given. Incidences of recurrent wheezing 
after bronchiolitis vary from 32 to 57%. Zweiman et al. 306 found this 
percentage to be constant when their patients were reexamined some 
years later. 
It has been noticed that the association of bronchiolitis with asthma 
is, among other factors, related to a positive family history of allergy 
and the suggestion has been made that the episode of bronchiolitis is in 
fact the infant's first asthmatic attack in many cases. 169 232 A hypo-
thesis that only children with bronchiolitis not caused by RSV are pre-
d;sposed to subsequent asthma was put forward by Simon and Jordan. 238 
This hypothesis was corroborated by a Swedish report of elevated IgE 
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Table 3-I Results of follow-up studies, indicating different inci-
dences of recurrent wheezing subsequent to acute bronchiolitis 
Authors 
Eisen et aZ. 67 
Hyde ei; aZ. 122 
Wittig et al. 295 
Zweiman et aZ.. 305 
Rooney et a"L 232 
No. of 
patients 
63 
77 
!00 
24 
62 
Follow-up 
period 
(yrs.) 
I- 7 
!- 2 
4-14 
3- 4 
2- 7 
%with aller-
gic family 
history 
44 
70 
29 
50 
54 
% with re-
current 
wheezing 
32 
40 
46 
50 
57 
levels in sporadic and normal levels in epidemic bronchiolitis 220 , but 
viral investigations were insufficient in this study. 
Some recent, well controlled studies have added substantial informa-
tion. Kat tan et aZ. 13 8 have shown that in subjects without respiratory 
symptoms studied 10 years after an episode of bronchiolitis a high in-
cidence of minor pulmonary function abnormalities are observed, indica-
ting the presence of a residual parenchymal or airway lesion. 
This observation was confirmed in follow-up studies by Pullan et al~ 22 
and Mok et al. 189 In both studies a significantly higher number of 
children with a history of bronchiolitis had alterations in lung 
function as compared to matched control subjects. Furthermore, a high 
incidence of airway hyperreactivity to histamine and exercise was ob-
served following bronchiolitis. However, no excess of allergic manifes-
tations or family atopic background was found and no differences were 
found between RSV positive and RSV negative bronchiolitis patients. 
3-3 Respiratory infection and chronic bronchitis 
3-3-1 Epidemiological studies 
There are numerous factors which are related to the development of 
chronic obstructive lung disease. Beside genetic determinants, these 
include area of residence, air pollution index, family's social class, 
family size, smoking habits, and the history of lower respiratory tract 
illness in early childhood. However, when all these factors are taken 
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into account,· the aetiological picture remains incomplete. 
The importance of respiratory tract infection in childhood in the 
pathogenesis of adult CNSLD has been stressed in many epidemiological 
studies. Serious respiratory tract infections, including bronchiolitis 
in childhood, were supposed to have occurred in a high proportion of 
adult New Guinea primitive tribal people with chronic cough and dimi-
nished lung function: 96 Colley and co-workers 47 in a prospective cohort 
study examined the prevalence of cough in young adults whose respiratory 
status in early life had been documented. More cough was noted in sub-
jects with lower respiratory tract illness in infancy, even after ac-
counting for smoking habits. This study confirmed older follow-up 
studies by McDonald et al. 16 8 , Reid and Fairbairn22 7 , and Case et az: 1 32 
Respiratory illness early in life is supposed to be associated with an 
increased susceptibility to recurrence of respiratory symptoms in later 
childhood. 17 Increased respiratory infection rates 1n patients with 
CNSLD have been found by several investigators. 165 182 190 291 Monto 
and Ross 191 suggest on the base of their findings that acute infection 
may play an important role in the pathogenesis of chronic respiratory 
disease. 
3-3-2 Physiological studies 
There are several surveys in which physiological parameters have been 
used to assess airway function in subjects with a history of childhood 
respiratory illness. Holland et al. 112 found that in a group of children 
aged 5-14 years, peak flow rates were adversely affected by a past his-
tory of pneumonia or bronchitis. A significant correlation between 
abnormalities in forced expiratory volume (FEV) and a history of fre-
quent cough, colds going to the chest, and episodes of lower respiratory 
tract illness was reported by Lunn et al. 167 Indications for residual 
damage to airways subsequent to lower respiratory tract illnesses were 
also found by Leeder an co-workers, using flow-volume curves and closing 
volume tests. 154 
Recent data confirm the suspected relationship between paediatric 
=espiratory disorders and the subsequent development of airway disease 
in adults. Burrows et al. 26 in a retrospective study showed that 
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subjects with a history of paediatric respiratory illness had only 
relatively mild impairment of ventilatory function at young adult age. 
However, these persons showed excessive decline in lung function with 
advancing years and with cigarette use, factors known to be of the 
utmost importance in the development of progressive airflow obstruc-
tion.73 
It is possible that these data similarly apply to the asymptomatic 
subjects with minor lung function deteriorations and increased bronchial 
reactivity to various stimuli, subsequent to croup (chapter 3-2-2-1) 
and bronchiolitis (chapter 3-2-2-2), in whom the infectious origin of 
paediatric illness was established. 
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CHAPTER4 
VIRAL RESPIRATORY INFECTIONS AND EXACERBATIONS OF CNSLD 
4-1 Introduction 
In the late fifties, when Asian influenza was- epidemic, several reports 
on the possible asthmatogenicity of the influenza H2N2 virus appeared. 
164 219 224 226 287 Numerous studies have been undertaken since which 
show that various respiratory viruses as well as MYcoplasma pneumoniae 
are able to cause exacerbations in patients with CNSLD. 
The majority of patients with CNSLD tend to react with an exacerba-
tion in the course of a respiratory viral infection. Table 4-I summa-
rizes the results of the studies which support this view. 
Table 4-1 Frequency of exacerbations ~n CNSLD during respiratory 
viral infections. Results of various studies 
Authors No. of viral Percentage with 
infections exacerbation 
Stenhouse2 51 16 50 
Minor et aZ. 183 32 53 
Stark et aZ. H9 23 57 
Stenhouse 250 13 62 
Minor et al. 184 38 63 
LOwenberg and Orie166 14 64 
Huhti et aZ. 1 2 1 43 77 
McNamara et aZ. 172 34 79 
Eadie e·t aZ. 64 17 82 
Total (studies combined) 230 67 
In most studies the population of patients is limited to the asthma 
-or the chronic bronchitis-group. In both groups the significance of 
bacterial infections in causing exacerbations seems ·to be of little 
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importance. 
Several investigations in asthmatics suggest that there is no rela-
tionship between bacterial infection of the respiratory tract and the 
occurrence of exacerbations. 13 70 1 ~ 8 170 184 235 This applies also to 
the patients defined as chronic bronchitics. 25 54 101 In view of these 
data and the emphasis of this thesis on respiratory viruses, the sub-
ject of bacterial infection will not be dealt with to further extent, 
whereas the literature on viral agents and tVYcopZasma pneumoniae will 
be discussed for asthma and chronic bronchitis apart. 
4-2 Viral respiratory infections in the course of bronchial asthma 
Berkovich et aZ. 12 were the first to report a prospective study onviral 
and MYcoplasma pnev~oniae infection causing exacerbations in asthmatic 
children. An attempt was made to culture viruses from the throat during 
attacks of asthma, but sampling was infrequent and few agents were 
isolated. However, it was concluded from serological tests that 33 out 
of 108 exacerbations occurred in the course of a viral infection. 
Influenza A, parainfluenza 3 and Mycoplasma pneumoniae accounted for 
the majority of these episodes. 
In an earlier period asthmatogenetic properties have been assigned to 
RSV, parainfluenza I and 3 viruses, and adenovirus by Freeman and Todd 60 
and to MYcoplasma pneumoniae by Hers and Mulder110 on the base of retro-
spective data. 
In the seventies several authors reported on the subject with diver-
gent conclusions. The majority of studies are dealing with asthmatic 
children, whereas data in adults are scarce. In children Disney etal. 51 
found evidence of viral infection in a minority of patients only. In 5 
of 51 children with an acute attack of asthma, a viral agent could be 
identified. However, the study is incomplete, because serological tests 
were done in 26 of the children only. 
A somewhat higher percentage was reported by Mitchell et al. 185 who 
found an infection rate of 17% in 267 children admitted to hospital 
because of wheezy bronchitis or asthma. Virus isolation was signifi-
cantly more common in readmissions than in first admissions. Lambert and 
Stern148 described a seven-year-old asthmatic boy in whom 3 virus iso-
51 
lations were made in the course of 5 asthmatic episodes. 
In a prospective study of viral respiratory infection in 32 one- to 
five-year-old children, hospitalized in the National Jewish Hospital in 
Denver, Mcintosh et al. 170 found 139 episodes of wheezing, 58 of which 
(42%) were associated with identifiable viral infection. Of 25 infec-
tions bY RSV, 24 caused exacerbations, whereas influenza A-H3N2 virus 
was not associated with wheezing in any of 11 children. 
Minor et al. 184 followed 16 children, aged 3 to II years, with non-
allergic asthma, who experienced 61 episodes of wheezing. Forty-two of 
these were coincident with an apparent symptomatic respiratory infection 
(SRI). Evidence of viral infection was found in 24 patients, rhinovirus 
being the agent most frequently isolated. All of 6 influenza A-H3N2 
episodes were associated with attacks of asthma. Asthma was precipitated 
during 21 of 23 severe SRis of viral origin, whereas no asthma was noted 
in episodes of asymptomatic virus shedding. The same authors stress the 
importance of rhinovirus and influenza A-H3N2 in another study18 3 , in 
which adult patients also participated. Seventeen out of 24 (71%) epi-
sodes of SRI by rhinoviruses and 4 of 5 influenza A infections were 
accompanied by wheezing. A high incidence 0f wheezy episodes during 
rhinovirus infections in asthmatic children was also reported byGregg 95 
who found that 46 out of 57 (80%) of these infections were associated 
with acute wheezy bronchitis. 
In a study of 51 asthmatic adults, Clarke45 suggested that respiratory 
infection is responsible for a small part of asthmatic flare-ups only. 
During Ill exacerbations proof of viral infection was found in 8 of 
these only. However, like in the study by Disney et al. 57 , serological 
investigation seemed to be incomplete. 
Higher figures were given in .a Finnish study121 in which 27 of 142 
patients who were admitted to hospital because of severe asthmatic 
attacks showed evidence of viral and Mycoplasma pnewnoniae infection. 
There were no differences between allergic and non-allergic patients 
and the use of oral corticosteroids did not influ_ence the frequency of 
infection. Comparable data were given by Migueres et az:so who found 
seroconversion in 54 out of 211 exacerbations in 178 adult patients. 
Influenza A and Mycoplasma pneumoniae were the agents most frequently 
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involved. 
Finally, Lambert and Stern 1 ~ 8 reported on a 25-year-old female in whom 
2 virus isolations were made in the course of 6 asthmatic episodes. 
The results of the above mentioned studies are summarized in table4-2 
Table 4-2 Summary of studies on the relationship between respira-
tory viral infection and excerbations in asthmatics 
Authors No.of 
pa-
tients 
Clarke45 51 
Disney et aZ. 57 51 
Mitchell et aZ. 18 5 192 
HuhtietaZ.. 121 63 
Migueres et al. 18 0 178 
Berkovich et al. 12 84 
MinoretaZ.. 184 16 
Mcintosh et aZ..1 7 0 32 
Lambert & Stern148 2 
Age No.of 
exacer-
bat ions 
average:35 111 
?(children) 51 
children>l 360 
15-77 142 
15-75 211 
0-16 108 
3-11 61 
1- 5 139 
7-25 II 
%with 
viral 
infec-
tion 
7 
10 
17 
19 
26 
31 
39 
42 
45 
Main 
agents 
RSV,rhino 
Infl.A, RSV 
M.pneum. 
Infl.A, 
M.pnewn. 
Infl.A, para-
infl., 
M.pneum. 
Rhino, 
infl.A 
RSV, para-
in£!. 2, 
corona 
Rhino 
4-3 Viral respiratory infections in the course of chronic bronchitis 
It has been known for a long time that flare-ups of chronic bronchitis 
can occur in combination with rises in antibody titre to influenza A259 
and adenovirus. 279 The first reported attempts to isolate a viral agent 
during exacerbations in chronic bronchiticswere by Jack and Gandevia125 
and Hennessy 1 0 8, both of whom failed to identify any viruses. However, Carilli 
et aZ. 3 0, who found serological evidence of viral infection in 24 out of 46 
exacerbations, succeeded to isolate a viral agent in 4 cases. RSV was 
the most common agent in this study, followed by influenza and the non-
viral agent .~eopZasma pneumoniae. The importance of the RSV was also 
stressed in a study by Sormnerville 244 , who reported that in 41 out of 82 
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seroconversions to this agent the clinical diagnosis of an acute bron-
chitic exacerbation was assessed. 
Stark et aZ. 249 reported that serological tests revealed 13 influenza 
B infections associated with 9 exacerbations and 10 parainfluenza in-
fections with 4 flare-ups in 199 patients suffering from chronic bron-
chitis. These viruses accounted for only 7% of exacerbations experien-
ced by these patients. 
Similar data were provided by Moffat and Sutherland 188 who calculated 
that only 3 of a total of 68 exacerbations were related to viral infec-
tions. In this study the sera from 20 male bronchitics were investigated 
at 8-week intervals for a period of more than 4 years. Only 6 signifi-
cant seroconversions were found which could be due to the relatively 
long intervals. 
Higher figures were given by Eadie et al. 64 , who followed 15 patients 
with chronic bronchitis every fortnight for a period of almost 2~ years. 
They identified 16 virus infections in the course of 75 exacerbations, 
rhinoviruses being the most frequently isolated agents. 
Stenhouse 250 also succeeded in isolating rhinoviruses in 8 of 34 
patients. The infections accounted for 14% of the exacerbations during 
the study period. In another 64 flare-ups experienced by these patients, 
7 seroconversions to a viral agent and 1 to Chlamydia psittaci were 
found. 251 
Similar figures were presented by Fisher et al. 72 , who identified 7 
viral and 2 Mycoplasma pneumoniae infections in the course of 63 exacer-
bations in 23 male bronchitics and by Ross et al. 234 , who found fourfold 
or greater rises in antibody titre in 20 out of 125 exacerbations, using 
serological methods only. 
Lambert and Stern148 , in a study mentioned before, found evidence of 
viral infection in 8 out of 30 deteriorations of chronic bronchitis in 
6 patients. Mufson et al. 194 imputed one-fifth of the 153 exacerbations 
studied by them to viral or Mycoplasma pneumoniae infections, whereas 
Gump et al. 101 were able to relate one-third of 116 periods of increased 
cough and sputum production in 25 patients to respiratory viruses and 
Mycoplasma pneumoniae. 
There are two reports in which a majority of bronchitic episodes could 
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be associated with viral or Mycoplasma pneumoniae infection. McNamara 
et ai. 172 found an association with rhinovirus (18 times), RSV (5 times) 
and MYcoplasma pneumoniae (4 times) in 27 out of 42 episodes of in-
creased bronchitic symptoms. Of 34 infections by these agents, 79% were 
related to excerbations. 
In a Belgian study Lamy et al. 149 reported 49 exacerbations experien-
ced by 44 of Ill patients they observed for periods ranging from I to 9 
months. A diagnosis of viral infection wa~ made in 31 cases (63%) by 
isolation and/or seroconversion, including 1 infection by Coxiella 
burneti and one by Mycoplasma pneumoniae. There was a remarkable rela-
tionship between parainfluenza infection and periods of increased symp-
toms of chronic bronchitis. The results of the above mentioned studies 
are summarized in table 4-3. 
Table 4-3 Summary of studies on the relationship between respira-
tory viral infections and exacerbations in chronic bronchitics 
Authors 
Moffat et al. 188 
No.of 
pa-
tients 
20 
Stark et al. 249 199 
Stenhouse251 34 
Stenhouse250 34 
Fisher et al. 72 23 
Ross et al. 234 172 
Mufson et al. 194 45 
Lambert & Stern 14 8 6 
Eadie et al. 64 15 
Gump et al. 1 0 1 25 
Carilli et al. 30 30 
Lamy et al. 149 Ill 
McNamara et al.172 29 
Age 
40-59 
20-79 
51-73 
51-73 
44-67 
> 40 
? 
46-74 
25-84 
31-72 
26-80 
30-80 
19-75 
No. of % with 
exacer- viral 
bations infec-
68 
185 
64 
56 
63 
125 
153 
30 
47 
116 
46 
49 
42 
tion 
4 
7 
12 
14 
14 
16 
20 
27 
28 
34 
52 
63 
64 
Main 
agents 
Infl.B, 
parainfl. 3 
Infl.A,B 
Rhino 
Infl.A, 
M.pneum. 
Infl.A, C,RSV 
Infl.A, 
parainfl. 
Parain£1.1 ,3 
Rhino 
Infl.A, para-
infl.3,RSV 
RSV, Infl. A, 
M.pneum. 
Infl.A,B, 
parainfl. 
Rhino, RSV, 
M.pnewn. 
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CHAPTER 5 
CNSLD AND HIGH MOUNTAINS 
5-I Introduction 
It is a widely known clinical phenomenon that patients with CNSLD, es-
pecially those with distinct asthmatic symptoms, react favourably upon 
moving to the high mountains. The first reports, cited by Van Geuns8 ~ 
date from Denz and Spengler, both of whom described in 1878 some asth-
matic patients with a remarkable improvement of their bronchial obstruc-
tive disease during their stay in a high mountain climate. Numerous 
reports on the subject have been published since and the literature 
~ntil 1956 has been reviewed in detail by Van Geuns. 86 
In this chapteJ; __ some hypotheses regarding the beneficial effects of 
climatic factors on CNSLD will be discussed briefly, completed by some 
of our own clinical observations. 
5-2 Theoretical considerations 
The various theories on the favourable effect of the high mountain 
climate in CNSLD patients can be roughly divided into 3 groups. 
a. The first group emphasizes the change of respiratory mechanisms in 
the thinner air, containing less oxygen. Especially Jaeger127 128 
pointed out that there is a correlation between the density of 
inhaled gas and the resistance in the airways.Inspired air at an 
altitude of 1500 m has a density of 83% as compared to 100% at sea-
leveL This relatively low density could be partly responsible for 
the beneficial effects of the high mountain climate. The use of 
light gas mixtures, such as helium-oxygen (80%-20%) in lung function 
studies and the therapy of asthma 10 is based on the same physical 
principles. 
b. The second group stresses the importance of biometereological influ-
ences. -MOrikofer192 gave a detailed review on the meter eo logical 
circumstances of Davos, emphasizing the low wind intensity, the 
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radiation conditions, especially with regard to ultraviolet light, 
the relatively scanty rainfall and low humidity, as well as the low 
oxygen content of the inspired air. Tromp and Bouma275 suggested 
that there is an association between sudden increases in atmospheric 
turbulence and asthmatic attacks and supposed that the susceptibility 
of asthmatic patients to these atmospheric changes is attributable 
to a dysfunction of hypothalamic thermoregulatory nuclei in these 
subjects. 
The stability of atmospheric conditions and the relative absence of 
sudden rises in turbulence could possibly account for the low fre-
quency of asthmatic attacks observed in Davos. 302 
c. The third and probably most important group emphasizes the absence 
or at least much smaller frequency of bronchial irritants, such as 
inhalation allergens. Over half a century ago Storm van Leeuwen 2 53 2 54 
reported that asthmatics with a distinct allergy to house-dust were 
free of complaints when staying in an alpine climate. In 1924 this 
_nvestigator took with him on a journey through Switzerland 3 pa-
tients suffering from asthma and studied the condition of these 
persons in Basel, Lugano, Ragaz, Vulpera, Daves, and St. Moritz, 
respectively. At Daves one of these patients, who was without com-
plaints there, was subjected to a test in which by means of inhala-
tion of dust from Holland an asthmatic attack was provoked. 
Varekamp 281 tested the allergenic effects of the house-dust collec-
ted during this trip on Dutch asthmatic patients and found strong, 
negative correlation between the allergenic potency and the altitude 
at which the house-dust was collected. (Table 5-I). 
Van Geuns 85 submitted 35 patients to inhalation tests with equally 
prepared Dutch and Davos house-dust extract. Eighteen of these patients 
showed a positive reaction to Dutch house-dust, whereas only one of them 
had a positive reaction to the Davos extract. Voorhorst and Spieksma 
corroborated these findings by some elegant studies in the sixties. 245 
247 282 283 It was found that a mite, Dermatophagoides pteronyssinus, 
is of particular importance with regard to the allergenic potency of 
house-dust and that its ideal growth conditions are high humidity and 
a temperature of approximately 25° C. This probably explains why house-
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Table S-1 Percentage of patients with positive skin tests to ex-
tracts of house-dust, collected at different altitudes 
House-dust from 
Holland 
Basel 
Lugano 
Ragaz 
Vulpera 
Daves 
St.Moritz 
According to Varekamp281 
Altitude (m) 
0 
100 
300 
800 
1200 
1500 
1800 
% of Dutch patients 
with positive skin test 
83 
67 
30 
35 
18 
12 
7 
dust allergy is often troublesome with old bedding, in damp houses, and 
during the wetter months of the autumn and winter. 176 
The low humidity in alpine climates, e.g. at Davos 192 , probably 
accounts for the much lower levels of contamination in the Swiss moun-
tains.248 Other approaches of comparing allergenic potencies of house-
dust from alpine and lowland regions, e.g. chemical investigations by 
Berrens et ar. 14 have yielded similar data. Davos house-dust turned out 
to have much lower allergenic activity than Dutch samples. 
In addition to the relative absence of the house-dust mite, other 
inhalation allergens, like moulds and pollens have been shown to occur 
less frequently in high mountain climates. 159 298 
5-3 Comment 
The numerous reports on the favourable influence of high mountain 
climate on CNSLD are confirmed by our own observations. Especially the 
data described in chapter 5-2 c. are ·in agreement with our experiences 
with house-dust allergic patients. We found a significantly greater 
frequency of improvements in asthmaticswith a distinct house-dust 
allergy as compared to matched non-allergic patients (Table 5-2). More-
over, most spectacular results have been obtained in young children in 
whom the factor allergy frequently is very pronounced. Severe asthmatic 
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Table 5-2 Resultsof house-dust allergic asthmatics as compared to 
non-allergic patients in Davos (according to Roldaan and van Rijn231 ) 
Patients-allergic 
to house-dust 
Patients non-
allergic to house-
dust 
No. 
21 
20 
No. with definite 
improvement in FEV1 
19 
6 
Percentage 
90 
30 
children, requiring oral corticosteroids in Holland, have been shown to 
manage without those medicaments within a short time when staying in 
the alpine climate of Davos. 141 
Furthermore, other patients suffering from obstructive disorders of 
a more irreversible character also tend to have fewer complaints. In a 
study by Arblaster and Zuidema7 83% of asthmatic patients showed an 
improvement, whereas 44% of chronic bronchitics did. 
It has been frequently noticed that subjects with marked hypersecre-
tion produce much less sputum during their stay in Davos. This might be 
associated with the statement of many patients that they experience 
fewer respiratory infections while staying there. Although some authors, 
like von Neergaard (cited by van Geuns86 ), drew attention to this in-
frequency of infective episodes long ago, there is no conclusive evi-
dence in literature that respiratory infections occur less often in 
alpine climates. Similarly, literature does not provide reliable data 
on the course of bronchial hyperreactivity in patients with CNSLD 
staying in alpine climates. Investigations into this field should be 
subject of future research activities. 
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Cl!AJ'TER 6 
DAVOS, THE NETHERLANDS ASTHMA CENTRE AND ITS PATIENTS 
6-l Daves and the Netherlands Asthma Centre 
Daves~ a village with approximately 12,000 inhabitants, is situated at 
an altitude of 1560 m in "GraubUnden", which is the largest of the 22 
Swiss cantons and is located at the eastern border of the country. 
Davos is surrounded by mountains, which makes it sheltered from wind to 
a great extent. Its favourable weather conditions and the extensive 
facilities, especially in winter, have turned the place into one of the 
most prominent wintersport areas of Europe. Moreover, because of its 
metereological advantages as compared to the conditions in the lowlands 
(see chapter 5) , the village has achieved a reputation as a leading 
"Kurort". At the end of the past century the relatively favourable 
effect of the alpine climate in the treatment of pulmonary tuberculosis 
arose interest in Holland and private initiatives led to the foundation 
of the Netherlands Sanatorium~ which was opened in 1897. For a period 
of over 70 years Dutch tuberculosis patients were treated in the Sana-
torium, but with the development of tuberculostatic medicaments and 
because of better hygienics the disease gradually got more or less 
overcome. 
Because of the good results, described by others, in patients suffer-
ing from asthma and bronchitis, a start was made with the treatment of 
these patients in the late fifties. In the course of time CNSLD patients 
have replaced tuberculosis patients and, accordingly, the clinic's name 
was changed into Netherlands Asthma Centre. 
6-2 Patients 
6-2-1 General considerations 
Within the Dutch medical care for patients suffering from CNSLD the 
clinic in Daves serves more or less as a terminal station, suitable for 
patients in whom good control of symptoms of the bronchial obstructive 
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disorder cannot be accomplished despite intensive medical treatment in 
The Netherlands. 
Severe bronchial asthma lS the diagnosis most commonly applied to the 
subjects referred to the centre, but other conditions within the spec-
trum of CNSLD as well as bronchiectasis of known and unknown origin are 
also frequently seen. Because almost all of the patients have a long 
history of severe disease when they are sent to Daves, serious inter-
ference in daily life before referral is frequently seen and consider-
able psychosocial implications of the illness are rule rather than 
exception. Therefore, an integral, holistic approach of treatment was 
chosen as a model some years ago, as described by Lanse~150 with a team 
comprising specialists from different therapeutic fields for each group 
of patients. Within this model, starting from a usually considerable 
somatic amelioration, thanks to extensive medical care and climatic 
factors~ patients are enabled to explore possibilities of improving 
their way of life in different respects. 
Subjects are divided into groups, mainly according to age. These 
groups have their own living units, which is of epidemiological impor-
tance in view of the survey described in this thesis. Patients partici-
pating in the study were, to a major extent, recruited from three 
groups, which will be discussed briefly. 
6-2-2 Group A - the "Senioren" 
This group comprises 20-25 patients of about 35 years of age onward, 
suffering from different conditions covered by the term CNSLD. On the 
one hand there are subjects to whom the term asthma can be applied, with 
complete reversibility of their bronchial obstructive disorder, on the 
other hand there are patients who are seriously disabled because of 
severe irreversible obstructive changes. The majority of persons can be 
regarded as asthmatic, a substantial part of them having no allergic 
features (intrinsic asthma). 
The therapeutic aims for this group can be roughly described as phy-
sical and mental rehabilitation. The time usually necessary to achieve 
these aims varies between 3 and 6 months, but longer periods are not 
infrequent. 
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Apart from medical care, the daily therapeutic programme for these 
patients consists of physical and movement therapy, creative therapy, 
group sessions twice weekly, house-keeping activities and, if necessary, 
individual psychotherapeutic support. Within movement therapy much 
attention is given to physical fitness and relaxation techniques, in-
cluding autogenic training. 
Within this group, readmissions are not infrequent and some of the 
elderly patients with chronic airflow obstruction are referred to the 
clinic every year in winter for a short rehabilitation. Since 1977 these 
patients form a special group, usually called "overwinteraars" or 
"veteranen". 
6-2-3 Group B - the "Junioren11 
This group consists of about 15 adolescents and young adults~ mostly 
between 17 and 30 years of age. The diagnosis extrinsic atopic bronchial 
asthma can be applied to most of them; in some of these subjects severe 
irreversible features are a~ready present. It is almost characteristic 
that these patients show signs of retardation in different ways, due to 
severe chronic illness. This goes especially for self-reliance and 
acceptance of responsibilities. Therapy is directed toward physical 
rehabilitation and mental growth, aiming to render these patients inde-
pendent, self-supporting people, who can manage to live with a chronic 
disease_ satisfactorily. It has become clear that group-directed activi-
ties can be used as a therapeutic tool in this respect. 
The programme offered to these patients does not differ essentially 
from that of group A~ but is more intensive and has more educational 
aspects. The average duration of treatment varies between 6 and 12 
months. 
6-2-4 Group C - the "Vossen" 
This group comprises 10 children of 9 to 14 years of age~ almost all of 
them suffering from severe extrinsic atopic bronchial asthma with 
(almost) complete reversibility of lung function. Asthmatic symptoms in 
most of these children used to persist, despite intensive medical care, 
in Holland and many of them were residents of Dutch asthma hosp.itals for 
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several years. These patients are frequently referred to the high moun-
tain climate because of the impossibility to avoid the use of oral cor-
ticosteroids in relatively high dosages for longer periods of time. A 
dramatic spontaneous improvement is usually seen and most of the child-
ren manage to be completely or almost totally symptom-free without the 
use of oral steroids. The house they are living in is somewhat remote 
from other living units in order to create a domestic atmosphere, a 
home of their own. 
Life is as normal as possible, school being the most time-consuming 
element of the day for these children. Within the daily programme, 
there is much attention for sports and fitness training, because of the 
sometimes severe motoric retardation. There are 4 pedagogically trained 
leaders, 2 females and 2 males, for this group. Parents are involved in 
therapy as much as possible. 
In order to obtain a better prognosis for these patients, who were 
severely disabled in Holland, it is necessary for them to stay for a 
relatively long period. After a stay of about 2 y;_ears improvement of 
their condition is maintained in approximately 70% of the children. 3 
In November 1978, a new group -the "Tussengroep11 - was instituted, 
formed by 8 children, aged 14-17 years. Some of these patients partici-
pated at the end of the study and were incorporated with the subjects 
of group C. 
PART II 
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CHAPTER 7 
PATIENTS, MATERIAL AND METHODS 
7-l Introduction 
The study of viral respiratory infections in patients of the Netherlands 
Asthma Centre was conducted for a period of 3 years and 7 months, from 
September 15, 1975 to April 15, 1979. The aim of the investigation was 
explained to the subjects and consent to participation was given by all 
patients without restraint. Principally, every patient with CNSLD refer-
red to the clinic could enter the study, but a total number of 40 to 45 
participants at any given time was aimed at. Because of the much greater 
turn-over of the group A patients, most participants came from this 
group, whereas the number of children in group C was relatively small. 
On the other hand, the follow-up periods of the latter patients were 
much longer. 
7-2 Patients 
7-2-1 Classification of patients 
In order to investigate whether various patterns of reaction to respi-
ratory infection can be found in patients with different types of CNSLD, 
the patient population was divided into 3 groups, maintaining the clas-
sification in groups A, B, and C as described in chapter 6-2. Patients 
were classified mainly on the base of anamnestic data and reversibility 
of lung function, but other parameters like physical examination, skin 
tests, total peripheral eosinophilic leucocyte counts, chest rOntgeno-
grams, and histamine threshold were also taken into account. Special 
attention was given to the occurrence of obvious asthmatic attacks with 
wheezing, alternated with symptom-free intervals either at present or 
in the past. Patients were asked to tell whether their main complaint 
nowadays was paroxysmal dyspnoea or progressive breathlessness on 
exertion and the importance of coughing and phlegm production as a 
symptom was judged. 
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Lung function measurements, including static lung volumina, FEV1, 
flow at various lung volumes, and airway resistance were done at 
least once in 4 weeks in all patients before and after bronchodilation 
using a bodyplethysmograph (Bodytest, Jaeger). The best of all measure-
ments of FEV1 after bronchodilation was compared to predicted values, 
according to Tammeling and Quanjer. 267 The following groups were formed: 
-Group I (asthma): patients with distinct asthmatic attacks, relatively 
symptom-free episodes and considerable reversibility of obstruction. 
~fuximum FEV 1 was at least SO% of the predicted value. 
-Group II (asthma+ GAO): patients with asthmatic attacks at present or 
in the past, but with signs of irreversible chronic airflow obstruction 
(CAO) and/or chronic mucous hypersecretion at present. Maximum FEV1 
varied between 65% and 80% of the predicted value. 
-Group III (CAO): subjects suffering from, usually severe, dyspnoea on 
exertion with only slight fluctuations, and distinct irreversible 
airflow obstruction, the best FEV1 measured being less than 65% of the 
predicted value. 
7-2-2 Group A - the "Senioren" 
Originally, 126 patients of this group, no. Al to A126, participated in 
the survey. Four patients were discharged from the clinic within 6weeks 
after entrance to the study and were excluded, leaving 122 "Senioren" 
patients. There were 45 females and 77 males with an average age of 52 
years (31-73 years). In Table 7-1 patients are classified according to 
sex and age. 
Table 7-1 Group A patients, according to sex and age 
Age (yrs) Male 
30-34 4 
35-44 12 
45-54 31 
55-64 19 
65-74 II 
Total 77 
Female 
13 
14 
15 
2 
45 
Total 
5 
25 
45 
34 
13 
122 
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With regard to classification according to clinical picture, as des-
cribed in chapter 7-2-1, 56 patients were categorized into group I 
(asthma), 42 into group II (asthma+ CAO) and 24 into group III (CAO). 
The most important characteristics of patients, according to clinical 
groups, are given in Table 7-2. 
Table 7-2 Characteristics of group A patients, 
according to clinical picture 
Group I 
Group II 
Group III 
No. 
56 
42 
24 
7-2-3 Group B - the "Junioren11 
Male/female Age 
29/27 
28/14 
20/ 4 
49.5 
52 
57 
Max.FEV1/ 
predicted FEV 1 (%) 
99 
69 
45 
Of the "Junioren" 79 patients were included in the study originally, 
no. Bl to B79. Seven patientsdropped out because of discharge within 6 
weeks and one patient was transferred to group A and is classified there. 
Forty-one male and 30 female patients remained, with an average age of 
22 years (14-35 years). In Table 7-3 these patients are classified 
according to age and sex. 
Table 7-3 Group B patients, according to sex and age 
Age (yrs) Male 
14 2 
15-19 20 
20-24 9 
25-29 5 
30-35 5 
Total 41 
Female 
10 
12 
4 
4 
30 
Total 
2 
30 
21 
9 
9 
71 
68 
Although uncomplicated bronchial asthma with good reversibility was 
the common diagnosis here:o to wit in 45 subjects" 23 had signs of asthma 
and irreversibility and 3 had features of progressive airflow obstruc-
tion without asthmatic attacks at present or in the past. Table 7-4 
lists some characteristics of these patients. 
Table 7-4 Characteristics of group B patients, 
according to clinical picture 
Group I 
Group II 
Group III 
No. 
45 
23 
3 
7-2-4 Group C - the "Vossen" 
Male/female Age 
25/20 
14/ 9 
2/ 
21 
25 
22 
Max.FEV1/ 
predicted FEV1 
(%) 
99 
71 
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Group C comprised 23 boys and 9 girls, Cl to C 32, none of whom dropped 
out. Ages varied from 9 to 16 years with an average of 12 years. Thirty 
patients had bronchial asthma with strong allergic features, 4 of them 
having incomplete reversibility (group II). One girl with totally re-
versible asthmatic signs without allergic features and one other girl 
with cystic fibrosis were categorized into groups I and III, respective-
ly. Thus the following score in clinical groups was achieved (Table 7-5). 
Table 7-5 Characteristics of group C patients, 
according to clinical picture 
Group I 
Group II 
Group III 
No. 
27 
4 
Male/female 
19/8 
4/-
-/1 
Max.FEV1/ 
predicted FEV 1 (%) 
105 
77 
61 
69 
7-2-5 Summary 
Summarizing and combining the data presented above,. we find a clear 
preponderance of patients with distinct asthmatic symptoms and complete 
reversibility of bronchial obstruction (group I). Subjects with the 
condition characterized by largely irreversible chronic airflow obstruc-
tion without paroxysmal dyspnoea (group III) are relatively scarce and for 
obvious reasons mainly to be found in group A. In Table 7-6 the diffe-
rent categories of patients are combined. 
Table 7-6 Population of patients, according to living unit, clinical 
picture and sex 
Group A Group B Group C 
"Senioren" "Junioren" "Vossen11 Subtotal Total 
M F M F M F M F 
Group I 29 27 25 20 19 8 73 55 128 
asthma 
Group II 28 14 14 9 4 46 23 69 
asthma + CAO 
Group III 20 4 2 22 6 28 
CAO 
Subtotal 77 45 41 30 23 9 131 84 
Total 122 71 32 225 
7-3 Clinic 
7-3-I Respiratory infection criteria 
Daily surveillance was carried out for each patient. The following symp-
toms were registered on a standard form: 
-running nose 
-stuffed nose 
-sneezing 
-sore throat 
-sore ear(s) 
-dry coughing 
-hoarseness 
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-malaise. 
A symptomatic respiratory infection (SRI) was supposed to be present if 
2 or more of the mentioned symptoms turned out to be positive for 36 h 
or longer afer having been negative for the previous 4 days at least. 
In that case, coexisting symptoms like headache, myalgia, chest pain, 
itchy eyes, vomiting, and diarrhoea were noted, and physical examina-
tion of ears, throat and thorax daily as well as rectal temperature 
measurements twice daily were carried out. 
7-3-2 Exacerbation criteria 
Daily scores for dyspnoea, wheezing, coughing and sputum production were 
registered, using the following criteria: 
-Dyspnoea. 
-Wheezing. 
-Coughing. 
-Sputum. 
Grade 1: No dyspnoea. 
Grade 2: Dyspnoea at heavy physical exertion only (walking 
uphill, climbing stairs). 
Grade 3: Dyspnoea at moderate physical exertion (walking 
on flat terrain). 
Grade 4: Dyspnoea at mild physical exertion (getting 
dressed). 
Grade 5: Dyspnoea at rest. 
Grade 1: No wheezing. 
Grade 2: Wheezing at physical exertion only. 
Grade 3: Wheezing at rest. 
Grade 1: No coughing. 
Grade 2: Mild to moderate coughing. 
Grade 3: Severe coughing or serious coughing spells. 
Grade 1 : 0-2 phlegms. 
Grade 2: 3-5 phlegms; a: white-greyish 
Grade 3: 6-9 phlegms; b: yellow-greenish 
Grade 4: 10 or more phlegms c: green-purulent. 
FEV1 was measured daily at 5.30 p.m. on a hot wire spirometer, type 
Monaghan M403 (Sandoz) until October I, 1977 and on a dry spirometer, 
type Vicatest (Mynhardt) thereafter. The better of 2 forced expiratory 
manoeuvres was noted. 
Scores for dyspnoea/wheezing (combined) and cough/sputum (combined) 
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as well as FEV1 in the course of an SRI were compared to the average of 
10 scores preceeding the SRI. An exacerbation was defined as: 
-An increase by at least 2 points in dyspnoea/wheezing or cough/sputum 
during 2 or more consecutive days. 
-A decrease in FEV1 by at least 25% during 2 or more consecutive days. 
Whenever justified, we tried to keep medication constant. 
7-3-3 Laboratory 
On the second or third day of an SRI and 2-3 weeks afterwards a venous 
blood sample was taken. Furthermore, every 4 weeks blood samples were 
collected to check whether any subclinical infections had occurred. 
After centrifugation the sera were stored at -20° C. CF tests were done 
as described by Lennette 158 , using the following antigens: 
-Influenza A and B virus. 
-Parainfluenza 1,2, and 3 virus. 
-Adenovirus. 
-RSV. 
-My cop Zasma pnewnoniae. 
-Chlamydia psittaei. 
Influenza A and B viruses were also tested by the HI method according 
to Masurel 173 , using specific epidemic strains. A fourfold or greater 
rise in antibody titre was regarded as seroconversion. If green or 
yellow sputum was produced, patients were asked to collect it and a 
gram stain of a carefully washed flake was made according to themethod 
of Mulder. 195 Bacteria in the adequate gram stain were considered as 
evidence of bacterial infection. 
In the course of an SRI the following laboratory investigations were 
done, whenever possible, on the· 2nd, 4th, 6th, and lOth day: 
-Sedimentation rate of erythrocytes. 
-Total leucocyte count and differentiation of leucocytes. 
-Eosinophilic leucocyte counts. 
Citrate for sedimentation rate and EDTA for eosinophilic leucocyte 
counts were added to venous blood samples, which were taken between 9 
and 10 a.m. Subjects were not under basal conditions at the time of 
blood collection. Once in 4 weeks the laboratory procedures were 
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routinely performed in combination with blood sampling for regular 
serological investigations. 
In case of SRI with severe symptoms and/or physical diagnostic signs 
of pulmonary infiltration, a frontal chest rOntgenogram was made and 
compared to previous X-ray photographs. Furthermore, from January I, 
1977 until April 1, 1978 a rOntgenogram of the thorax was a standard 
procedure in the course of an SRI. 
7-4 Influenza vaccination 
After detailed information with regard to influenza vaccination as well 
as the purposes of the study had been given to all participants, pa-
tients were left free to chose for or against vaccination. If urgent 
indication for vaccination was present in the opinion of t.he medical 
attendant, patients were strongly advised to have themselves vaccinated. 
Decisions with respect to vaccination in children were taken in consul-
tation with their parents whenever possible. 
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CHAPTER 8 
RESULTS FOR LIVING-GROUPS A, B, AND C 
8-I Introduction 
From an epidemiological point of view it is of interest to look at the 
clinical and serological results in groups of patients divided accor-
ding to living-units. Thus, in this chapter, a survey of the various 
periods of infection will be given separately for the groups A C'Se-
nioren"), B ("Junioren"), and C ("Vossen 11 ). Frequencies of respiratory 
infection are compared and effects on symptoms and signs of CNSLD will 
be estimated. The clinical picture of symptomatic respiratory infection 
(SRI), defined according to criteria mentioned in chapter 7-3-1, serves 
as a guideline throughout this chapter and the next ones. Furthermore, 
special attention will be given to periods in which seroconversion was 
found without obvious symptoms of respiratory infection. 
8-2 Group A - the "Senioren" 
8-2-1 Incidence of respiratory infection 
As was described in chapter 7-2-2, 122 patients of group A took part in 
the study. The duration of participation varied from 1.5 to 17 months 
with an average of 5.9 months. Twelve persons participated in the course 
of 2 different periods, 5 in 3 periods. If a month during which one 
patient was under observation is considered as one patient month, there 
were 720.5 patient months in this group. A total of 127 SRis were regis-
tered in the course of the survey, which is equivalent to approximately 
0.18 SRI per patient month and 2.1 SRI per patient year. SRis were more 
frequently observed during the months of December to April: 0.26 per 
patient month, compared to 0.12 during the remaining months. The number 
of SRis per patient varied from 0 to 5 in accordance with differences 
in duration of participation (Table 8-I). 
In 44 out of 127 episodes of SRI (34.7%) a viral agent was detected 
by means of serological investigations. In the remaining 83 SRis no 
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agent could be identified. Seroconversions to the various agents in the 
course of 44 SRis are listed in Table 8-2. 
Table 8-1 No. of SRis per patient and average study 
period. Group A patients. 
No. of SRis No. of patients Average study period 
(months) 
2-5 34 8.2 
40 6.9 
0 48 4.7 
Table 8-2 Agents involved in 44 periods of SRI, detected 
by fourfold or greater rise in antibody titre. Group A 
patients. 
Agent 
Influenza A virus 
Influenza B virus 
Adenovirus 
Parainfluenza 3 virus 
Influenza A virus + RSV 
Total 
*double infection 
No. of SRis 
with seroconversion 
29 
5 
4 
3 
2 
1* 
44 
Fig. 8-1 gives a review of all SRis experienced by group A patients 
in the course of the study. 
In addition to the significant rises in titres found in SRI, 23 sere-
conversions were noted by means of routine investigations performed 
every 4 weeks. Agents involved are summarized in Table 8-3. In 15 of 
these cases the time of infection could be traced because of clinical 
symptoms too mild to exceed the threshold set for SRI, while in 6 sere-
conversions there were no symptoms of respiratory infection at all. 
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Fig, 8-1 Periods of SRI with results of serological and gram stain investigations in group A 
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Fig. 8-2 summarizes the 23 seroconversions without SRI, wheras Fig. 
8-3 (Appendix II) shows all episodes of interest, experienced by the 
individual subjects in the periods in which they participated in the 
study. 
According to clinical and serological data~ three different groups 
were formed, the results of which will be discussed separately. 
Table 8-3 No. of seroconversions to various 
agents, without the occurrence of SRI in 
group A patients 
Agent No. of 
Influenza A virus 
RSV 
Influenza B virus 
Parainfluenza 3 virus 
Total 
8-2-2 SRI of proven viral origin 
8-2-2-1 Clinical data 
sera conversions 
10 
9 
2 
2 
23 
In the 44 periods of SRI with positive serology clinical features were 
usually distinct. The average amount of symptoms was somewhat over 6 
and varied from 2 to 11. The minimum threshold of 2 symptoms was regis-
tered in 3 patients only. In 42 of these episodes data regarding body 
temperature were provided. Maximum values in the course of the infect-
ive illnesses are given in Table 8-4. The majority of SRis (76%) were 
accompanied by fever, if a threshold value of 38° C is employed. On 
physical examination 14 patients showed marked signs of upper respira-
tory infection. 
0 Subclinical infection ~ 5 
0 
·~ ~ 4 ~ MRI (mild respiratory infection) 
8 3 
~ [) Clinical data unknown A A 
~2 f:\f-;1 ~ 
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Fig. 8-2 Seroconversions without SRI in group A patients, A= influenza A; B = influenza B; 
RS = respiratory syncytial virus; P3 = parainfluenza 3; + = positive sputum gram stain; ? = yellow/ green sputum, no gram stain made 
" 
" 
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Table 8-4 Highest body temperatures in 
the course of SRI of viral origin in 
group A patients 
Maximum rectal 
temperature (O C) 
<38 
38-39 
39-40 
>40 
Unknown 
Total 
8-2-2-2 Effects on CNSLD parameters 
No. of SRis 
10 
13 
15 
4 
2 
44 
In the course of 44 viral SRis, exacerbation was noticed in 38 (86%). 
A bronchial obstructive pattern could be objectivied by means of daily 
FEV1 measurements in a majority of patients. According to our standards 
(chapter 7-3-2), a .decrease of FEV 1 was registered in 24 subjects. 
Twenty-nine patients complained of increased breathlessness and whee-
zing. Augmented productive coughing was also noticed in 29 SRis. The 
various patterns of scores are summarized in Table 8-5. 
Decrease in FEV1 by 25% or more usually lasted for a relatively short 
period of 2-4 days. In 7 patients a reaction of 5 days or longer was 
noticed. One patient suffering from an adenovirus infection had pro-
longed symptoms of malaise and lassitude and his asthma was poorly con-
trolled for several weeks, whereas a st.eady state existed before the 
SRI. Data of this patient are shown in case report I (Appendix I). Eight 
patients showed relatively severe bronchial obstructive reactions with 
FEV 1 decreasing to less than 50% of the baseline value. Two examples 
are given in case reports 2 and 3 (Appendix I). 
Eight patients were removed to a special unit for more intensive 
medical care and in I 1 subjects corticosteroid treatment was started or 
pre-infection steroid doses were raised. 
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Table 8-5 Patterns of exacerbation in the course of 
SRI with positive serology in group A patients 
FEV1 t Dyspnoea/wheezingt Cough/ sputum t 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
8-2-2-3 Results of sputum gram stains 
15 
5 
2 
2 
7 
2 
5 
6 
44 
In the course of 25 SRis with positive serology yellow or green sputum 
was produced. Material suitable for washing and gram staining was pro-
vided in 20 of these episodes. Seventeen of the gram preparations were 
assessed to be positive, whereas in 3 no bacteria were found. Eighteen 
of the patients produced coloured sputum and did not do so during the 
period preceeding the SRI. Two subjects developed a pneumonia by Sta-
phylococcus aureus following influenza A infection. Antibiotic treatment 
was administered to 83% of the patients with yellow-green sputum, where-
as 45% of the remaining subjects were also treated with antibiotics. 
Results of sputum gram stains are incorporated in Fig. 8-I and in 
Appendix II, Fig. 8-3. 
8-2-2-4 Results of laboratory investigations 
Sedimentation rate, total leucocyte and eosinophilic leucocyte counts 
were made according to the programme in 34 out of the 44 episodes. Sedi-
mentation rates showed a distinct increase of at least 15 mm in the 
first and/or second hour in 19 SRis, usually in association with influ-
enza A or bacterial superinfection. In general, total and eosine-
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philic leucocyte counts did not seem to be of much value. Leucocytosis 
of over 10 x 10 9 /1 was observed in 6 cases, whereas obvious leucopenia 
did not occur. Eosinophiles tended to decline in the course of SRI, 
especially when body temperature was high, but data were not consistent 
enough to draw conclusions. 
Chest rOntgenograms were made in 15 episodes of viral SRI. One of 
these showed multiple infiltrative changes associated with infection by 
adenovirus. The rOntgenogram and relevant data are presented in case 
report 1 (Appendix I). 
8-2-3 SRI without positive serology 
8-2-3-1 Clinical data 
In 83 periods of SRI no causative agent could be identified by means of 
serological tests. The clinical picture of respiratory infection was 
usually obvious, as in viral SRI, the average amount of symptoms being 
almost 7, varying between 2 and 12. Only 2 patients had the minimum of 
2 symptoms. Rectal body temperature data were handed in by the patients 
in 78 instances. Maximum values were 38° C or more in the course of 42 
SRis (54%). Data are summarized in Table 8-6. 
Table 8-6 Highest body temperature in 
the course of SRI without positive 
serology in group A patients 
Maximum rectal No. of SRis 
temperature (OC) 
<38 36 
38-39 24 
39-40 17 
>40 
Unknown 5 
Total 83 
81 
8-2-3-2 Effects on CNSLD parameters 
In the course of 2 SRis without positive serology data were insufficienL 
to draw any conclusions. In the remaining 81 an association with exa-
cerbation of the obstructive disease was found in 53 (65%). Dyspnoea 
and wheezing increased in 38 patients and cough and sputum in 37~where­
as significant decline of FEV1 was noted in fewer patients, namely 25. 
Various combinations of parameters are shown in Table 8-7. 
Table 8-7 Patterns of exacerbation in the course of 
SRI without positive serology in group A patients 
FEV1 t Dyspnoea/wheezingt Cough/sputumt 
+ + + 12 
+ + 7 
+ + 2 
+ 4 
+ + !4 
+ 5 
+ 9 
28 
Inconclusive Inconclusive Inconclusive 2 
Total 83 
Presence of fever did not influence the exacerbation rate: 23 out of 
36 SRis without fever (64%) and 26 out of 40 periods accompanied by 
fever (65%) were related to exacerbation~ 
Serious obstructive reactions with FEV1 decreasing by over 50% were 
seen in 8 SRis. One example of these in shown in case report 4 (Appen-
dix I). Patients in whom increased bronchial obstruction could be con-
firmed by FEV1 measurements usually had reductions of FEV 1 of short 
duration. Fifteen decreases in FEV1 lasted for 2 or 3 days, whereas 4 
prolonged reactions of at least 7 days were observed~ In 2 subjects a 
stationary situation was thrown out of balance in the course of SRI. 
One. of these, a 61-year-old asthmatic female patient, never returned to 
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her pre-infection condition and required significantly more. bronchodi-
lating drugs than before SRI. Some of the data of this patient are shown 
in case report 5 (Appendix I). In all other participants with exacerba-
tions, symptoms subsided without problems and no long term effects were 
observed. 
8-2-3-3 Results of sputum gram stains 
Yellow or green sputum was produced in the course of 41 of the SRl~ v£ 
unknown origin. Suitable samples were handed in by patients in 34 in-
stances. Thirty-one of the gram-stained preparations were positive, 
whereas in 3 no bacteria were detected. Data are incorporated in Fig.S-1 
and in Appendix II, Fig. 8-3. 
On the base of clinical, bacteriological and laboratory findings an 
attempt was made to separate the SRis that were thought to be of prima-
rily bacterial origin. In 9 cases there were relatively few upper respi-
ratory tract symptoms, considerable increases in sedimentation rate and/ 
or leucocytosis. Yellow-greenish sputum was produced following a period 
of increased bronchial obstruction for other than infectious reasons in 
6 of these SRis. Two subjects showed the interesting phenomenon of in-
creased bronchial obstruction following influenza vaccination, compli-
cated by bacterial infection. One example is given in case report 6 
(Appendix I). 
Although bronchial obstruction usually preceeded infected sputum, FEV1 
tended to decrease further in a number of episodes. In 7 of the SRis, 
presumably of bacterial origin, serious obstructive reactions with dis-
tinct effects on FEV1 were noted. Case report 7 (Appendix I) shows one 
of these. 
Antibiotics were given to 32 of the subjects producing yellow or green 
sputum. Furthermore, 9 of the remaining patients received antibiotic 
treatment. 
8-2-3-4 Results of laboratory investigations 
Investigations with regard to sedimentation rate, total and eosinophilic 
leucocyte counts were done at least twice in the course of 75 SRis. As 
with SRI of viral origin, data were precarious and did not allow definite 
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conclusions. 
Sedimentation rates showed increases of at least 15 rom in 20 periods, 
8 of these being referred to as primarily bacterial. Leucocytosis of 
over 10 x 109 /1 was noted in II episodes, 5 of which were considered to 
be of bacterial origin. On one occasion only, laboratory results were 
used as a diagnostic tool. In the course of an apparent respiratory 
infection a considerable increase of eosinophilic leucocytes was found, 
despite rectal body temperature of over 39° C. Moreover, pulmonary 
shadows were seen on the chest rOntgenogram (see case report 8, Appen-
dix I). These findings, together with relief of complaints at the in-
stitution of corticosteroids made the diagnosis eosinophilic pneumonia 
plausible. 
Frontal rOntgen photographs of the thorax were made in 42 periods of 
SRI. Infiltrative changes were found on 3 occasions~ including theabove 
mentioned episode of eosinophilic pneumonia. 
8-2-4 Seroconversions without SRI 
8-2-4-1 Clinical data 
At the routine serological examinations 23 rises in titre were found, 
while in the relevant period no SRI occurred, according to our criteria. 
Fifteen subjects turned out to have experienced mild respiratory symp-
toms during the period in which seroconversion was noted~ Usually only 
one symptom of infection was positive or two were, but had a very mild 
character. These episodes were named ,.mild respiratory infection" (MRI). 
One patient had slight malaise 
rectal body temperature of 39° 
complaints associated with an elevated 
C for one day. In 
measured body temperature, values did not exceed 
4 other subjects who 
38° C. Four persons 
produced yellow-green sputum in. the course of MRI. Gram stains were 
made of 2 specimens, both of which were positive. Six infections passed 
off without clinical symptoms at all and were called "subclinical 
infections". In 2 patients clinical data were insufficiently noted, 
because they were not under observation at the relevant time. 
Because SRI was not supposed to be present, laboratory and rOntgeno-
logic examinations were not undertaken in the majority of instances. 
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8-2-4-2 Effects on CNSLD parameters 
The various scores for CNSLD parameters in 15 MRis and 6 subclinical 
infections are summarized in Table 8-8. Subclinical infections did not 
cause any exacerbation of CNSLD, whereas MRI was associated with flare-
ups in 6 out of 15 episodes (40%). Two patients had reactions in FEV1 
of at least 25% for 2 or more days, whereas another subject had decrea-
ses of 26 and 23% on 2 consecutive days, because of which corticoste-
roids were raised. On the base of retrospective data, exacerbation was 
suspected in both patients whose clinical data were unknown. 
Table 8-8 Patterns of exacerbation in seroconversion without SRI 
in group A patients 
FEV!t Dyspnoea/wheezin~ Cough/ sputumf MRI Sul:lclinical 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 3 
9 6 
Total 15 6 
8-3 Group B - the "Junioren" 
8-3-1 Incidence of respiratory infection 
Of group B, 71 patients participated in the study (see chapter 7-2-2 for de-
tails). The average study period for these subjects was 8. 7 months, varying 
from 1.5 to 20.5 months. Six patients were involved in the survey twice. 
There were a total of 616.5 patient months, in which 98 SRis occurred, 
yielding a frequency of 0.16 SRI per patient month and of 1.9 SRI per 
patient year. The frequency in the months of December, January, Febru-
ary, and March was 0.22 compared to 0.13 per patient month in there-
maining months. The number of symptomatic infections per person ranged 
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from 0 to 4, related to duration of participation in the study, as is 
shown in Table 8-9. 
Table 8-9 No. of SRis per patient and average study 
period. Group B patients 
No. of SRis No. of patients Average study period 
(months) 
2-4 30 10.2 
26 8.9 
0 15 5.3 
In 27 out of 98 SRis (28%) significant rises in titre were detected by 
means of serological investigations; only 2 different agents were in-
volved, as shown in Table 8-10. A survey of all episodes of SRI is given 
in Fig. 8-4. 
Table 8-10 Agents involved in 27 periods of SRI, detected 
by fourfold or greater rise in antibody titre. Group B 
patients 
Agent 
Influenza A virus 
Parainfluenza 3 virus 
Total 
No. of SRis 
with seroconversion 
21 
6 
27 
In addition to the seroconversions found in SRI, 23 significant rises 
in antibodies to various agents, including 2 double ones were noted at 
the routine serological investigations. Results are shown in Table 8-11. 
In 12 of these patients an MRI could be shown to have occurred,where-
as 7 subclinical infections were ~oted. In 2 periods clinical data were 
insufficiently collected, because subjects were out of observation. Data 
are summarized in Fig. 8-5. A survey of all relevant episodes per subject 
is given in Fig. 8-6 (Appendix II). 
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Table 8-11 No. of seroconversions to various agents, 
without the occurrence of SRI in group B patients 
Agent 
Influenza A virus 
Parainfluenza 3 virus 
RSV 
MYeopZasma pneumoniae 
RSV + Chlamydia psittaei 
RSV + parainfluenza 3 virus 
Total 
*double infection 
8-3-2 SRI of proven viral origin 
8-3-2-1 Clinical data 
No. of 
sera conversions 
I I 
5 
2 
23 
In the course of the SRiswith positive serology, clinical features were-
~n general distinct but slightly milder than in group A. An average 
amount of 5 symptoms were present, varying from 2 to 10. The minimum of 
2 symptoms were noted once. Twenty-four patients measured rectal body 
temperature and IS of them (75%) showed values of at least 38° C. Data 
are shown in Table 8-12. On physical examination 11 subjects showed 
marked signs of upper respiratory tract infection. 
Table 8-12 Highest body temperatures in the course 
of SRI of viral origin in group B patien~s 
Maximum rectal No. of SRis 
temperature (0 C) 
<38 6 
38-39 7 
39-40 9 
>40 2 
Unknown 3 
Total 27 
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8-3-2-2 Effects on CNSLD parameters 
Of 27 infections with positive serology 20 (74%) were associated with 
exacerbation, according to the criteria mentioned in chapter 7-3-2. 
Distinct bronchoconstrictive patterns were frequently noted: 17 subjects 
had decreases in FEV1, but only 11 of them complained of increased dys-
pnoea and wheezing. Increase in productive coughing was observed in 14 
SRis and Was the only factor accounting for exacerbation in 3 of these. 
Detailed data are presented in Table 8-13. 
Table 8-13 Patterns of exacerbation in the course of 
SRI with positive serology in group B patients 
FEVI t Dyspnoea/wheezingt Cough/ sputum t 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
7 
4 
4 
2 
3 
7 
27 
Obstructive reactions were relatively severe with FEV1 decreasing by 
over SO% in 8 subjects. Two examples are given in case reports 9 and 10 
(Appendix I). In 10 SRis FEV1 returned to baseline values within 4 days, 
whereas 7 reactions of at least 5 days were observed. Two prolonged 
reactions were seen in the course of parainfluenza 3 infections (see 
case report 11, Appendix I, for one example), but no real long-term 
effects were noted. 
Two patients suffering from influenza A infection were taken to a 
special care station, whereas one patient, in spite of medical instruc-
:ions, travelled to Holland in the course of an influenza A infection 
and was admitted to hospital there. To one subject a single dose of 
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tetracosactide depot was administered and in 3 patients who were on 
corticosteroids, doses had to be raised. 
8-3-2-3 Results of sputum gram stains 
Coloured sputum, suspected of bacterial infection, was coughed up by 13 
patients in the course of an SRI. Nine sputum samples were handed in and 
g!am stained, and all of these turned out to be positive (Fig. 8-4 and 
Appendix II, Fig. 8-6). In the remaining 4 cases, sputum was either not 
collected or unsuitable for preparation. Increased obstruction was fre-
quently associated with bacterial infection, namely in 11 instances. 
Changes in sputum colour were preceeded by obstruction in 7 patients, 
one of whom is described in case report 12 (Appendix I). Six patients 
received antibiotic treatment. 
8-3-2-4 Results of laboratory investigations 
Laboratory parameters were sufficiently established in 22 patients. 
Eleven of them showed increases of sedimentation rates of over 1.5 mm, 
whereas leucocytosis of over 10 x 10 9 /1 was observed in 5 subjects. 
Marked eosinopenia in the course of SRI was noted in 10 patients and 
occurred in the presence of fever only. No further correlations between 
clinical data and laboratory investigationswerefound. Chest rOntgeno-
grams were manufactured of 6 patients. No infiltrative changes were 
observed. 
8-3-3 SRI without positive serology 
8-3-3-1 Clinical data 
SRis in which serology remained negative were, as in group A, usually 
associated with marked symptomatology. An average of over 6 symptoms 
werenoted, the minimum of 2 being registered only twice. Sixty-seven 
subjects presented body temperature data; of these patients 41 (61%) 
had maximum values of at least 38° C. Table 8-14 summarizes results of 
rectal temperatures. 
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Table 8-14 Highest body temperatures in the 
course of SRI without Positive serology in 
group B patients 
Maximum rectal 
temperature (O C) 
<38 
38-39 
39-40 
>40 
Unknown 
Total 
8-3-3-2 Effects on CNSLD parameters 
No. of SRis 
26 
31 
9 
4 
71 
A considerable part of SRis could be related to exacerbation of CNSLD. 
A total of 50 flare-ups were observed in the course of 71 episodes of 
SRI (70%). Exacerbation was associated with decreasing FEV1 in 27 in-
stances, whereas increases in dyspnoea/wheezing and cough/sputum were 
reported by 28 and 32 subjects, respectively. Augmentation of cough and 
sputum alone accounted for 13 exacerbations. Data are listed in Table 8-15. 
Table 8-15 Patterqs of exacerbation in the course of 
SRI without positive serology in group B patients 
FEV 1 ~ Dyspnoea/wheezingt 
+ + 
+ + 
+ 
+ 
+ 
+ 
Total 
Cough/ sputum t 
+ 
+ 
+ 
+ 
II 
7 
5 
4 
3 
7 
13 
21 
71 
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Fever was not related to exacerbation; of 26 SRis without fever, 18 
(69%) were associated with exacerbation, whereas this was true for 28 
out of 41 SRis (68%) with body temperatures of over 38° C. Severe asth-
matic reactions were frequently observed. During 15 SRis, FEV1 decreas-
ed by 50% or more, no matter whether the reaction was of short, inter-
mediate, or long duration. Examples are given in case reports 13 and 
14 (Appendix I). 
Reactions lasted for 2 or 3 days in 13 subjects, for 4 or 5 days in 
5, and for one week or longer in 9. One female patient showed a pro-
longed reaction of a few weeks, but finally FEV1 returned to pre-
infection levels (case report 15, Appendix I). 
8-3-3-3 Results of sputum gram stains 
Forty-six subjects notified that yellow or green sputum was produced 
in the course of SRI. Acceptable samples were obtained in 39 cases, the 
gram stains of which were positive in 35 and negative in 4. Data are 
incorporated in Fig. 8-4 and in Appendix II, Fig. 8-6. 
As in group A, an attempt was made to select periods that were pro-
bably due to bacterial infection alone. Using clinical, bacteriological, 
and laboratory data, 9 episodes were supposed to be of bacterial origin 
without being triggered by unidentified viral agents. Again it was 
found that bacterial infection frequently occurred following periods of 
increased bronchial obstruction, be it related to possible viral in-
fections or not. Eighteen of the periods with yellow-green sputum were 
preceeded by augmented obstruction. Case report 16 (Appendix I) shows 
an example. Sixteen patients received antibiotic treatment in the course 
of SRI without positive serology. 
8-3-3-4 Results of laboratory investigations 
Laboratory results could be sufficiently obtained in 59 patients. In-
creases in sedimentation rate and leucocytosis were observed in 21 and 
15 subjects, respectively, usually in association with bacterial sputum 
infection. Marked reduction in eosinophilic leucocytes occurred in 6 
SRis only. 
ROntgen photographs of the chest were made in 36 instances, one of 
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which revealed pulmonary infiltrative abnormalities • 
8-3-4 Seroconversions without SRI 
8-3-4-l Clinical data 
As reported in chapter 8-3-I seroconversion to various agents without 
the occurrence of SRI was detected on 23 occasions, including 2 double 
rises in titre. MRI was notified in 12 subjects. Symptoms were always 
too few and/or too short-lasting to exceed the threshold, set for SRI. 
One patient had a rectal body temperature of 38° C, all other subjects 
did not supply data with regard to fever. 
Seven infections were regarded as subclinical because of the absence 
of any upper respiratory symptoms, whereas in 2 patients clinical data 
remained unknown, as they were not under observation in the relevant 
period. 
8-3-4-2 Effects on CNSLD parameters 
Combinations of scores for MRI and subclinical infections are presented 
in Table 8-16. Five out of 12 MRis (42%) were related to exacerbation, 
4 of these in association with changes in FEV 1. Two distinct asthmatic 
reactions in the course of influenza A and parainfluenza 3 infection 
Table 8-16 Patterns of exacerbation in seroconversion without 
SRI in group B patients 
FEVI Dyspnoea/wheezing Cough/sputum MRI Subclinical 
+ + + 
+ + 
+ + 
+ 2 
+ + 
+ 
+ 
7 5 
Total 12 7 
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are shown in case reports 17 and 18 (Appendix I), respectively. Long-
term effects were not noted. 
Subclinical infection connected with exacerbation was observed twice 
(29%). MYcoplasma pneumoniae and RSV were associated with productive 
coughing, the latter of green sputum, of which no gram stain was made. 
The patient with seroconversion to RSV had a slight increase of obstruc-
tion as well, but decline in FEV1 was insufficient to exceed threshold 
value, namely 16 and 27% on 2 consecutive days. 
8-4 .Group C - the "Vossen"* 
8-4-1 Incidence of respiratory infection 
Of the 32 children belonging to group C, the average duration of parti-
cipation in the study was 14.5 months, varying from 3.5 to 30.5 months. 
None of the subjects took part in the study more than once. A total of 
465 patient months was noted, in which 59 SRis occurred. This is equi-
valent to a respiratory infection frequency of 0.13 per patient .month 
and 1.5 per patient year. SRI was only slightly more frequent in the 
months of December to April: 0.15 per patient month, compared to 0.11 
during the remaining months. 
The number of infection periods per subject varied strongly, namely 
from 0 to 7, and was related to the duration of the study period, as is 
shown in Table 8-17. 
Table 8-17 No. of SRis per patient and average study 
period. Group C patients 
No. of SRis No. of patients Average study period 
(months) 
4-7 4 27.5 
2-3 13 17.5 
0-1 15 8.5 
*Part of this chapter will be published in the European Journal of 
Respiratory Diseases (A.C.Roldaan & N.Masurel) 
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In 19 out of 59 SRis (32%) a viral causative agent was detected sero-
logically. Of the remaining 40 episodes a pharyngitis by S-haemolytic 
group A streptococci was noticed in 5, whereas in 35 no agent could be 
identified. Various viral agents and !1ycoplasmapneumoniae detected in the 
course of SRI are listed in Table 8-18. 
Furthermore, 29 periods with a total of 31 seroconversions were found 
in routine serological investigations, performed every 4 weeks. The 
agents involved are presented in Table 8-19. 
Table 8-18 Agents involved in 19 periods of SRI,detected by 
fourfold or greater rise in antibody titre. Group C patients 
Agent 
Influenza A virus 
Influenza B virus 
Parainfluenza I virus 
RSV 
MYcoplasma pneumoniae 
Total 
No. of SRis 
with seroconversion 
13 
3 
19 
Table 8-I 9 No. of ·seroconversions to various agents:o 
without the occurrence of SRI. Group C patients 
Agent 
Influenza A virus 
Parainfluenza 3 virus 
Influenza B virus 
Adenovirus 
RSV 
Chlamydia psittaci 
M.pneumoniae + parainfluenza 3 virus 
Influenza A virus + RSV 
Total 
·*double infection 
No. of 
seroconversions 
I 0 
8 
4 
2 
2 
31 
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On 12 occasions mild respiratory symptoms were shown to haveoccurred 7 
whereas 9 infections passed off without any symptoms. Ten rises in anti-
body titre, including the 2 double ones, were noted in periods during 
which children were not under observation because they spent their 
school holidays with their families. Fig. 8-7 and Fig. 8-8 show SRis 
and seroconversions without SRI, respectively, whereas Fig. 8-9 (Appen-
dix II) lists all relevant episodes per subject. 
8-4-2 SRI of proven viral origin 
8-4-2-1 Clinical data 
During the 19 periods of SRI with positive serology, clinical features 
again were generally distinct. The minimum of 2 symptoms was found 
only twice and the average amount of symptoms was 6. Eighteen subjects 
registered body temperature correctly, with the following results 
(Table 8-20). 
Table 8-20 Highest body temperatures in the course 
of SRI of viral origin in group C patients 
Maximum rectal 
temperature (O C) 
<38 
38-39 
39-40 
>40 
Unknown 
Total 
No. of SRis 
0 
6 
8 
4 
19 
All children had fever in the course of viral SRL Nine patients had 
distinct signs of upper respiratory tract infection on physical examination. 
8-4-2-2 Effects on CNSLD parameters 
Of all viral SRis in this group, in 1 influenza B infection data were 
insufficiently collected to draw any conclusions. The remaining 18 epi-
sodes were associated with exacerbation in 16 instances (89%). Twelve 
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patients showed significant decreases in FEV1, whereas only 7 complained 
of increased dyspnoea and wheezing. Furthermore, 12 subjects experienced 
augmented scores for cough/sputum. Data are summarized in Table 8-21. 
Table 8-21 Patterns of exacerbation in the course of 
SRI with positive serology in group C patients 
Dyspnoea/wheezingf Cough/sputumt 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Inconclusive 
Total 
4 
2 
4 
2 
3 
2 
19 
Serious asthmatic attacks accompanied by decrease in FEV1 of over 50% 
were noticed in 9 patients. Some striking examples are shown in case 
reports 19 and 20 (Appendix I). In 6 children FEV1 was reduced by at 
least 25% for 2 or 3 days, whereas in the remaining 6 the reactions 
lasted from 5-9 days. The most persistent reaction was seen in the pa-
tient suffering from MYcoplasma pneumoniae infection, who had only minor 
upper respiratory complaints (case report 21, Appendix I). Long-term 
effects were not observed in any of the episodes. In 2 patients ACTH or 
corticosteroids had to be given in the course of 4 SRis. 
8-4-2-3 Results of sputum gram stains 
In the course of 13 episodes yellow or green sputum was produced. Sam-
ples could be obtained in 11 of these, the gram stains of which all 
turned out to be positive. Results are incorporated in Fig. 8-7 and in 
Appendix II, Fig. 8-9. 
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Positive gram stains were associated with obstruction on 8. occasions. 
One patient with bronchiectatic deformations in his middle and right 
upper lobe repeatedly developed severe pulmonary infiltrations in viral 
infection as well as in SRI without positive serology. One of these 
episodes is shown in case report 22 (Appendix I). 
Antibiotic treatment was started in the course of 9 SRis, including 
tetracyclins in the MYcoplasma pneumoniae infection, although sputum 
was not coloured. 
8-4-2-4 Results of laboratory investigations 
Laboratory data could satisfactorily be collected in 15 instances. While 
leucocytosis of over 10 x 10 9 /1 was infrequent, namely in 2 patients, 
increased sedimentation rates and marked falls in eosinophilic leuco-
cytes were observed in 12 and 11 patients, respectively. 
Chest rOntgenograms were made in 9 SRis. The above mentioned boy had 
severe infiltrative changes during 3 periods of viral SRI, whereas 
rOntgenograms were negative in the remaining instances. 
8-4-3 SRI without positive serology 
8-4-3-1 Clinical data 
Forty episodes of SRI occurred in which serological investigations did 
not show any rise in titre. Symptoms of SRI were again obvious, with an 
average amount of 6, ranging from 3 to 11. Body temperature was recorded 
on 37 occasions. Data are given in Table 8-22. 
Table 8-22 Highest body temperature in the course of· 
SRI without positive serology in group C patients 
Maximum rectal temperature (oC) 
<38 
38-39 
39-40 
>40 
Unknown 
Total 
No. of SRis 
10 
15 
10 
2 
3 
40 
I 01 
Fever was present in 27 subjects (73%). Five children presented with 
symptoms and signs of serious pharyngitis, accompanied by pus in ton-
sillar crypts and enlargement of cervical lymphnodes. Body temperatures 
ranged from 37.9° to 39° C. Bacteriological investigations yielded posi-
tive results for e-haemolytic group A streptococci. 
8-4-3-2 Effects on CNSLD parameters 
Before rating the scores for CNSLD, SRis by haemolytic streptococciwere 
separated. None of the streptococcal pharyngitis episodes caused any 
asthmatic reaction and FEV1 values were remarkably consistent. Case 
report 23 (Appendix I) shows one of these instances. 
In the remaining 35 SRis exacerbation was noted in 23 (66%). Fourteen 
significant declines of FEV1 were observed. Thirteen patients complain-
ed of increased breathlessness and wheezing, whereas 18 children men-
tioned augmented coughing and sputum production. Table 8-23 summarizes 
these results. 
Table 8-23 Patterns of exacerbation in the course 
SRI without positive serology in group C patients 
FEV1 + Dyspnoea/wheezingt Cough/ sputum t 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
of 
7 
3 
3 
2 
6 
12 
35 
Eight severe reactions with FEV1 decreasing to less than 50% of the 
baseline values were noted. Case report 24 (Appendix I) shows one of 
these. Obstructive exacerbations usually were of short duration: FEV1 
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returned to pre-infection levels within 4 days in 10 children, whereas 
reactions of about one week were observed 4 times. 
8-4-3-3 Results of sputum gram stains 
Sixteen periods were associated with yellow or green sputum. Suitable 
material was handed in by 14 children. Thirteen gram stains came out 
positive. Infections were judged to be of bacterial origin solely in 6 
instances. Four of these were preceeded by periods of increased asthma-
tic symptoms (see case report 25, Appendix I, for an example). 
Results of gram preparations are incorporated in Fig. 8-7 and in 
Appendix II, Fig. 8-9. 
8-4-3-4 Results of laboratory investigations 
In case of streptococcal pharyngitis, SRI was associated with remarkable 
increases in erythrocyte sedimentation rates and leucocytosis in all 
subjects. Two patients with streptococcal infections showed distinct 
declines in eosinophilic leucocytes. 
Of the remaining 35 SRis data could be collected according to pro-
gramme in 32. Ten children had increases of over 15 mm in sedimentation 
rate, whereas leucocytosis was observed in 4 and eosinopenia in 5 sub-
jects. Data were suggestive for leucopenia in some patients, but the 
results were not consistent enough to draw conclusions. 
ROntgen photographs of the chest were made in the course of 20 SRis. 
The boy with repeated infiltra~ions showed a marked pulmonary shadow 
again on one occasion, all other X-rays were without abnormalities. 
8-4-4 Seroconversions without SRI 
8-4-4-l Clinical data 
Out of 31 seroconversions detected by routine serological examinations, 
12 were related to MRI. Symptoms were too few or too short-lasting to 
exceed the threshold set for SRI in all but one patient, who on review-
ing clinical data could have been regarded as having SRI, but 2 symp-
toms were present in a mild degree only. Another child had unexplained 
fever without obvious respiratory symptoms and turned out to have been 
infected by influenza A virus. Nine infections occurred without any 
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symptoms. In the remaining 8 episodes of 10 seroconversions (2 double 
ones were noted), patients spent their holidays outside the clinic, 
usually in Holland. Retrospective anamnestic data revealed features of 
SRI in 3 of them and were negative in this respect in 2, whereas doubt-
ful history was given in the remaining subjects. 
8-4-4-2 Effects on CNSLD parameters 
Scores for MRI and subclinical infections are given in Table 8-24. 
Table 8-24 Patterns of exacerbation in seroconversion without 
SRI in group C patients 
Dyspnoea/wheezingt Cough/sputumt ~I Subclinical 
+ + + 
+ + 
+ + 
+ 2 
+ + 
+ 
+ 
8 7 
Total 12 9 
Four exacerbations occurred in the course of 12 MRis (33%), 2 of these 
associated with serious asthmatic reactions. Malaise was present, but 
any upper respiratory symptoms were not noted. Influenza A and adeno-
virus were detected serologicaily (case reports 26 and 27, Appendix I). 
Asthmatic reactions also occurred in 2 seroconversions in which symptoms 
were completely absent (22%) . One interesting example of subclinical 
influenza A infection associated with severe asthmatic signs is given 
in case report 28 (Appendix I). 
Although data were hardly registered during school vacations, when 
children were out of observation, retrospective information was useful 
in some instances. In the course of 8 outclinic episodes related to 
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seroconversion, 5 exacerbations were reported with certainty (63%). In 
2 of these anamnestic data could be confirmed by FEV1 measurements, 
which were made accidentally. Data are shown in Table 8-25 as complete 
as possible. 
Table 8-25 Anamnestic data in the course of seroconver-
sion in group C patients during outclinic periods 
Infection with 
Parainfluenza 3 virus 
Parainfluenza 3 virus 
Parainfluenza 3 virus 
Influenza A virus + RSV 
M.pnewn. + parainfl-3 virus 
RSV 
Chhunydia psittae{ 
Parainfluenza 3 virus 
8-5 Combination of data 
SRI Exacerbation 
? + 
? 
+ + 
+ 
? 
+ 
If data are combined, the following results are obtained: 
1. A total number of 225 CNSLD patients were followed for 1802 patient 
months. 
2. Subjects experienced 284 periods of SRI, defined according to cri-
teria, as described in chapter 7-3-1. This stands for an SRI fre-
quency of 0.16 per patient month and 1.9 per patient year. 
3. In the course of 90 out of 284 SRis (32%) significant rises in anti-
body titre to various viral agents as well as MYcoplasma pneumoniae 
were detected. 
4. Routine serological investigations performed every 4 weeks revealed 
ano~her 81 seroconversions including 4 double ones. Of these, 39 
could be related to MRI, whereas 22 were regarded as subclinical 
infections. The remaining conversions occurred while the relevant 
subjects were not under observation. 
5. SRI of proven viral origin was associated with exacerbation of CNSLD, 
defined according to criteria in chapter 7-3-2, in 74 out of 89 
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periods (83%) in which data could be collected satisfactorily. 
6. SRI without positive serology was related to exacerbation in 126 out 
of 192 episodes (66%). 
7. In the· course of se.roconversion in which MRI occurred, exacerbation 
was noted on 15 out of 39 occasions (38%), whereas flare-ups were 
observed in 4 out of 22 periods of subclinical infection (18%). 
8. Features were various with regard to exacerbation. Different combi-
nations of increase in dyspnoea/wheezing and cough/sputum and/or 
decline in FEV1 were observed. Results are summarized in Tables 8-26, 
8-27, and 8-28. 
Table 8-26 Patterns of exacerbation in the course of 
SRI with positive serology. All patients 
Dyspnoea/wheezingf Cough/ sputum t 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Inconclusive 
Total 
26 
II 
10 
6 
8 
2 
II 
15 
90 
106 
Table 8-27 Patterns of exacerbation in the course of 
SRI without positive serology. All patients 
Dyspnoea/wheezingt Cough/sputum t 
+ + + 30 
+ + 17 
+ + 10 
+ 9 
+ + 19 
+ 13 
+ 28 
66 
Inconclusive 2 
Total 194 
Table 8-28 Patterns of exacerbation in seroconversion without SRI. 
All patients 
FEV1t Dyspnoea/wheezingf Cough/sputumf MRI Subclinical 
+ + + 
+ + 2 
+ + 
+ 5 
+ + 
+ 
+ 5 
24 18 
Total 39 22 
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CHAPTER 9 
RESULTS FOR DIFFERENT CLINICAL GROUPS I, II, AND III 
9-1 Introduction 
In order to investigate whether differences with regard to respiratory 
infection exist between the various subpopulations of patients with 
CNSLD,. the results were analysed again after dividing the study group in 
3 subgroups according to clinical picture. The criteria of classifica-
tion are given in chapter 7-2-1. In this chapter special attention will 
be given to the incidence of respiratory infection, the effects onCNSLD 
parameters, and the occurrence of bacterial sputum infection. The results 
are presented for group I (asthma), group II (asthma and chronic airflow 
obstruction (CAO)), and group III (CAO) separately and compared after-
wards. 
9-2 Group I - Asthma 
9-2-I Incidence of respiratory infection 
By far most patients of the population studied were classified into 
group I, i.e. 128. These subjects participated in the study for a total 
of 1066 patient months, which stands for an average of 8.3 months per 
person. 
A total of 158 periods of SRI were noted, yielding an incidence of 
0.15 SRI per patient month for this group. Forty-five episodes of SRI 
were accompanied by significant rises in antibody titre to one or more 
of the agents tested (28%). The agents involved are described in Table 
9-J. 
In the remaining 113 episodes, serology remained negative. In addi-
tion, 51 seroconversions including 3 double ones, were detected in 
group I patients without the occurrence of SRI or in the absence of 
known clinical data. This equalizes to 0.05 seroconversions without SRI 
per patient month. In 24 instances seroconversion could be related to 
mild respiratory infection (MRI), whereas 15 subclinical infections and 
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9 periods of unknown clinical data were noted. The agents detected by 
routine serology are listed in Table 9-2. 
Table 9-1 Agents involved in 45 periods of SRI detected by 
fourfold or greater rise in antibody titre. Group I patients 
Agent 
Influenza A virus 
Influenza B virus 
Parainfluenza 3 virus 
Parainfluenza virus 
RSV 
My cop Zasma pnewnoniae 
Total 
No. of SRis 
with seroconversion 
33 
5 
4 
45 
Table 9-2 No. of seroconversions to various agents without the 
occurrence of SRI in group I patients 
Agent 
MRI 
Influenza A virus 11 
Parainfluenza 3 virus 6 
RSV 5 
Influenza B virus 
Adenovirus 
RSV + parain£1.3 virus 
RSV + ChZam.psittaci 
M.pneum.+ parain£1.3 
Total 
*double infection 
24 
No. of seroconversions 
Subclinical Clinical 
infection 
7 
2 
3 
I* 
16 
data 
unknown 
2 
4 
I* 
I* 
II 
Total 
20 
II 
8 
4 
2 
I* 
I* 
* I 
51 
9-2-2 Effects on CNSLD parameters 
9-2-2-1 SRI with positive serology 
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Of the 45 relevant periods, data with regard to the course of CNSLD could 
be collected satisfactorily in 44. Exacerbation was noted in 37 instan-
ces (84%). Significant decrease in FEV 1 was observed in 32 out of 44 
episodes (73%). Augmentation of dyspnoea/wheezing and cough/sputum was 
registered. in 20 (45%) and 25 (57%) periods, respectively. Different 
combinations are shown in Table 9-3. 
Table 9-3 Patterns of exacerbation in the course of 
SRI with positive serology in group I patients 
Dyspnoea/wheezingf Cough/sputum t 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Unknown 
Total 
II 
7 
9 
5 
2 
3 
7 
45 
Severe bronchial obstructive reactions with FEV1 decreasing by over 50% 
were observed in the course of 19 of the 44 SRis (43%). Changes of at 
least 25% lasted 4 days or less on 21 and 5 days or more on I I occasions. 
9-2-2-2 SRI without positive serology 
Out of the 113 episodes of SRI in which serological investigationswere 
negative, data could be sufficiently collected in 111. Exacerbation was 
registered on 77 occasions (69%), with decrease of FEV1 in 46 (41%), 
increase in dyspnoea/wheezing in 4] (42%), and augmentation of cough/ 
sputum in 53 (48%) subjects. The various patterns of exacerbatiOn are 
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summarized in Table 9-4. 
Table 9-4 Patterns of exacerbation in the course of 
SRI without positive serology in group I patients 
Dyspnoea/wheezingt Cough/sputumt 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Unknown 
Total 
21 
9 
9 
7 
9 
8 
14 
34 
2 
113 
Asthmatic reactions were accompanied by decline in FEV1 to less than 
50% of the baseline value in 21 periods (19%). Obstructive reactions as 
measured by FEV1 were of 4 days duration or less in 29 cases, and 
longer-lasting in 17. 
9-2-2-3 Seroconversions without SRI 
As was mentioned in chapter 9-2-1, 39 episodes were noted in which an 
MRI or subclinical infection was detected by means of routinely per-
formed serological investigations. Out of 24 MRis, an association with 
exacerbation was observed in 10 instances ~42%), whereas only 2 out of 
15 subclinical infections (13%) coincided with exacerbation during the 
period in which seroconversion occurred. The exacerbations that were 
regis_tered were associated with a decline in FEV1 on 8 occasions, in 6 
of which decreases of more than 50% were noted. Data are summarized in 
Table 9-5. 
Ill 
Table 9-5 Patterns of exacerbation in seroconversion without SRI 
in group I patients 
Dyspnoea/wheezingf Cough/sputumf MRI Subclinical 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
9-2-3 Results of sputum gram stains 
2 
4 
3 
14 
24 
13 
15 
Seventy-one out of 158 periods of SRI (45%), experienced by group I 
patients, were accompanied by the production of yellow-green coloured 
sputum. In the course of SRI with positive serology yellow-green sputum 
was produced in 20 instances (44%). Fifteen samples suitable for wash-
ing and gram staining were collected. All gram stains were assessed to 
be positive. Subjects with SRI of unknown origin notified the product-
ion of coloured sputum 51 times (45%). Forty-three gram stains were 
made, 40 of which were judged positive. Nine SRis were thought to be of 
primarily bacterial origin. 
9-3 Group II - Asthma and chronic airflow obstruction (CAO) 
9-3-I Incidence of respiratory infection 
Sixty-nine subjects were categorized into group II on the base of anam-
nestic and lung function data. They were supposed to have an asthmatic 
background like group I patients, but in almost all of them the bron-
chial obstructive disease had caused more or less irreversible air flow 
limitation. These patients took part in the study for 532 patient months, 
which yields an average participation of 7.7 months. 
Ninety-three SRis were experienced by these patients, which stands for 
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an incidence of 0.17 SRI per patient month. Positive serological results 
were obtained in 36 infection episodes (39%), ~hereas in the remaining 
SRis no significant rises in antibody titre could be found. The agents 
involved in the SRis with positive serology are listed in Table 9-6. 
Table 9-6 Agents involved in 36 periods of SRI detected by 
fourfold or greater rise in antibody titre.Group II patients 
Agent 
Influenza A virus 
RSV 
Parainfluenza 3 virus 
Influenza B virus 
Adenovirus 
Influenza A virus + RSV 
Total 
-x·double infection 
No. of SRis 
with seroconversion 
24 
4 
3 
2 
2 
1* 
36 
Table 9-7 No. of seroconversions to various agents without the 
occurrence of SRI in group II patients 
Agent No. of seroconversions 
Influenza A virus 
Parainfluenza 3 virus 
Influenza B virus 
RSV 
MYcoplasma pneumoniae 
Chlamydia psittaci 
Influenza A virus + RSV 
Total 
*double infection 
MRI 
5 
4 
11 
Subclinical Clinical 
infection 
3 
6 
data 
unknown 
3 
Total 
8 
4 
2 
2 
20 
113 
Furthermore, 20 seroconversions, including a double one, were detected 
by means of routine serological investigations. This corresponds with 
0.04 seroconversion without SRI per patient month. Eleven seroconver-
sions could be related to MRI, whereas 6 infections passed off without 
any clinical symptoms. Three seroconversions, including the double one, 
were found, while the relevant subjects were not under observation. 
Clinical and serological data are summarized in Table 9-7. 
9-3-2 Effects on CNSLD parameters 
9-3-2-I SRI with positive serology 
Viral SRI was associated with exacerbation in 31 out of 36 periods 
(86%). Decrease in FEV1 was registered in 20 subjects (56%), whereas 
increases in dyspnoea/wheezing and cough/sputum were observed in 21 
(58%) and 26 (72%) instances, respectively. Various combinations of 
exacerbations are shown in Table 9-8. 
Table 9-8 Patterns of exacerbation in the course of 
SRI with positive serology in group II patients 
Dyspnoea/wheezingf Cough/ sputumt 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
13 
4 
3 
3 
7 
5 
36 
Marked obstructive reactions, with FEV1 decreasing by at least SO%, were 
noted in the course of 8 viral SRis (22%) in this group. Eleven exacer-
bations involving FEV1 lasted 4 days or shorter, whereas 9 reactions of 
at least 5 days were noted. 
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9-3-2-2 SRI without positive serology 
Group II patients experienced 57 SRis of unknown origin, 34 of which 
could be related to exacerbation of the bronchial obstructive disease 
(60%). Significant changes in FEV 1, dyspnoea/wheezing and cough/sputum 
were present in 18 (32%), 25 (44%), and 22 (39%) patients, respectively in 
different combinations. The patterns of exacerbation are presented in Table 
9-9. Decreases in FEV1 of over 50% were observed 7 times (12%). Twelve 
obstructive reactions were short-lasting, whereas 6 of these lasted for 
5 days or more. 
Table 9-9 Patterns of exacerbation in the course of 
SRI without positive serology in group II patients 
Dyspnoea/wheezingt Cough/ sputum t 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
9-3-2-3 Seroconversions without SRI 
8 
7 
2 
7 
3 
6 
23 
57 
Eleven periods of MRI and 6 subclinical infections were noted in group 
II patients. In case of MRI, 5 exacerbations (45%) were observed, 3 of 
these with significant changes in FEV 1. One subject showed an FEV 1 de-
cline of over 50%. Two out of 6 subclinical infections were associated 
with an increase in symptoms, however, without changes in FEV1. Dataare 
summarized in Table 9-10. 
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Table 9-10 Patterns of exacerbation in seroconversion Yithout SRI 
in group II patients 
Dyspnoea/wheezingt Cough/sputumt 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
9-3-3 Results of sputum gram stains 
MRI 
2 
6 
II 
Subclinical 
4 
6 
Bacterial infection was suspected because of the production of yellow 
or green sputum in 64 out of 93 SRis (69%). Viral symptomatic respira-
tory infection was attended with coloured sputum in 24 instances (67%). 
Nineteen suitable samples were obtained, washed, and coloured; 18 of 
these turned out to be positive. SRI of unknown origin was associated 
with the production of yellow-greenish coloured sputum in 40 of 57 epi-
sodes (70%). Thirty-four sputum gram stains were prepared and 30 of 
these were assessed to be positive. Eight infection periods were thought 
to be of bacterial origin in first instance. 
9-4 Group III - Chronic airflow obstruction (CAO) 
9-4-1 Incidence of respiratorY infection 
Of patients participating in the study, only 28 were suffering from 
conditions characterized by chronic dyspnoea on exertion and largely 
irreversible obstruction of airflow. The term pulmonary emphysema could 
be applied to most of them on clinical, rOntgenologic and pathophysio-
logical grounds. These subjects accounted for 204 patient months, which 
equals an average of 7.3 months of participation per person. Thirty-
three SRis were notified by these patients, yielding an SRI incidence 
116 
of 0.16 per patient month. A viral agent could be detected by means of 
serological investigation in 9 cases (27%), which are summarized in 
Table 9-1 I. 
Table 9-II Agents involved in 9 periods of SRI detected by 
fourfold or greater rise in antibody titre. Group III patients 
Agent 
Influenza A virus 
Parainfluenza 3 virus 
RSV 
Adenovirus 
Total 
No. of SRis 
with seroconversion 
6 
9 
In addition, 6 seroconversions were detected by means of routine blood 
sampling, which equalizes to 0.03 seroconversion without SRI per patient 
month. Four significant rises in titre could be related to MRI, whereas 
one subclinical infection and one period with unknown data occurred. 
Agents involved in these episodes are listed in Table 9-12. 
- :~-s 
T~ble 9-12 No. of seroconversions to various agents without the 
oCCUrrence of SRI in group III patients 
MRI 
I;::~!.;ter;:_~ __ A virus 
.. _, .. .r . .::c ... _s ~·. :.c..:e: 
3 
RSV 
4 
No. of seroconversions 
Subclinical Clinical 
infection data 
unknown 
Total 
3 
3 
6 
9-4-2 Effects on CNSLD parameters 
9-4-2-1 SRI with positive serology 
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Exacerbation was registered in 6 out of 9 viral SRis (67%). An example 
is shown in case report 29 (Appendix I). Increases in dyspnoea/wheezing 
and cough/sputum were both noted in 5 instances (56%), whereas increas-
ed bronchial obstruction could be confirmed by means of FEV1 measure-
ments in one patient (II%) only, in whom a maximum decrease of 42% com-
pared to baseline value was noted. Different reaction patterns are 
shown in Table 9-13. 
Table 9-13 Patterns of exacerbation in the course of 
SRI with positive serology in group III patients 
Dyspnoea/wheezingf Cough/ sputum f 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
9-4-2-2 SRI without positive serology 
3 
3 
9 
Out of 24 SRis of unknown viral origin 15 could be related to exacer-
bation (63%). Dyspnoea/wheezing and cough/sputum were present on 7 (29%) 
and 12 (SO%) occasions, respectively, whereas fall in FEV1 was regis-
tered only twice (8%). One subject had a decline in FEV 1 of over 50%. 
Table 9-14 shows the different combinations of CNSLD parameters in the 
course of unknown SRI in these patients. 
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Table 9-14 Patterns of exacerbation in the course of 
SRI without positive serology in group III patients 
Dyspnoea/wheezingt Cough/sputumt 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
3 
2 
8 
9 
Total 24 
9-4-2-3 Seroconversions without SRI 
None of the seroconversions, in which clinical data could be collected 
and SRI was absent, could be related to exacerbation. 
9-4-3 Results of sputum gram stains 
SRI was attended by the occurrence of yellow-greenish sputum in 23 out 
of 33 instances (70%). In viral SRI coloured sputum was coughed up by 
7 patients (78%). Gram stains were made of 6 samples, 4 of which turned 
out to be positive. SRI of unknown origin coincided with yello~reenish 
sputum in 16 out of 24 instances (67%). Fourteen gram stains were made, 
13 of which were assessed to be positive. Five SRis were thought to be 
of bacterial origin primarily. 
9-5 Assessment of results 
In order to investigate whether different reaction patterns exist in 
patients with various clinical entities within the spectrum of CNSLD, 
the parameters scored in the course of SRI were compared for the three 
groups. For every SRI of viral and unknown origin the occurrence of exa-
cerbation, significant decrease in FEV1, 50% decrease in FEV1 (at least 
one day), increase in dyspnoea/wheezing and cough/sputum, and production 
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of coloured sputum were noted. Tables 9-15 and 9-16 give the results for 
SRI with and without positive serology, respectively. As can be seen, 
there seems to be a stiong tendency for patients classified as asthma-
tics (group I) to react with increased bronchial obstruction (lowering 
of FEV1) in viral SRI and to a lesser extent in SRI of unknown origin. 
Also in group II a considerable proportion of subjects show decreases 
in FEV1 • In the patients categorized in group III, however, significant 
changes in FEV 1 are rare, whereas in these pa.tients as well as in those 
of group II there seems tO be a greater tendency for the production of 
coloured sputum as compared to group I subjects. 
A difficulty arises when statistical analysis has to be done on these 
result?, as some patients experienced several SRis, whereas others had 
only one. ThiS implicates that host factors determining reactionpatterns 
are overscored for those patients with more than one SRI. In order to 
avoid this problem results were reassessed and two statistical analyses 
were done. x2 tests were carried out for the exacerbation parameters 
in the various patient groups. The statistical analyses were done, using 
every first and every last SRI per patient, respectively, so that only 
one infection per patient was taken into account in both tests. Some sig-
nificant differences in the reaction patterns of the patient groups were 
found. D~creases in FEV 1 occur more frequently in patients with an asth-
matic background (groups I and II) in the course of SRI (p < 0.01) and 
coloured sputum is less often observed in group I patients (p < 0.01). 
The detailed figures are summarized in Tables 9-17, 9-18, and 9-19 for 
viral, unknown, and all SRis, respectively. 
Table 9-15 Occurrence of changes in CNSLD parameters in SRI with positive serology according to diffe-
rent clinical groups 
Total no. With exa- FEVI ~ FEVI H Dyspnoea/ t Cough/ t Yellow/green 
cerbation wheezing sputum sputum 
Group I 44 37 32 I9 20 25 20 
Group II 36 3 I 20 8 2 I 26 24 
Group III 9 6 I a 5 5 7 
Table 9-16 Occurrence of changes in CNSLD parameters in SRI without positive serology according to 
different clinical groups 
Total no, Hith exa- FEVI~ 
cerbation 
Group I I I I 77 46 
Group II 57 34 I8 
Group III 24 I 5 2 
Tables 9-I5 to 9-I9: 
Group I = asthma 
Group II = asthma + chronic airflow obstruction (CAO) 
Group III = CAO 
FEVI H Dyspnoea/t 
wheezing 
2 I 47 
7 25 
I 7 
FEV 1 ~ =decrease in FEV 1 of~ 25% for at least 2 consecutive days 
Cough/t Yellow/green 
sputum sputum 
53 7 I 
22 40 
I 2 I6 
FEV 1++ =decrease in FEV 1 of~ 50% for at least I day Dyspnoea/wheezingf =increase in dyspnoea/wheezing of> 2 points for at least 2 consecutive days 
Cough/sputumt =increase in cough/sputum of> 2 pOints for at least 2 consecutive days 
N 
0 
Table 9-17 Total number of first and last SRis with positive serology and scores of different para-
meters of exacerbation in relation to the various clinical subgroups of CNSLD (x 2 test) 
First SRis with positive serology 
Total no. ~Vith exa- FEVI I FEV ill Dyspnoea/f Cough/ j Yellow/green 
cerbation lvheezing sputum sputum 
Group I 38 31 26 15 17 22 15 
Group II 28 24 16 7 16 20 18 
Group III 8 5 I 0 5 4 6 
"' NS p < o. 02 p<O.JO NS NS p< 0.10 
Last SRis with positive serology 
Group I 38 33 27 15 18 23 16 
Group II 28 23 15 6 17 18 18 
Group III 8 5 I 0 4 4 6 
NS p<O.OI p<0.05 NS NS p<O.IO 
Table 9-18 Total number of first and last SRis without positive serology and scores of different para-
meters of exacerbation in relation to the various clinical subgroups of CNSLD (x 2 test) 
First SR!s without positive serology 
Total no, Hith exa- FEV I~ FEVIH Dyspnoea/ t Cough/ t Yellow/green 
cerbation wheezing sputum sputum 
-
Group I 71 49 32 II 27 33 30 
Group II 40 26 14 5 19 17 27 
Group III 17 9 2 0 5 6 10 
N 
N 
NS p<0.05 NS NS NS p<0.05 
Last SRis without positive serology 
Group I 71 45 29 14 27 34 31 
Group II 40 25 13 5 19 18 30 
Group ·III 17 10 2 0 5 8 10 
NS p<O.IO NS NS NS p<O.OI 
Table 9-19 Total number of all first and last SRis and scores of different parameters of exacerbation 
in relation to the various clinical subgroups of CNSLD (x 2 test) 
-
First SRis 
Total no, Hith exa- FEVI I FEVIH Dyspnoea/f Cough/t Yellow/green 
cerbation wheezing sputum ·sputum 
Group I 109 80 58 26 44 55 45 
Group II 68 50 30 12 35 37 45 
Group III 25 14 3 0 10 10 16 
N 
w 
NS p<O.OI p<0.05 NS NS p<O.OI 
Last SRis 
Group I 109 78 56 29 45 57 47 
Group II 68 48 28 I I 36 36 48 
Group III 25 15 3 0 9 I 2 16 
NS p<O.OI p<O.OI NS NS p<O.OI 
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CHAPTER 10 
RESULTS RELATED TO SEROCONVERSION TO DIFFERENT INFECTING AGENTS 
10-1 Introduction 
For a comparison of effects brought about by the various agents tested 
for in the study, the results were readjusted according to seroconver-
sion to the different viruses, Mycoplasma pneumoniae, and Chlamydia 
psittaei. Clinical diagnoses regarding CNSLD subgroups were not taken 
into account, as in all groups the distribution of various agents was 
more or less similar, influenza A accounting for about 2/3 of all SRis 
with positive serology, and for about 2/5 of all seroconversionswithout 
SRI. Seroconversions were reexamined and the occurrence of possible 
differences with regard to clinical picture, effects on CNSLD parameters, 
and bacterial superinfection were investigated for the various infecting 
agents. In this chapter, the results of sputum gram stains vill be pre-
sented together with the effects on CNSLD parameters. 
10-2 Influenza A virus 
10-2-1 Epidemiology and clinical picture 
In the course of the study, 94 fourfold or greater rises in titre to 
influenza A virus vere found. Of these seroconversions 63 (67%) were 
related to SRI, according to the criteria given in chapter 7-3-1,where-
as 19 (20%) could be associated with MRI and 10 (11%) remained clinic-
ally undetected. In 2 instances (2%) clinical data were unknown. Epide-
mics due to influenza A infection vere observed in all living-units with 
outbreaks in March 1977 and December 1977 in group A, in February 1976 and 
March 1977 in group B, and in February 19.76, March 1977, and- January I 978 
in group C. Epidemics did not occur during the winter of 1978/1979, but 
the rate of influenza vaccination was higher than in the previous seasons 
then. 
Of the seroconversions with known clinical data, 76 (83%) occurred in 
the months of December, January, February, and March; 55 of the episodes 
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were associated with SRI, whereas 18 MRis were noted and only 3 infect-
ions remained subclinical. On the other hand, 16 rises in titre (17%) 
were found outside the influenza seasons, 7 of which were subclinical, 
whereas 8 were related to SRI and 1 to MRI. 
10-2-2 Effects on CNSLD parameters 
10-2-2-1 Influenza A virus with SRI 
Sixty-three SRis due to infection by influenza A virus were observed. 
In the course of these episodes a total of 53 (84%) exacerbations were 
noted. Augmented dyspnoea/wheezing was observed in 33 (52%) instances, 
and increased productive coughing in 37 (59%), whereas significant 
changes in FEV1 were noted on 43 occasions (68%). Results are summarized 
in Table 10-1. 
Table 10-1 Patterns of exacerbation in influenza A 
infection, associated with SRI 
~~l Dyspnoea/wheezingf 
+ + 
+ + 
+ 
+ 
+ 
+ 
Total 
Cough/sputumf 
+ 
+ 
+ 
+ 
18 
II 
10 
4 
3 
6 
10 
63 
FEV1 decreased by more than 50% of the baseline value in 22 subjects 
(35%). Thirty-six patients (57%) stated to produce yellow-green sputum 
during the episode of infection. Twenty-seven sputum samples suitable 
for staining were handed in, gram preparations were positive in 25 of 
these. 
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10-2-2-2 Influenza A virus without SRI 
Seroconversion to influenza A virus without SRI was associated with 
exacerbation in 6 out of 29 instances (21%). Four MRis and 2subclinical 
infections were related to exacerbation, which was on all occasions 
accompanied by decreases in FEV1. Dyspnoea/wheezing as well as cough/ 
sputum increased in 2 subjects. Data are shown in Table 10-2. 
Table 10-2 Patterns of exacerbation in influenza A infection, not 
associated with SRI 
FEV 1 ~ Dyspnoea/wheezingf Cough/sputumf MRI Subclinical 
+ + + 
+ + 
+ + 
+ 2 
+ + 
+ 
+ 
15 8 
Total 19 10 
10-3 Parainfluenza viruses 
10-3-I Epidemiology and clinical picture 
~eroconversions to parainfluenza 3 virus were detected in 23 paired 
serum samples and to parainfluenza I virus once. This last infectionand 
8 of the parainfluenza 3 infections were related to SRI~ whereas lOMRis, 
subclinical infection and 4 episodes in which patients were not under 
observation were noted. Parainfluenza infections were scattered through-
out the study period with relatively few seroconversions in winter. In 
the months of December to March only 4 rises in titre were found. Epi-
demic outbreaks did not occur. 
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10-3-2 Effects on CNSLD parameters 
10-3-2-1 Parainfluenza viruses with SRI 
Out of 9 SRis caused by parainfluenza viruses, 6 were associated with 
exacerbation. SRI due to parainfluenza I infection did not show signs 
of exacerbation. Productive coughing was observed on 5 occasions and 
increases in dyspnoea/wheezing on 4, whereas FEV1 decreased in 3 sub-
jects, 2 of these showing values below 50% of the baseline value. 
The obstructive changes observed lasted 5 days in one patient and 10 
days in the remaining 2 subjects. The patterns of exacerbation are 
shown in Table 10-3. Four patients notified production of yellow-green 
sputum; 3 gram stains were made, all of which turned out to be positive. 
Table 10-3 Patterns of exacerbation in infection by 
parainfluenza viruses associated with SRI 
Dyspnoea/wheezingt Cough/ sputum f 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
I0-3-2-2 Parainfluenzaviruses without SRI 
2 
2 
3 
9 
Ten seroconversions to parainfluenza 3 virus could be associated with 
MRI. In 6 instances a concomitant exacerbation was observed. Productive 
coughing was most frequent, namely in 5 patients, whereas decr~asing 
FEV1 and increasing dyspnoea/wheezing occurred twice and once, respect-
ively. Subclinical parainfluenza 3 infection was not associated with 
exacerbation. Data are summarized in Table 10-4. Of 4 infection periods 
with unknown clinical data, I anamnestic exacerbation was reported, 
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whereas in the remaining 3 this was not so. 
Table 10-4 Patterns of exacerbation in infection by parainfluenza 
viruses not associated With SRI 
FEV 1+ Dyspnoea/wheezingt Cough/ sputumt 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
Total 
I0-4 Respiratory syncytial virus (RSV) 
10-4-1 Epidemiology and clinical picture 
MRI 
4 
4 
10 
Subclinical 
A total of 19 single seroconversions to RSV were found. In group A 2 
outbreaks were observed in February, I 977 and February-March, 1979, 
which accounted for 11 infections. Sixteen of the seroconversions were 
found in the winter seasons. 
RSV was associated with signs of SRI in 6 patients, whereas 7 MRis 
and 4 subclinical infections were registered, and clinical data were 
insufficiently collected in 2 subjects. 
10-4-2 Effects on CNSLD parame·ters 
10-4-2-1 RSV with SRI 
All seroconversions to RSV associated with SRI could be related to exa-
cerbation. Increasing cough/sputum scores were obtained in all cases, 
whereas dyspnoea/wheezing increased in 3 subjects, and declining FEV1 
was observed once. Data are shown in detail in Table 10-5. Four patients 
coughed up coloured sputum and 3 of them handed in suitable samples, of 
which gram stains came out positively. 
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Table 10-5 Patterns of exacerbation in SRI by respira-
tory syncytial virus 
Dyspnoea/wheezingt Cough/ sputum t 
+ + + 
+ + 
+ + 
+ 
+ + 2 
+ 
+ 3 
Total 6 
10-4-2-2 RSV without SRI 
Four out of 7 MRis and I out of 4 subclinical infections were related to 
exacerbation. Four periods were accompanied by augmented cough/sputum, 
3 by increased dyspnoea/wheezing, and 2 by declining FEV 1• In 3 MRis 
yellow/green sputum was coughed up. Two gram stains were made, both 
being positive. Data are summarized in Table 10-6. In both infections 
Table 10-6 Patterns of exacerbation in infection by respiratory syn-
cytial virus, not associated with SRI 
FEVIt Dyspnoea/wheezingt Cough/sputumt MRI Subclinical 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
3 3 
Total 7 4 
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in which clinical data were not satisfactorily collected exacerbation 
was supposed to have occurred retrospectively. 
10-5 Influenza B virus 
10-5-1 Epidemiology and clinical picture 
Seroconversion to influenza B virus was found 13 times. Concomitant SRI 
was observed in 7 patients. Six of the seroconversions with SRI were 
detected in the winter months and one in April. Two MRis were register-
ed, one in winter and one in autumn, whereas 4 subclinical infections 
all occurred out of the winter season. Outbreaks as seen by influenza A 
infections were not observed. 
10-5-2 Effects on CNSLD parameters 
10-5-2-I Influenza B virus with SRI 
In one patient data were not collected properly and conclusions could 
not be drawn. In the remaining 6 subjects with SRI due to influenza B 
virus, 4 exacerbations were noted with FEV1 declining in 3, and pro-
ductive coughing and dyspnoea/wheezing increasing in 3 and 2 subjects, 
respectively. Table 10-7 shows the various patterns. Four patients 
Table 10-7 Patterns of exacerbation in influenza B 
infection, associated with SRI 
Dyspnoea/wheezingt Cough/sputumt 
+ + + 
+ + 
+ + 
+ 
+ + 
+ 
+ 
2 
Unknown 
Total 7 
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coughed up coloured sputum and handed in suitable specimens. Three gram 
stains were judged to be positive, whereas in the remaining prepara-
tion no bacteria could be found. 
I0-5-2-2 Influenza B virus without SRI 
None of the patients with MRI or subclinical influenza B infection 
showed signs of exacerbation of CNSLD. 
10-6 Remaining single seroconversions 
I0-6-1 Adenovirus 
Significant rises in titre to the antigen of the group of adenoviruses 
were found in 5 patients. Three SRis and I MRI were related to exacer-
bation, whereas a subclinical infection was not. Two bacterial super-
infections were noted. 
I0-6-2 Mycoplasma pneumoniae 
Evidence of MYcoplasma pneumoniae infection was detected serologically 
in 2 patients only. One SRI was associated with a severe asthmatic epi-
sode in a 13-year-old boy (see case report 21, Appendix I), whereas in 
another patient no symptoms of upper respiratory tract infection were 
Table !0-8 Patterns of exacerbation in infection by adenovirus and 
Myc:opZasma pneumoniae 
FEV 1+ Dyspnoea/wheezingt Cough/ sputum f SRI URI Subclinical 
+ + + Ad,Mp* 
+ + 
+ + 
+ Ad 
+ + Ad 
+ Ad 
+ Mp 
Ad 
*Ad adenovirus; Mp Mycoplasma pnewnoriiae 
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found, but productive coughing increased markedly. The data for adeno-
virus and Mycoplasma pneumoniae are shown together in Table I0-8. 
I0-6-3 Chlamydia psittaci 
In one patient seroconversion to Ch~dia psittaei was detected during 
the school holidays, which he spent with his parents in Daves. Although 
clinical data were not registered suf-ficiently, it could be found that 
no symptoms of upper respiratory tract infection were observed in the 
relevant period. However, a distinct asthmatic exacerbation was repor-
ted, which could be objectivied by some lung function measurements in 
which FEV 1 was below 50% of the normal baseline value for this patient. 
10-7 Double seroconversions 
Five double infections were registered in the course of the study. In3 
of these episodes clinical data were not fully known, because the rele-
vant subjects were not under observation at that time. One patient had 
an SRI with decreasing FEV1 as well as augmentation of dyspnoea/wheezing 
and cough/sputum. Moreover, he experienced a bacterial superinfection. 
One subclinical infection without signs of exacerbation was noted. In 
2 of the out-clinic patients some anamnestic data regarding SRI and 
exacerbation could be registered. Results regarding all double serocon-
versions are listed in Table 10-9. 
Table 10-9 Occurrence of SRI and exacerbation in infection by 
more than one agent 
Serological,findings 
Influenza A virus/RSV 
Influenza A virus/RSV 
M.pneum./parainfl.3 virus 
RSV/ parainfluenza 3 virus 
RSV/Chlamydia psittaei 
SRI Exacerbation Remarks 
+ 
+ 
+ 
? 
+ 
+ 
+ 
? 
Anamnestic 
data only 
Ibid 
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10-8 Summary of results 
When the above-mentioned results are combined, including only those sera-
conversions in which clinical data and exacerbation parameters could be 
collected well enough to draw conclusions, it appears that a great deal 
of all seroconversions that were found are associated with signs of exa-
cerbation of CNSLD. In general, SRI is related to exacerbation more often 
than MRI and subclinical infection, as was shown in chapter 8-5. This 
seems to be true for all infecting agents, but only to a small extent for 
parainfluenza 3 virus and RSV, in which a considerable proportion of MRI 
was concomitant with exacerbation. Influenza B was less often related to 
exacerbation than the other offending agents, but figures are too small 
to draw any definite conclusions. The various infecting agents as found 
by means of significant rises in titre in the course of the study period, 
and the extent to which they were linked to signs of SRI and exacerbation 
are listed in Table 10-IO. 
Table 10-10 Seroconversions to different infectious agents and their 
relation to clinical picture and exacerbation 
Agent 
Infl.A 
Parainfl. 
RSV 
Infl.B 
Adeno 
M.pnewn. 
Total 
No.of serocon- No. with 
versions with 
known clinical 
data 
92 
20 
17 
12 
5 
2 
148 
exacerba-
tion (%) 
59 ( 64%) 
!2(60%) 
11(65%) 
4 ( 33%) 
4 ( 80%) 
2 (I 00%) 
92 ( 62%) 
No.ofSRis/ No.ofMRis/ No~of sub-
no.with 
exacerba-
tion 
63/53 
9/ 6 
6/ 6 
6/ 4 
3/ 3 
I/ 
88/73 
(83%) 
no with 
exacerba-
tion 
19/ 4 
10/ 6 
7/ 4 
2/ 0 
I I 
0/ 0 
39/15 
(38%) 
clinical 
infections/ 
no.with 
exacer-
bation 
10/ 2 
I/ 0 
4/ 
4/ 0 
I/ 0 
I I 
21/ 4 
(19%) 
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CHAPTER II 
DISCUSSION OF RESULTS 
Il-l Incidence of respiratory infection 
11-1-1 Introduction 
In the present study symptomatic respiratory infection (SRI) was suppos-
ed to be present if 2 or more of the symptoms, mentioned in chapter 7-
3-1, were present for at least 36 hours. This threshold was chosen in 
order to avoid a high number of false positive episodes. False positive 
SRis may occur in case of allergic rhinitis with symptoms like rhino-
rrhoea and sneezing and therefore special attention was given to the 
occurrence of these episodes. Combinations of these symptoms alone were 
few and almost always associated with systemic effects like malaise and 
fever, so that it can be assumed that allergic rhinitis did not give 
rise to a considerable number of false positive SRis. Comparison of SRI 
frequencies in patients with CNSLD to those in other reports is diffi-
cult for various reasons: 
-Many studies on the relationship between viral respiratory infection 
and flare-ups of CNSLD use the occurrence of an exacerbation of asth-
matic or bronchitic symptoms as the moment from which on virological 
studies are started. The number of SRis that take place without exa-
cerbation is usually not mentioned. 
-The definition of SRI is not identical in different studies. In most 
reports patients were asked to notify any acute respiratory illness, 
but the threshold to call any episode as such is usually not set. 
-Compositions of study groups, for example with regard to age, differ 
strongly in various studies. Likewise, observation periods vary from 
one report to another. 
In spite of these difficulties, some data can be compared to the results 
presented in this thesis. 
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11 -1-2 SRI in asthma 
Data with regard to the frequency of respiratory infection in patients 
categorized as asthmatics are scarce and almost exclusively limited to 
children. Mcintosh et aZ. 170 found a high frequency of respiratory in-
fection of proven viral origin in young asthmatic children, namely 0.43 
per patient month. Their study was limited to 2 subsequent winter sea-
sons, whereas no information was collected during summer periods. Upper 
respiratory infection was defined as either rhinorrhoea or pharyngitis, 
or both, and otitis media was considered separately. In a group of 41 
children, aged 13-17 years, and 8 adults, aged 22-60 years, Minor et 
al. 183 found 128 episodes of SRI, employing a threshold of one symptom 
of upper respiratory tract infection in the course of 392 patientmonths, 
which is equal to 0.33 SRI per patient month. In another study by these 
authors 184 of 16 children aged 3-11 years, incidences of 0.6 SRI (thres-
hold: one symptom of upper respiratory tract infection) per patient 
month and 0.38 severe SRI (threshold: 2 symptoms and/or fever) were 
found. 
Il-1-3 SRI in chronic bronchitis 
There are some studies from which SRI rates in patients diagnosed as 
"chronic bronchitics" can be calculated. Stenhouse250 found 38 upper 
respiratory tract infections in 255 patient months, which equals a fre-
quency of 0.15, whereas Eadie et aZ. 64 observed 75 episodes in 435 
patient months, which stands for an incidence of 0.17. These figures 
correspond well with the group III patients in this study, in which a 
rate of 0.16 SRI per patient month was observed. 
11-1-4 SRI with positive serology 
In the survey 90 out of 284 episodes of SRI (31. 7%) could be related to 
viral infection by means of systematically conducted serological inves-
tigations. This percentage is comparable to those found by others in 
similar studies, although in most of these studies isolation techniques 
were used in combination with serology. Table 11-1 summarizes the 
results of some previous reports. 
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Table 11-1 Frequencies of virus detection in the course of SRI in 
different studies 
Author(s) No. of SRis No. of SRis of Percentage 
proven viral origin 
Eadie et al. 64 75 !6 21 
Minor et al 183 128 33 26 
LOwenberg & Orie166 282 87 31 
Horn et al. 11 s 1934 614 32 
Gregg 95 2635 891 34 
Lambert & Stern148 73 29 40 
Minor et al-. 1 8 4 78 38 49 
Present study 284 90 32 
Thoroughly conducted serological investigations offer a good possibility 
to detect a substantial part of demonstrable viral infections, and the 
use of isolation techniques does not add much information if both methods 
are combined. Gump et al. 101 compared both techniques and found that 81% 
of the viral infections they were able to demonstrate, were detected by 
serology alone, whereas 14% were detected by isolation alone. 
However, the use of serology alone has one major disadvantage, namely 
the impossibility to measure infection rates with common cold viruses, 
which are divided morphologically into the rhinoviruses and coronaviru-
ses. There is a great multiplicity of different types of these agents 
with relative immunological specificity. At present over 100 different 
antigenic rhinovirus types are known. Therefore, cell culture is the 
standard method for rhinovirus isolation, and propagation and serologi-
cal study is possible only when the types of circulating viruses are 
known from viral cultures. As these agents tolerate the process of 
freezing and thawing less well than other viruses, in the present survey 
it was impossible to collect reliable information with regard to infect-
ion rates with common cold viruses. 
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11-I-5 Comment 
The incidences of respiratory infection in asthmatics found in studies 
mentioned in chapter IO-I-2 are higher than the present ones~ even if 
SRI and MRI are combined, in which case a frequency of 0.23 episode per 
patient month can be estimated. However, reports describe results in 
younger children. These data are in agreement with results of large 
population surveys. The incidence of acute respiratory tract infection 
is highest in infants under I year of age with a second peak in children 
aged 5 years. There is a sharp decrease in rates to the age of IOyears, 
after which a more or less equal frequency for the different age groups 
can be found as was shown-by Miller in a study by the Public Health 
Laboratory Service and the Medical Research Council's Committee onAcute 
Respiratory Virus Infections. 181 
In the survey described in this thesis SRI rates did not differ sig-
nificantly for the various age groups A, B, and C, although the group 
of youngsters showed a somewhat lower incidence. This could be due to 
the fact that children tended to deny any respiratory symptoms for fear 
of regular vena punctures because of SRI. In this respect it is inte-
resting that the frequency of seroconversion related to MRI and subcli-
nical infection was highest in this group: 0.05 per patient month com-
pared to 0.03 for both other groups. 
Different degrees of irreversible functional disability within the 
spectrum of CNSLD do not seem to be associated with varying rates of 
symptomatic respiratory infection, as similar frequencies were found in 
groups I, II, and III: 0.15, 0.17, and 0.16 SRI per patient month, res-
pectively. 
The impossibility to detect infections by common cold viruses is a 
deficiency of importance in the present study. Rhinoviruses have been 
shown to be important agents in producing exacerbations in asthmatics 
95 183 184 185 as well as in chronic bronchitics~ 4 172 250 There are 
only·few data concerning coronaviruses in this respect which indicate 
that these agents are also able to induce flare-ups in asthma 170 and 
chronic bronchitis. 101 
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11-2 Exacerbations of CNSLD in the course of respiratory infection 
11-2-1 Introduction 
One of the major problems in comparing results of the present study to 
those found by other investigators is the absence of a universally 
accepted definition of exacerbation. In CNSLD the symptoms fluctuate 
from day to day, so that for the patient it is difficult to always re-
cognize the onset of a worsening of symptoms. Furthermore, different 
definitions of exacerbation are usually applied to the various symptom 
complexes within the spectrum of CNSLD. As patients suffering from 
conditions covered by the omnibus term CNSLD are characterized by the 
presence of cough, sputum, and breathlessness with wheezing, it seems 
logical to consider all these symptoms when rating exacerbations. In 
other words, information is incomplete if exacerbations in asthma are 
only characterized by increased breathlessness with wheezing, and by 
change in production and colour of sputum in chronic bronchitis, as is 
usually done. In the present study it was possible to combine subject-
ive data of symptom scores with more objective daily FEV1 registrations, 
which adds substantial information and allows the follow-up of bronchial 
obstructive changes in respiratory infection. In defining the term exa-
cerbation a threshold of 2 days persistance of increased symptoms and/ 
or decreased FEV1 was chosen in order to avoid the problem of calling 
one bad day an exacerbation. In literature no attention is given to the 
problem of relating increased symptoms to a certain time limit, which 
makes comparison to other studies even more difficult. Of course, the 
threshold set for exacerbation in the present study is arbitrarily 
chosen as well, but at least the term has the advantage of being well-
defined (see chapter 7-3-2). 
II-2-2 Exacerbation in infections of different clinical severity 
Exacerbation rates were associated with the severity of clinical symp-
toms caused by viral infection. Out of ISO episodes with positive sero-
logy in which parameters were satisfactorily collected, 89 were related 
to SRI, 39 to MRI, and 22 to subclinical infection. In SRI 74 exacerba-
tions (83%) were notified, whereas MRI was related to exacerbation in 
IS (38%) and subclinical infection in only 4 (18%) instances. 
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11-2-3 Patterns of exacerbation in different clinical states of CNSLD 
11-2-3-1 Exacerbation in asthma 
As was described in chapter 9, a total of 44 SRis with positive serology 
and known clinical data were found in a group of 128 patients classified 
as asthmatics according to criteria mentioned in chapter 7. Exacerbations 
were observed in 37 patients (84%). If dyspnoea and wheezing would have 
been the only parameters under investigation, an exacerbation rate of 
45% would have been found. Increases in productive coughing were noted 
in 25 instances, equal to 57%. Distinct changes in FEV1, however, were 
registered in a majority of patients: 32 (73%) scored 25% or less of 
the baseline value during at least 2 consecutive days. This. means that 
for these patients FEV1 was a more sensitive parameter than subjective 
symptom scores~ which is an important finding if the results are to be 
compared to other studies. 
Minor et aZ. 183 184 found 24 periods of asthma in the course of 38 
viral SRis (63%) in children and 17 wheezy episodes in 32 viral infect-
ions (53%) in a group of 49 persons aged 3-60 years. In both studies, 
patients with allergic asthma were excluded and only subjects with 4 or 
more. attacks of asthma associated with respiratory illness during the 
previous year were selected. Severity of asthma was rated on a 5 points 
scale, and asthma was considered to be associated with symptomatic res-
piratory infection if it occurred any time during the first 3 days of 
illness and if it was greater than score 1 in severity. Huhti et aZ. 121 
found somewhat higher exacerbation rates. Out of 43 SRis of proven 
viral origin 33 (77%) coincided with a worsening of asthma as scored in 
a symptom book. Furthermore, 6 out of 16 infections (38%) noted bysero-
conversion in routinely collected blood samples were associated with 
asthma. This figure is slightly higher than in the present group, in 
which 19 out of 61 MRis and subclinical infections (31%) could be rela-
ted to exacerbation. Huhti et al. 121 did not find any indication of 
differences with regard to the type of asthma being intrinsic or extrin-
sic and whether or not the patients were treated with corticosteroids. 
This absence of relation was also noted when the data in the present 
study were examined in this respect. 
The episodes of SRI without positive serology were associated with 
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exacerbation in 77 out of 113 instances (68%) in the asthma group. The 
various parameters showed changes compatible with exacerbation in about 
equal frequencies: dyspnoea and wheezing increased in 47 subjects~ pro-
ductive coughing in 53, and FEV1 decreased in 46 patients. It can be 
assumed that besides infections undetectable by presently available 
diagnostic procedures and infections by still unknown agents, common 
cold viruses were responsible for a substantial part of these episodes. 
In this respect, it is interesting to notice that the percentage of 
exacerbations is identical to the figures found in rhinovirus infect-
ions. Minor et al. in studies already mentioned183 184 observed 24 exa-
cerbations in 39 rhinoviral SRis (62%), whereas Gregg95 reported 62 
wheezy episodes in the course of 93 rhinovirus infections (67%). Of the 
pharyngitis episodes caused by group A streptococci, none resulted in 
asthmatic reactions. This finding confirms clinical observations by 
Freeman. 79 
11-2-3-2 Exacerbation in chronic airflow obstruction (CAO) 
Exacerbation rates in SRI with and without positive serology were almost 
identical in group III patients, namely 67% and 63%, respectively. These 
figures correspond with those found by other authors in chronic bron-
chitis. Percentages of exacerbation vary from 50 to 82 in different 
reports. In almost all studies increase in productive coughing has been 
used as the sole parameter of exacerbation. Also in the present study 
this symptom was observed most frequently, namely in 56% of viral and 
in 50% of unknown SRis. 
Nevertheless, dyspnoea and wheezing seem to be factors which should 
be given attention as well, as they increased to 36% of all SRis inthis 
group, almost as high as the 42% found in the asthma group. However, 
FEV1 changed significantly less often in the patients with distinct 
irreversible bronchial obstructive syndromes than it did in asthmatics. 
On the other hand, SRI was more frequently associated with the product-
ion of coloured sputum in CAO than it was in asthmatic patients. 
11-2-3-3 Exacerbation ~n asthma and chronic airflow obstruction (CAO) 
Exacerbation rates in asthmatic patients with partly irreversible 
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changes were very similar to group I subjects: 86% for viral and 60% 
for unknown SRI. These figures can hardly be compared to data from the 
literature, because all studies are limited to patients classified as 
either asthmatics or chronic bronchitics. However, patterns of exacer-
bation can be related to those of group I and group III patients. In 
this respect, it is interesting to note that group II patients for a 
great deal tend to react asthmatic, because changes in FEV 1 are rather 
high: 56% in case of viral and 32% in unknown infections. On the other 
hand, there is a tendency toward features of group III, because like in 
the CAO group the production of coloured sputum during SRI occurs more 
frequently than in the asthma group. 
11-2-4 Comment 
Differences in exacerbation rates related to variations in clinical 
severity of respiratory tract symptoms have been observed before. In 
the study by Minor et al. 184 subclinical infections failed to exacer-
bate asthma totally, and MRis were related to wheezing episodes in 2 
out of 12 instance& only, whereas SRis caused flare-ups in 21 Out of 
23 episodes. 
Although most subclinical infections passed off without increasing 
CNSLD symptoms in the present study, some distinct bronchial obstructive 
eP.{sodes were noted. Some increases in obstructive signs and symptoms 
were also observed following in-fluenza vac-cination. These observations 
possibly have impprtant theoretical implications, which will be dis-
cussed in the next chapter. 
The exacerbation rates associated with viral SRI in the groups with 
distinct asthmatic symptoms are· the highest reported hitherto, whereas 
the figures for patients with chronic airflow obstruction are in agree-
ment with those reported for chronic bronchitis. This is probably due 
to the attention given to more than one parameter in rating exacerba-
tion. Especially in groups I and II, FEV1 turned out to be a valuable 
parameter, and decreases in FEV1 accounted for a great deal of flare-
ups. On the other hand, in group III patients significant changes in 
FEV1 were rare, whereas increasing productive coughing was responsible 
for a majority of exacerbations. On account of differences in patterns 
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of reaction between patients with reversible and largely irreversible 
airflow obstruction, it could be suggested that these clinical entities 
have different pathogenetic bases and are not as closely related as 
supposed by those who support the concept of one fundamental background 
for CNSLD. However, the figures found in a group of patients with asth-
matic attacks in the past or at present, and signs of partly irreversi-
ble changes, rather suggest that there is a state of transition between 
both clinical entities. Many clinicians would probably call this symptom 
complex asthmatic/bronchitis, indicating the presence of asthmatic and 
j 
bronchitic symptoms. In the present study patients classified into this 
group indeed showed characteristics of both asthma and chronic airflow 
obstruction in the course of an SRI, be it of proven viral origin or 
not. Accordingly, it seems appropriate to consider clinical syndromes 
associated with generalized bronchial obstruction as a continuum with 
at one extreme patients with complete reversibility of obstruction 
reacting on SRI mainly with asthmatic symptoms (dyspnoea/wheezingf 
FEV1tt , but also cough/sputumf), and on the other pole patients with 
largely irreversible obstruction, in whom SRI tends to show mainly 
bronchitic signs (cough/sputumft, dyspnoea/wheezingt , ·however, hardly 
FEVIt ). 
Pathogenetic mechanisms, to be discussed in chapter 12, are likely to 
be important in CNSLD in general, but seem to predominate to various 
extents in different clinical entities of the disease. 
11-3 Bacteriological investigations 
11-3-1 Results 
Gram stain preparations of carefully washed sputum samples were made in 
40 out of 51 viral SRis in which yellow-greenish sputum was expectorated. 
Of all 90 episodes of viral SRI a positive gram stain was found in 37, 
which is equal to 41%. Of 194 SRis without positive serology, 5 were due 
to streptococcal pharyngitis. Of the remaining 189 episodes, 107 were 
associated with the production of coloured sputum. Ninety-one gram 
stains were made and 83 of these were considered to be positive. Hence 
a positive gram stain was found in 44% of episodes of SRI without posi-
tive serology. If the assumption is made that positive gram stains 
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would have been found in equal frequencies in those instances in which 
coloured sputum was expectorated but no samples were handed in, it can 
be estimated that bacterial sputum infection can be detected by means of 
gram staining in 52% of episodes of SRI with or without ~ositive serol-
ogy. 
Group I patients, with the above assumption made, in the course of 45 
viral infections would have bacterial superinfection in 20 instances 
(44%), whereas in group II+ III this would be the case in 27 out of 
45 viral SRis (60%). This last figure is in accordance with data given 
by Smith et aZ. 242 who, using bacterial culture techniques, were able 
to show 102 bacterial infections in the course of 168 SRis of viral 
origin (61%) in patients diagnosed as chronic bronchitics. LOwenberg 
and Orie166 also presented comparable figures, as they found 7 bacterial 
sputum infections in the course of 13 viral SRis (54%) in nurses suffer-
ing from CNSLD. These authors consider virus-induced increase in bronchial 
obstruction as an important local cause of secondary bacterialinfect-
ion.207 In reviewing the present data expectoration of yellow-green 
sputum with positive gram stain was preceeded by increased bronchial 
obstruction in approximately 50% of instances. Obstructive changes in-
deed seem to be of importance as a predisposing moment with regard to 
bacterial infection. However, it is not an obligatory factor in this 
respect. 
11-3-2 Connnent 
The most important aim of the present study was to investigate to which 
extent respiratory viral and mycoplasmal infections cause exacerbations in 
patients with different clinical syndromes belonging to the group of cNSLD. 
Several reports suggest that there is no association between bacterial 
respiratoy tract infection and asthma13 70 146 170 184 235 and also in 
patients with chronic bronchitis, bacteria do not seem to play a major 
role in causing exacerbations. 25 54 101 In view of these observations 
and because bacteriological laboratory facilities were poor, especially 
at the beginning of the study, it was decided not to give extensive 
attention to bacteriological investigations. Sputum had to be sent to 
other laboratories for culturing and for economical reasons it was 
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impossible to do this routinely in the course of every SRI in which 
sputum was expectorated. On the other hand, it has been shown that 
viral-bacterial interrelationships are of importance in patients with 
CNSLD, and Stuart-Harris256 even suggested that the combination of viral 
and bacterial infection accounts for the chronic smouldering phases of 
the disease. 
Therefore, it was decided to do small scale bacteriological studies 
and to accept the presence of bacteria in sputum gram stains, washed 
according to the method of Mulder195 , as evidence of bacterial sputum 
infection. Although this method of investigation does not offer complete 
information, as bacteria should be identified by culture methods, it is 
not incorrect, provided that the sputum sample is well selected and 
properly treated, and the technique is still in use nowadays. 179 
The results of gram staining are presented throughout the chapters 
in which results are described, but for the statistical analysis given 
in chapter 10, expectoration of yellow-green sputum was used, as this 
parameter was scored daily for every subject, whereas sputum samples 
suitable for preparation and staining were available in a proportion of 
cases only. 
In the SRis presented as streptococcal pharyngitis, S haemolytic group 
A streptococci were cultured from pus taken by pharyngeal swabs, so 
that in these subjects bacteriological diagnosis seems to be sufficient-
ly established. 
11-4 Exacerbation related to infecting agent 
11-4-1 Results 
Data presented in chapter 10 show that all of the agents to which sig-
nificant rises in antibody titre were found are capable of provoking 
flare-ups of CNSLD symptoms. Infection by all viruses except influenza 
B gave rise to exacerbation in a majority of instances, even if SRI was 
combined with MRI -and subclinical infection. Highest rates were found 
for MYeoprasma pneumoniae and the adenovirus group, but seroconversions 
to these agents were too few to set value on this observation. 
Almost identicial exacerbation rates, varying from 60% to 70%, were 
found in RSV, influenza A, and parainfluenza infections. Influenza B 
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was related to exacerbation in 4 out of 12 infections only. MRI and sub-
clinical infection were never associated with exacerbation in influenza 
B, whereas all other viruses and MYcoplasma pneumoniae provoked flare-
ups at least once in seroconversions with absent or mild clinical symp-
toms. 
11-4-2 Comment 
It is difficult to compare results observed in infections by different 
viruses to those found in other studies. The absence of uniformity in 
patient groups with regard to age and diagnosis as well as differences 
in defining SRI and exacerbation, and in laboratory methods are factors 
that should be taken into account if comparisons are made. Nevertheless, 
it is interesting to summarize the results of some reports in which 
exacerbation rates for the various agents are mentioned. This is done 
in Table 11-2. In general, exacerbation rates for different agents in 
Table 11-2 Number of infections with exacerbation related to number 
of all infections observed for different viral agents and MYcopZasma 
pneumoniae. Results of various reports 
Infl.A Infl.B Parainfl. RSV Adeno M.pneum. 
1,2,3 
Minor 184 4/ 5* I/ 2 2/ 3 2/ 3 
Minor183 6/ 6 0/ 0/ 3 0/ 4 0/ 
Stark249 9/ 13 4/ I 0 
McNamara172 5/ 6 4/ 5 
Mcintosh170 0/ 8 I/ 3 12/ 27 19/ 20 4/ 13 
Gumpl o 1 14/ 23 I/ 3 9/ 18 5/ 7 3/ 3 
Lamyl49 7/ 9 7/ 9 12/ 15 3/ 7 0/ 3 I I 2 
Present 59/ 92 4/ 12 12/ 20 II I 17 4/ 5 2/ 2 
study 
Total 90/143 22/ 41 50/ 95 45/ 60 13/ 31 7 I 10 
(studies (63%) (54%) (53%) (75%) (42%) (70%) 
combined) 
*No. of infections with exacerbations/no. of all infections observed 
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the present study are in agreement with a combination of those of pre-
vious reports, except for influenza B and adenoviruses, for which pre-
sent rates are lower and higher, respectively. This could be due to 
differences in clinical symptoms of these infections, as severity of 
respiratory infection symptoms is related to exacerbation rate. 

12-1 Introduction 
149 
CHAPTER 12 
THEORETICAL DISCUSSION 
The mechanisms by which viral infections are related to the cause and 
course of CNSLD are not completely understood. Nevertheless, there are 
many reports on the subject indicating that several pathogenetic mecha-
nisms might be involved. Especially bronchial hyperreactivity, which 
is a major feature in patients with CNSLD 19 52 91 274 286 , seems to 
play an important role in virus-induced exacerbations of the disease. 
In this chapter a summary of the most important studies in this field 
will be given. Furthermore, some hypothetical considerations based on 
the results of the survey, described in this thesis, will bepresented. 
12-2 Studies in healthy subjects 
It is worthwhile looking at studies indicating that acute viral and 
mycoplasmal infections affect lung function and the state of bronchial 
reactivity to various stimuli in normal subjects, since subtle effects 
might easily be overlooked in the presence of advanced disease. More-
over, the study of hyperreactivity in patients is complicated by hyper-
trophy and hyperplasia of airway smooth muscle, treatment with drugs 
and variable degrees of airway obstruction, making it difficult to es-
timate virus-induced changes in this respect. 
Stonehill et al. 252 and Johansen et al. 131 were the first to report 
on minor restrictive spirometric changes in some subjects with acute 
viral respiratory disease. Picken et aZ. 218 and Blair et al- 16 found 
frequency dependency of dynamic compliance in otherwise healthypersons 
after clinically mild respiratory infection. These changes were found 
4-8 weeks after infection and a further 6 weeks were required for lung 
function to return entirely to normal. 
Reversible alterations in closing volume and He-02 flow rates at low 
lung volumes in smokers with rhinovirus infections were reported by 
!50 
Fridy et az~ez Prolonged reductions in carbon monoxide diffusing capa-
city have been described after infection by influenza 118 , Mycoplasma 
pneumoniael 5, and rhinovirus.33 
The results of these studies have in common that they are consistent 
with lower respiratory tract involvement in the course of viral illness 
in healthy persons. There are several reports indicating that in healthy 
human subjects viral respiratory infections cause a transient but some-
times striking increase in the bronchial response to various stimuli. 
Parker et a&.21o observed an enhanced response to metacholine in normal 
subjects during and after acute respiratory infections. Similarly, 
transient increased bronchial reactivity to histamine in subjects with 
colds was reported by Empey et aZ. 68 and after successful inoculation 
of live attenuated influenza virus by Laitinen et al. 146 In another 
study by Little et aZ. 160 a heightened responsiveness to inhaled carba-
chol was notified. Recently, it has been demonstrated that during upper 
respiratory infection normal subjects develop transient airway hyper-
reactivity to exercise with cold, dry air. 6 In healthy subjects bron-
chial reactivity is seen to return to control levels within 6 to 8 
weeks.6 68 146 160 210 
The most plausible explanation for the observed changes in bronchial 
reactivity is presented by Empey et at. 68 They provide evidence that 
the epithelial damage, known to occur in respiratory viral infection 
111 113 sensitizes the rapidly adapting irritant receptors causing an 
increase in bronchomotor response to inhaled histamine through choli-
nergic, vagal pathways. Prior inhalation of atropine aerosol blocked 
the increase in responsiveness, an observation confirmed by Aquilina 
et az.6 Recently, the importance of vagal pathways in the increased 
bronchial responsiveness to histamine in respiratory infection has been 
confirmed again in an experimental study by Dixon et al. 58 
12-3 Studies in CNSLD patients 
The study of Parker et al. 210 , already mentioned, indicated that in 
patients with bronchial asthma a heightened responsiveness to various 
stimuli exists in the course of respiratory infection as compared to 
their baseline hyperreactivity. There are some reports in which it is 
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suggested that influenza and measles vaccination have similar effects. 
A significant increase in sensitivity to inhaled metacholine after in-
fluenza vaccination, administered by subcutaneous injection, was noti-
fied in 9 out of 10 asthmatics by Ouellette and Reed208 and in 11 out 
of 24 patients by Anand et a~. 5 A similar effect after inoculation of 
live measles vaccine was reported by Kumar et at. 144 , cited by Chai. 35 
More recently, Laitinen and Kava147 demonstrated an increased response 
to histamine in asthmatics but not in control persons following admini-
tration of influenza A virus by nasal drops. The heightened response 
was blocked by prior administration of both salbutamol and ipratropium 
bromide. 
Studies with regard to vaccination in patients classified as chronic 
bronchitics are rare. There is one observation of increased respiratory 
symptoms with slight lung function alterations 3 weeks following local 
influenza vaccination. 301 The above-mentioned studies by Ouellette and 
Reed208 and Anand et az.s bear important theoretical implications, as 
these investigators used vaccines given by injection in order to avoid 
bronchial epithelial damage. Despite the absence of local irritation, 
significant increases in bronchial reactivity were found. This means 
that in patients with asthma there must be some mechanism apart from 
epithelial damage capable of changing bronchial responsiveness. Allergy 
to viral products has been propagated as a possible explanation 66 104 , 
but there is little evidence to support this hypothesis! 14 Some recent 
data suggest that chemical mediators such as histamine are involved in 
virus-induced wheezing. Ida et al. 123 have demonstrated that incubation 
of human leucocytes from atopic individuals with virus in vitro enhances 
their histamine release when they are subsequently axposed to ragweed 
antigen or antihuman IgE. Welliver et al. 290 reported that continued 
presence of cell-bound IgE was more common in patients with RSV-induced 
bronchiolitis or asthma than in patients with pneumonia or upper respi-
ratory tract infection caused by RSV. Persistence of IgE was also rela-
ted to the family history of wheezing. Thus local production of IgE in 
the respiratory tract and subsequent release of histamine may contribute 
to the clinical outcome of respiratory illness from infection by RSV. 
Szentivanyi 264 introduced the idea of beta-adrenergic receptor 
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blockade as the mechanism underlying bronchial asthma, and his theory 
has recently been put forward again in a slightly modified way. 265 This 
hypothesis is based, in part, on the observation that mice vaccinated 
with BordeteZZa pertussis became hypersensitive to histamine and other 
mediators of anaphylaxis. 143 Infection was postulated to be the most 
important factor leading to blockade of beta-adrenergic receptors. 
Subsequent investigations have shown that beta-adrenergic responsive-
ness of granulocytes is impaired by respiratory viral infection27 28 29 
and this observation provides a possible explanation for virus-induced 
asthmatic exacerbations. 
12-4 llyp-othetical considerations 
One of the most important findings of the study described in this thesis 
is the existence of different patterns of reaction to viral respiratory 
infection in patients with various clinical entities covered by the term 
CNSLD. Although exacerbation rates did not differ significantly between 
patients with asthma and those with chronic airflow obstruction, the 
asthmatic subjects had increases of bronchial obstruction, confirmed by 
FEV1 measurements, more frequently. On the contrary, the subjects with 
chronic airflow obstruction were more often inclined to expectorate 
coloured sputum in the course of SRI of viral and unknown origin. Pa-
tients with features of asthma as well as chronic airflow obstruction 
showed reaction patterns compatible with those of both conditions. 
In our opinion the bronchial reaction to respiratory viruses is de-
termined by a complex interaction between infecting agent and host 
response. Viral characteristics such as in vitro pathogenicity, the 
destructive effect at the cellular level, and the affinity for certain 
areas of the respiratory tract play an important role. 169 
On the other hand, host factors have been shown to be of the utmost 
importance in determining the clinical outcome of viral respiratory 
infection. 94 116 This observation is in agreement with our data. 
It is tempting to speculate on the possible mechanisms underlying the 
differences in reaction patterns that were observed in the present study. 
The above-mentioned hypothesis of increased cholinergic activity 
caused by epithelial damage 68 is well established and it accounts for 
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one of the possible factors involved in alterations in bronchial hyper-
reactivity seen both in healthy and CNSLD subjects. However, in our 
opinion this theory is not sufficient to explain the data described in 
this thesis completely. Additional mechanisms must be involved in order 
to clarify the different patterns of reaction that were observed. GOke-
meijer91 found differences in bronchial hyperreactivity profiles between 
a group of asthmatics and a group of chronic bronchitics. In general, 
the bronchitics were less hyperreactive. Furthermore, their pattern was 
supposed to be determined mainly be an increased cholinergic activity, 
whereas in the asthma-group decreased responsiveness of the sympathico-
adrenergie receptors was thought to be the central disturbance. Other 
studies have also demonstrated that beta-adrenergic function distur-
bances are distinct in subjects with asthma24 , whereas chronic bronchi-
ties have only moderate reduction in responsiveness 1 55 or none at all. 13 0 
These observations and the results of some of the studies mentioned in 
chapter 12-35 27 28 29 208 are suggestive of a beta adrenergic block-
ade to be one of the fundamental mechanisms underlying the sometimes 
severe bronchial obstructive reactions notified in the group of asth-
matics. Increased cholinergic activity is an additional important back-
ground in this respect. 6 68 19 7 
We suppose that the reaction patterns in the group of patients with 
chronic airflow obstruction are determined by factors other than beta-
receptor blockade. Impairment of local defensive mechanisms, such as 
mueociliary clearance, macrophage function 178 and secretory-IgA pro-
duction245 together with mucous hypersecretion per se 73 may be possible 
pathogenetic conditions in this respect. 
In the transitory clinical state with features of both asthma and 
chronic airflow obstruction, often referred to as asthmatic bronchitis, 
involvement of a combination of the above-mentioned mechanisms is likely 
to occur. 
Fig. 12-1 shows a schematic representation of these hypothetical con-
siderations. The survey described in this thesis can be regarded as a 
clinical field study into the effects of viral infection in patients 
with CNSLD. Further investigations, for example studies on the effects 
of inhalation of attenuated viral material on lung function and bronchial 
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Fig. 12-1 Schematic representation of possible factors deter-
mining the final reaction patterns in CNSLD patients with 
respiratory viral infection 
hyperreactivity, are needed to elucidate the exact mechanisms under-
lying the observed phenomena. 
Simultaneously, research efforts toward the development of effective 
viral vaccines have to be stimulated in order to obtain possibilities 
to protect subjects with CNSLD against the adverse effects of viral 
respiratory infection. 
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SUMMARY 
This thesis describes the results of an investigation into the effects 
of respiratory infections caused by viruses, MYeoprasma pneumoniae and 
Ch~dia psittaci in a group of patients with chronic non-specific lung 
disease (CNSLD) during their stay in the Netherlands Asthma Centre 
Daves, situated at 1560 m above sea level. After a short introduction 
in which the aims of the study are summarized by formulating six ques-
tions, part I deals with general information and literature data regar-
ding CNSLD, respiratory virology, effects of respiratory infection on 
cause and course of CNSLD, and effects of climatic factors in Daves. 
Chapter 1 reviev.rs the terminology applied for conditions attended with 
breathlessness and wheezing, cough, and expectoration of sputum. In The 
Netherlands, the general opinion is that these conditions should be 
grouped and the name "Chronische Aspecifieke. Respiratoire Aandoeningen" 
(CARA = CNSLD) has become a well adapted omnibus term for these. The 
arguments in favour of this term, put forward especially by the Gronin-
gen workgroup of Orie and associates, are described in this chapter and 
the necessity of characterizing each individual patient according to a 
number of parameters is mentioned. Subsequently, attention is given to 
the different diagnoses commonly used in Anglo-Saxon literature, such 
as bronchial asthma, chronic bronchitis, and pulmonary emphysema. A 
brief description of these clinical syndromes as well ·as a concise 
comment on bronchiectasis are given. 
In chapter 2 general remarks are made with regard to the respiratory 
agents that were studied in the survey. After a short introduction, the 
characteristics and use of different laboratory methods are discussed 
for adenovirus, influenza, and parainfluenza viruses, and RSV, as well 
as the non-viral agents MYeopZasma pneumoniae and ChZamydia psittaei. 
Brief comments are made on the association of these microorganisms with 
human illness. 
Chapter 3 summarizes literature data on the role of respiratory 
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infection in the pathogenesis of CNSLD. The importance of respiratory 
tract illnesses in infancy and early childhood in this respect is es-
pecially emphasized in paragraphs on subglottic laryngotracheobronchitis 
(croup) and bronchiolitis. These conditions have been shown to be asso-
ciated with a subsequent heightened bronchial reactivity to various 
stimuli, which is a major pathogenetic hallmark in bronchial obstructive 
disorders. Several studies indicate that respiratory infection can act 
as a trigger mechanism for the appearance of symptoms in subjects gene-
tically predisposed to develop signs and symptoms of CNSLD. 
In chapter 4 a review is given of literature dealing with the effects 
of respiratory viral infections on the clinical course of CNSLD. The 
majority of patients ..-rith bronchial obstructive diseases tend to react 
with an exacerbation in the course of viral infection of the respira-
tory tract. However, literature data are very divergent, mainly because 
of the absence of uniform definitions of SRI and exacerbation. As most 
reports deal with patients categorized as asthmatics or chronic bron-
chitics only, literature data are discussed for these groupsseparatel~ 
Subsequently, the effects of climatic factors and the situation of 
the Netherlands Asthma Centre are described. In chapter 5 three theories 
on the favourable influence of a high mountain climate are discussed, 
i.e.: low density of inspired air, biometereological conditions, and 
relative absence of certain allergens, especially those produced by the 
house-dust mite, Dermatophagoides pteronyssinus. The clinic 1 s model of 
treatment, strongly directed toward physical and mental rehabilitation, 
is presented for 3 different groups of patients in chapter 6. 
Part II of this thesis deals with the design of the study and the 
results. 
In chapter 7 the patients participating are categorized according to 
living-unit and mainly based on age, into group A- "Senioren", group 
B - "Junioren", and group C - "Vossen". Moreover, a classification is 
made of clinical categories on the base of anamnestic data and reversi-
bility of bronchial obstruction, measured by lung function tests. Thus, 
3 groups are formed: group I - asthma (good reversibility at lung func-
tion), group II- asthma and chronic airflow obstruction (moderate 
reversibility), and group III- chronic airflow obstruction (GAO) (poor 
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reversibility). Table 7-6 shows the population of patients classified 
according to living-unit, clinical picture, and sex. In the course of 
the study daily surveillance was carried out for each patient. Special 
attention was given to the occurrence of symptomatic respiratory in-
fection (SRI), according to criteria described in chapter 7-3-1. Scores 
for dyspnoea/wheezing and cough/sputum production, as well as measure-
ments of FEV
1 
were noted daily for each patient. Criteria for exacerba-
tion of CNSLD are given in chapter 7-3-2. In case of SRI, serological 
investigations of paired blood samples were done using the following 
antigens: influenza A, influenza B, parainfluenza 1, 2, and 3 viruses, 
adenovirus, RSV, Mycoplasma pneumoniae and Chlamydia psittaci. Further-
more, sera were tested routinely at 4-week intervals in order to check 
whether any subclinical infections had occurred. 
If yellow or green coloured sputum was expectorated in the course of 
SRI, a gram stain of a carefully washed flake was made. Additional labo-
ratory investigations that were carried out are described in chapter 
7-3-3. 
In chapter 8 the results of the survey are presented for living-groups 
A, B, and C. Group A patients experienced 127 episodes of SRI with a 
rate of 0.18 SRI per patient month. Exacerbation was noted in 38 out of 
44 SRis with positive serology (Table 8-5) and in 53 out of 81 SRis 
without positive serology (Table 8-7). Green or yellow coloured sputum 
was expectorated in 25 and 41 of these SRis, respectively. Seroconver-
sion without SRI could be related to exacerbation in 6 out of 15 episodes 
with mild symptoms (MRI = mild respiratory infection) and in none of the 
6 subclinical infections (Table 8-8). 
In group B, 98 SRis were found with a rate of 0.16 SRI per patient 
month. Twenty-seven SRis were related to seroconversion, 20 of these 
with exacerbation (Table 8-13). Coloured sputum was reported in 13 in-
stances. Fifty out of 71 remaining SRis were associated with exacerba-
tion (Table 8-15). Yellow/green sputum was noted in 46 subjects. Exa-
cerbation was observed in 5 out of 12 MRis with seroconversion and in 
2 out of 7 subclinical infections (Table 8-16). 
Group C patients reported 59 SRis in 465 patient months, equal to a 
rate of 0.13 • Rxacerbation was observed in 16 out of 18 SRis with 
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positive serology (Table 8-21) and coloured sputum was expectorated 13 
times. In SRI without positive serology streptococcal pharyngitis was 
diagnosed in 5 subjects, none of them with any sign of exacerbation. 
A flare-up of CNSLD was noticed in 23 out of the remaining 35 SRis 
(Table 8-23). Sixteen patients coughed up coloured sputum. MRI could 
be related to exacerbation in 4 out of 12 and subclinical infection in 
2 out of 9 subjects (Table 8-24). In chapter 8-5 these results are com-
bined. 
Chapter 9 summarizes the results for patients of different clinical 
groups I, II, and III. Although infection rates and incidence of exa-
cerbation do not differ significantly, it is shown that SRI gives rise 
to different patterns of exacerbation in these subgroups of CNSLD pa-
tients. Subjects categorized in group I (asthma) react with marked 
bronchial obstruction, whereas group III patients (CAO) tend to react 
with increasing cough and sputum production. Patients of group II 
(asthma + CAO) have features of both phenomena. These data are shown 
in Tables9-15 to 9-19. 
The effects brought about by the various microorganisms tested for in 
the study, are summarized in chapter 10. For each agent epidemiology 
and clinical picture as well as effects on CNSLD parameters in SRI and 
seroconversion without SRI are described. Infections by all agents 
except influenza B virus could be related to exacerbation in a majority 
of instances. The results are shown in Table 10-10. 
In chapter 11 the results of the present study are compared to lite-
rature data. SRI rates in asthma are difficult to compare because of 
differences in age of various populations studied, whereas frequency of 
SRI in CAO is similar to that reported for chronic bronchitis by others. 
Figures of viral identification in SRI are similar to those found in 
other studies. The exacerbation rate of viral infection in asthma in 
the present study is the highest reported hitherto, while the frequency 
of exacerbation in CAO does not differ from other reports. This is 
probably due to the attention given to more than one parameter in 
rating exacerbations. Especially in groups I and II, daily FEV1 measure-
ment turned out to be a valuable parameter. The frequenCy of bacterial 
sputum infection in SRI as judged by gram stain preparations, is in 
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agreement with previous reports. 
In chapter 12 some theoretical contemplations on the background of 
CNSLD exacerbation in respiratory viral infection are presented. A 
hypothesis is put forward emphasizing the importance of beta-adrenergic 
blockade being one of the central mechanisms in virus-induced exacer-
bations in asthma. The phenomena observed in patients with chronic air-
flow obstruction do not seem to depend on beta-adrenergic blockade, but 
rather on impaired local defense mechanisms and chronic mucous hyper-
secretion. Fig. 12-1 is a schematic representation of these hypothetical 
considerations. 
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SAME NV ATTING 
In dit proefschrift worden de resultaten beschreven van een onderzoek 
naar de gevolgen van luchtweginfecties veroorzaakt door een aantal 
virussen, Mycoplasma pneumoniae en Chlamydia psittaei bij een groep 
patienten met chronische aspecifieke respiratoire aandoeningen (CARA) 
tijdens hun verblijf in het Nederlands Astmacentrum Daves, gelegen op 
1560 m hoogte. Na een korte inleiding, waarin het doel van het onder-
zoek door het formuleren van een zestal vragen wordt uiteengezet,worden 
in deel I algemene informatie en literatuurgegevens betreffende CARA, 
respiratoire virologie, de betekenis van luchtweginfecties bij CARA, 
alsmede de invloed van de klimatologische omstandigheden in Daves 
samengevat. 
In hoofdstuk 1 wordt ingegaan op de terminologie van de aandoeningen waar-
bij kortademigheid en piepen op de borst, hoesten en opgeven van sputum 
de symptomen vormen. In Nederland is de algemene opvatting dat deze aan 
doeningen onder een noemer gebracht dienen te worden en de term CARA is 
in dit verband een algemeen aanvaarde benaming geworden. De argumenten 
hiervoor, zoals die met name door de Groningse groep van Orie en mede-
werkers naar voren zijn gebracht, worden besproken en de noodzaakiedere 
patient individueel aan de hand van een aantal parameters te karakteri-
seren wordt vermeld. Vervolgens krijgen de veelal in de Engelstalige 
literatuur gebruikte diagnoses asthma bronchiale, chronische bronchitis 
en longemfyseem enige aandacht. Deze klinische beelden, alsmede het 
begrip bronchiectasie, worden kort besproken. 
Hoofdstuk 2 is gewijd aan de in het onderzoek bestudeerde verwekkers 
van luchtweginfecties. Na een korte inleiding worden enige eigenschappen 
en laboratoriumtechnieken besproken van achtereenvolgens adenovirussen, 
influenza virussen en parainfluenza virussen, RSV en de niet-virale 
verwekkers MYeop~ma pneumoniae en Ch~dia psittaci. De relatie 
tussen infectie met deze agentia en de kliniek wordt beknoptbecommenta-
rieerd. 
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Hoofdstuk 3 vat de belangrijkste literatuurgegevens samen betreffende 
de rol van luchtweginfecties in de pathogenese van de CARA. Het belang 
van luchtwegaandoeningen in de vroege jeugd in dit opzicht wordt bena-
drukt in gedeelten over laryngotracheobronchitis (croup) en bronchioli-
tis. Er is aangetoond dat deze syndromen veelal in verband kunnenworden 
gebracht met het optreden van de voor CARA kenmerkende hyperreactiviteit 
van de luchtwegen op latere leeftijd. Diverse onderzoekingen geven aan 
dat luchtweginfectie als triggermechanisme kan optreden voor het ver-
schijnen van symptomen bij daarvoor genetisch gepredisponeerdepersonen. 
In hoofdstuk 4 wordt een literatuuroverzicht gegeven van de gevolgen 
van respiratoire infecties voor het verloop van de ~~-symptomen. Pa-
tienten met CARA reageren in een merendeel der gevallen op een virale 
infectie met een exacerbatie van hun aandoening. De literatuurgegevens 
zijn echter niet eensluidend, hoofdzakelijk omdat geen uniforme defini-
ties bestaan voor begrippen als symptomatische respiratoire infectie 
(SRI) en exacerbatie. Aangezien de meeste publicaties betrekking hebben 
op patienten met asthma bronchiale of chronische bronchitis, wordt de 
literatuur voor deze groepen afzonderlijk samengevat. 
Vervolgens worden de klimatologische omstandigheden van het hoogge-
bergte en de situatie in het Nederlands Astmacentrum beschreven. In 
hoofdstuk 5 worden drie theorieen besproken die omtrent de voor CARA 
gunstige werking van het hooggebergte zijn opgesteld, t.w. de lage 
dichtheid van de inademingslucht, de biometereologische omstandigheden 
en het in geringe mate voorkomen van bepaalde allergenen, vooral die 
geproduceerd door de huisstofmijt, Dermatophagoides pteronyssinus. 
Het behandelingsmodel van het Nederlands Astmacentrum, sterk gericht 
op fysieke en mentale revalidatie, wordt in hoofdstuk 6 aan de hand van 
3 verschillende groepen patienten naar voren gebracht. 
In deel II van dit proefschrift worden de opzet en de verkregen resul-
taten van het eigen onderzoek behandeld. In hoofdstuk 7 wordt een onder-
verdeling van de patienten gemaakt aan de hand van de verschillendewoon-
afdeliugen waarbinnen de diverse leeftijdsgroepen zijn ondergebracht. 
Aldus worden de groepen A - Senioren, B - Junioren en C - Vossen onder-
scheiden. Bovendien worden de deelnemers geclassificeerd in verschillen-
de.klinische categorieen op grand van anamnestische gegevens en de bij 
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longfunctieonderzoek gemeten reversibiliteit van luchtwegobstructie. 
Op deze wijze worden 3 groepen gevormd: groep I - astma (grote rever-
sibiliteit), groep II- astma en chronische obstructieve luchtweg-
aandoening (matige reversibiliteit) en groep III - chronische obstruc-
tieve luchtwegaandoening (geringe reversibiliteit). Tabel 7-6 toont de 
patientenpopulatie, verdeeld volgens woonafdeling, klinisch beeld en 
geslacht. Tijdens de studieperiode werd een aantal parameters voor 
iedere patient dagelijks vastgelegd. Op het v66rkomen van verschijnse-
len van een luchtweginfectie ("symptomatic respiratory infection" = 
SRI) werd bijzonder gelet, overeenkomstig de in hoofdstuk 7-3-I be-
schreven criteria. Scores voor kortademigheid/piepen en hoesten/sputum 
opgeven en meting van het expiratoire I-seconde volumen werden dagelijks 
geregistreerd. De criteria, volgens welke het begrip exacerbatie werd 
omschreven, worden weergegeven in hoofdstuk 7-3-2. Indien een SRI op-
trad werd serologisch onderzoek van gepaarde bloedmonsters verrichtmet 
de volgende antigenen: influenza A en B virussen, parainfluenza I, 2 
en 3'virussen, adenovirus, respiratoir syncytieel virus, MYcoplasma 
pneumoniae en Chlamydia psittaei. Voorts werd routinematig serologisch 
onderzoek verricht van iedere 4 weken verkregen sera om na te gaan of 
subklinische infecties waren voorgekomen. Bij expectoratie van geel of 
green gekleurd sputum tijdens een SRI, werd een grampreparaat van een 
zorgvuldig gewassen sputumvlok gemaakt. Aanvullend laboratoriumonder-
zoek, zeals dat werd verricht, wordt beschreven in hoofdstuk 7-3-3. 
In hoofdstuk 8 worden de resultaten van het onderzoek gegeven voor 
de leefgroepen A, B en C. De patienten in groep A rapporteerden 127 
SRI's, hetgeen overeenkomt met 0,18 SRI per patientmaand. Een exacer-
batie werd gezien tijdens 38 van de 44 SRI's met positieve serologie 
(tabel 8-5) en tijdens 53 van de 81 SRI's zonder positieve serologie 
(tabel 8-7). Expectoratie van green of geel gekleurd sputum kwam voor 
bij respectievelijk 25 en 41 van deze SRI's. Titerstijgingen zonder 
SRI vielen samen met een CARA-exacerbatie bij 6 van de 15 period~n 
waarin op grond van zeer geringe luchtwegverschijnselen het tijdstip 
van infectie kon worden achterhaald ("mild respiratory infection"= MRI) 
en bij geen der 6 geheel symptoomloze infecties (tabel 8-8). In groep 
B werden 98 SRI's gevonden met een frequentie van 0,16 SRI per patient-
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maand. Zevenentwintig SRI's gingen gepaard met een titerstijging; in 20 
van deze perioden trad .een exacerbatie op (tabel 8-13). In 13 gevallen 
werd gekleurd sputum opgehoest. Van de overige 71 SRI's trad bij 50 
een exacerbatie van de CARA op (tabel 8-15). Geel/groen sputum werd 
geexpectoreerd door 46 patienten. Een exacerbatie werd geregistreerd 
in 5 van de 12 MRI's met titerstijging en in 2 van de 7 subklinische 
infecties (tabel 8-16). De patienten in groep C gaven in 465 patient-
maanden 59 maal het voorko:men van een SRI aan-, hetgeen gelijk is aan 
0,13 SRI per patientmaand. Bij 16 van de 18 SRI's met positieve serolo-
gie werd een exacerbatie gevonden (tabel 8-21) terwijl 13 maal gekleurd 
sputum werd opgegeven. Bij 5 kinderen met een SRI zonder titerstijging 
werd een streptococcen-faryngitis vastgesteld; in geen van dezeepisoden 
werd enig teken van exacerbatie gevonden. Een verergering van de CARA 
werd gezien tijdens 23 van de 35 resterende SRI's (tabel 8-23). Zestien 
patienten hoestten tijdens een dergelijke periode gekleurd sputum op. 
Een exacerbatie werd geregistreerd tijdens 4 van de 12 MRI's en 2 van 
de 9 subklinische infecties (tabel 8-24). In hoofdstuk 8-5 worden de 
bovenstaande resultaten gecombineerd weergegeven. 
Hoofdstuk 9 behandelt de resultaten voor de patienten van de groepen 
I, II en III met verschillende klinische verschijningsvormen. Hoewel 
het v66rkomen van infecties en exacerbaties per groep niet significant 
verschillend is, is te zien dat symptomatische luchtweginfecties aan-
leiding geven tot verschillende uitingsvormen van exacerbatie bij deze 
subgroeperingen van CARA-patienten. Patienten, geclassificeerd in groep 
I (astma) reageren met uitgesproken luchtwegobstructie, terwijl de pa-
tienten van groep III (chronische obstructieve luchtwegaandoening) meer 
geneigd zijn tot vermeerderd hoesten en expectoreren van sputum. Pa-
tienten van de overgangsgroep II hebben een combinatie van bronchus-
obstructie en productief hoesten. Deze gegevens worden weergegeven in 
de tabellen 9-15 tot en met 9-19. 
De gevolgen van infectie met de verschillende in het onderzoek bestu-
deerde microOrganismen worden samengevat in hoofdstuk 10. De epidemio-
logische en klinische bevindingen van infectie met de diverse agentia, 
alsmede de gevolgen op de CARA-parameters in het geval van SRI en titer-
stijging zonder SRI, worden beschreven. Voor alle agentia, behalve 
164 
influenza B, werd gevonden dat infectie in het merendeel der gevallen 
gepaard ging met een exacerbatie van de CARA. De rPsultaten worden ver-
meld in tabel 10-10. 
In hoofdstuk 11 worden de resultaten van het onderhavige onderzoek 
vergeleken met uit de literatuur bekende gegevens. De SRI-frequentie 
bij asthmatici is moeilijk met die van andere studies te vergelijken 
vanwege verschillen in de leeftijdsopbouw van de diverse bestudeerde 
patientenpopulaties, terwijl de frequentie van SRI in het geval van 
chronische obstructieve luchtwegaandoeningen overeenkomt met gegevens van 
andere onderzoekers voor chronische bronchitis. Het percentage SRI's 
met een geidentificeerde verwekker is overeenkomstig de getallen van 
andere publicaties. Voor de astma-groep is het aantal virusinfecties 
dat tot exacerbatie aanleiding geeft het hoogst in de literatuur ver-
meldetot nu toe, terwijl voor de obstructieve luchtwegaandoeningen met 
irreversibele afwijkingen geen duidelijke verschillen met andere stu-
dies gevonden worden. Dit is waarschijnlijk het gevolg van het feit dat 
bij het beoordelen van het begrip exacerbatie rekening werd gehouden 
met meer dan een parameter. Vooral voor de groepen I en II bleek het 
dagelijks registreren van het expiratoire 1-seconde volumen een waarde-
vol meetinstrument. De frequentie van het optreden van bacteriele spu-
tuminfecties bij SRI's is in overeenstemming met de literatuurgegevens. 
Hoofdstuk 12 is gewijd aan enige theoretische overwegingen betreffen-
de de achtergronden van het optreden van door virusinfecties geindu-
ceerde exacerbaties bij CARA-patienten. Het belang van beta-adrenerge 
receptor blokkering als een van de centrale mechanismen bij exacerbaties 
van astma tijdens virale infecties wordt als een hypothese naar voren 
gebracht. De verschijnselen zoals die gezien worden bij patienten met 
chronische obstructieve luchtwegaandoeningen lijken niet gebaseerd te 
zijn op beta-adrenerge blokkade, maar eerder op beschadiging van locale 
afweermechanismen en chronische hypersecretie. Fig. 12-1 is een schema-
tische afbeelding van deze hypothetische overwegingen. 
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LIST OF ABBREVIATIONS 
CA Croup-associated 
CARA "Chronische aspecifieke respiratoire aandoeningen" 
CAO Chronic airflow obstruction 
CF Complement fixation 
CNSLD Chronic non-specific lung disease 
GOAD Chronic obstructive airway disease 
COLD Chronic obstructive lung disease 
COPD Chronic obstructive pulmonary disease 
C/S Cough/sputum 
D/W Dyspnoea/wheezing 
ECF-A Eosinophil chemotactic factor of anaphylaxis 
FEV1 Forced expiratory volume in 1 second 
H Haemagglutinin 
HA Haemadsorption 
HI Haemagglutination inhibition 
MRI Mild respiratory infection 
N Neuraminidase 
PAF Platelet activating factor 
PPLO Pleuro-pneumonia like organism 
RSV Respiratory syncytial virus 
SRI Symptomatic respiratory infection 
SRS-A Slow reacting substance of anaphylaxis 
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LEGEND TO CASE REPORTS: 
FEV1 = forced expiratory volume in I sec. 
SRI symptomatic respiratory infection 
D/W scores for dyspnoea/wheezing 
C/S scores for cough/sputum 
ESR erythrocyte sedimentation rate 
MRI mild respiratory infection 
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81 
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9 
Case report 1 
A48 Male 54 yrs Group A-II 
SRI symptoms: Malaise, dry coughing, hoarseness, headache, myalgia, 
chest pain. Malaise and fatigueness lasting for about 
4 weeks. Mamixum rectal body temperature: 39.7° Con 2nd 
day of SRL 
Serology: Rise in CF titre to adenovirus from <7 to 32. 
Asthma relatively well controlled before SRI. Less good control in the 
course of SRI and during the next 3 weeks, in spite of raising oral 
prednisolon from 15 mg to 40 mg daily. First discolouration of sputum 
on 2nd day of SRI. Sputum gram stain positive. Antibiotic treatment 
during 10 days of SRI and from 13th day onward. X-thorax: see page 196. 
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X-thorax patient A48 (case report I). Triangular infiltrate in 
left lower part. Small spotty infiltrate in right middle 
section. Obliteration of left coste-diaphragmatic angle. 
t 2600 
FEVt 2400 
{ml) 
2200 
2000 
1800 
1600 
1400 
1200 
1000 
8 
SRI 
~ 
I 
I 
197 
--+days t 6 
0/W • 
1--------___/1 '--------
2 
t B CIS 
' ' 
I 
I 
·~· .-:=::---:-: Last control I Next control 
" 
Case report 2 
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78 
A25 Male 47 yrs Group A-I 
SRI-symptoms: Malaise, sore throat, headache, myalgia, vomiting. 
Serology: 
Maximum rectal body temperature: 39.90 C on 1st day of 
SRI. 
Rise in HI titre to influenza A/Texas/1/77 (H3N2) virus 
from 50 to 1950. 
Asthma stable before SRI. Long-term corticosteroid therapv necessary: 
dosage before SRI 1.5 mg dexamethasone daily. Distinct bronchial 
obstructive reaction in the course of influenza A infection. No raise 
in steroid dosage. Return to pre-infection FEV 1 within I week. Prophy-lactic treatment with antibiotics. No discolouration of sputum. 
X-thorax unchanged. 
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SRI symptoms: Malaise, running and stuffed nose, sore throat, dry 
coughing, hoarseness, headache, myalgia, chest pain. 
Maximum rectal body temperature: 39.60 C on 2nd day of 
SRI. 
Serology: Rise in CF titre to influenza A from <7 to 160. 
Severe bronchial obstructive reaction following influenza A infection. 
Admission to intensive care unit, FEV being 560 at noon on 1st day of 
SRI. Infusion treatment with corticos!eroids and aminophylline. Rernrn 
to pre-infection condition within I week. Slight discolouration of 
sputum during first 3 days of SRI. No gram stain made. No antibiotics. 
X-thorax unchanged. 
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Case report 4 
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SRI-symptoms: Malaise, running and stuffed nose, sore throat, hoarse-
ness, headache, chest pain. Maximum rectal body tempera-
ture: 37.80 C during several days. 
Serology: Negative 
Asthmatic exacerbation in patient with fluctuating degrees of bronchial 
obstruction before SRI. Poor control of obstructive symptoms in spite 
of high dosages of predisolon -75 mg daily- and aminophylline. A second 
exacerbation occurred when prednisolon was gradually diminished to 
20 mg daily after 3 weeks. Sputum colour changed from white to yellow-
green on 1st day of SRI. Sputum gram stain positive. Antibiotic treat-
ment was given. X-thorax unchanged. 
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Case report 5 
A67 Female 61 yrs Group A-I 
SRI symptoms: Malaise, stuffed nose, hoarseness, headache, chest pain. 
Maximum rectal body temperature: 38.8° C o~ 2nd day of 
SRI. 
Serology: Negative. 
Asthma relatively well controlled. Increased bronchial obstruction 
starting 1 day before SRI. Poor control of asthma with large variations 
in FEV
1 
in the course of SRI and several months afterwards. Only slight 
improvement after therapy with higher dosage of corticosteroids. No 
sputum expectoration. X-thorax unchanged. 
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Case report 6 
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SRI symptoms: Malaise, chest pain. }UL~imum rectal body temperature 
<37.8° c. 
Serology: Negative. 
SRI with expectoration of green, purulent sputum after some days of 
increased bronchial obstruction probably due to subcutaneous admini-
stration of influenza vaccine. Sputum gram stain was positive and cul-
tures yielded growth of Streptococcus pneumoniae and Eaemophilus 
infZuenzae. Good control of obstruction before vaccination. Return to 
pre-infection stable condition within 10 days. Corticosteroids were 
raised temporarily and antibiotics were administered. 
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SRI symptoms: Malaise, sore throat, running nose, sneezing, chest pain. 
Maximum body temperature: 37.20 C. 
Serology: Negative. 
Bronchial obstructive exacerbation for unknown reasons, followed by SRI 
associated wi'th bacterial sputum infection: gram stain positive, Strep-
tococcus pneumoniae in culture. Severe asthmatic reaction in the course 
of SRI, necessitating admission to intensive care unit and treatment 
with intravenous corticosteroids and aminophylline as well as admini-
stration of antibiotics. Recovery within a period of 10 days. X-thorax: 
see page 203. 
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X-thorax patient A3 (case report 7). Diffuse cloudy oblitera-
tion of right coste-diaphragmatic angle. 
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Case report 8 
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SRI symptoms: Malaise, stuffed nose, dry coughing, hoarseness, head-
ache, myalgia, chest pain, vomiting, diarrhoea. Maximum 
rectal body temperature: 39.5° C on lst day of SRI. 
Serology: Negative. 
Symptoms of SRI associated with fever and increase in total eosino-
philic leucocyte counts. Expectoration of white-greyish sputum with 
abundant amounts of eosinophils. Institution of corticosteroids from 
4th day of SRI onward gave gradual relief of signs and symptoms. These 
findings together with rOntgenologic changes (X-thorax: see page 205) 
made the diagnosis "eosinophilic pneumonia" plausible. 
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X-thorax patient A57 (case report 8). Parahilar infiltrate in 
left midfield. Diffuse cloudy obliteration of right costa-
diaphragmatic angle. 
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SRI symptoms: Malaise, running nose, dry coughing, headache, sore 
throat, sore ears. Maximum rectal body temperature: 390 C 
on 3rd day of SRI. 
Serology: Rise in CF titre to parainfluenza 3 from <7 to 770. 
Distinct asthmatic reaction related to parainfluenza 3 infection with 
upper respiratory symptoms. Relatively prolonged exacerbation with 
spontaneous return to pre-infection condition within 2 weeks. No sputum 
expectorated. 
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SRI symptoms: Malaise, dry coughing, headache, vomltlng. Maximum rectal 
body temperature: 39° C on 3rd day of SRI. 
Serology: Rise in CF titre to parainfluenza from 7 to 160. 
Marked increase ofbronchialobstruction associated with SRI by para-
influenza 3. Signs of exacerbation preceeding symptoms of respiratory 
infection. Yellow-green coloured sputum from day preceeding SRI onward, 
lasting for about 1 week. Sputum gram stain positive. Spontaneous 
return to condition comparable to pre-infection state within I week. 
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SRI symptoms: Malaise, running nose, sneezing, sore throat, dry 
coughing, headache, myalgia, chest pain, itchy eyes. 
Maximum rectal body temperature: 38.1° Con 1st day of 
SRL 
Serology: Rise in CF titre to parainfluenza 3 from <7 to 20. 
Prolonged bronchial obstructive exacerbation in the course of SRI by 
parainfluenza 3. No spontaneous improvement. Return to pre-infection 
level after administration of high dosages of corticosteroids, on 12th 
day following begin of SRI (·>f-). Change in sputum colour into yellow-
greenish from 2nd day of SRI onward. Sputum gram stain positive. Anti-
biotics administered for period of 10 days. 
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Case report 12 
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SRI-symptoms: Malaise, stuffed nose, sneezing, headache, myalgia, itchy 
eyes, vomiting. Maximum rectal body temperature: 39.20 C 
on 1st day of SRI. 
Serology: Rise in CF titre to influenza A from <7 to 80. 
Short-lasting, but marked increase in bronchial obstruction, related to 
influenza A infection. Discolouration of sputum from 5th day of SRI 
onward, lasting 4 days. Sputum gram stain positive. Spontaneous dis-
appearance of productive coughing associated with spontaneous improve-
ment of FEV1 to levels higher than those before SRI~. 
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SRI symptoms: Malaise, sore throat, running nose, dry coughing, snee-
zing, hoarseness, chest pain. Hamixum rectal body tempe-
rature: 38.5° C on 1st day of SRI. 
Serology: Negative. 
Marked asthmatic reaction with FEV decreasing by more than 50% of 
baseline value in the course of SR± without positive serology. Sponta-
neous return to pre-infection FEV1 within 2 weeks. No sputum expectorated during SRI in patient normally coughing up moderate amounts of sputum. 
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SRI symptoms: Malaise, sore throat, running nose, sneezing, headache, 
chest pain. Maximum rectal body temperature: 39.1° Con 
2nd day of SRI. 
Serology: Negative. 
Short-lasting, but distinct increase of bronchial obstruction in SRI of 
unknown origin. Expectoration of white coloured sputum starting on 1st 
day of SRI, lasting for 1 week. No additional medication administered. 
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Case report 15 
B36 Female 19 yrs Group B-I 
SRI symptoms: Malaise, running and stuffed nose, sneezing, sore throat, 
sore ears, dry coughing. Maximum rectal body temperature: 
38.1° Con lst-3rd day of SRI. 
Serology: Negative. 
Severe prolonged asthmatic exacerbation during SRI of unknown, possibly 
common cold-viral origin. Bad control of bronchial obstruction for a 
period of several weeks with large fluctuations of FEV1• After 4 weeks 
occurrence of bacterial sputum infection, after which good management 
of asthma was re-established without problems. Corticosteroid treatment 
was refused by patient. Additional bronchodilating agents administered 
on first 2 days of SRI only. 
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SRI symptoms: Malaise, sore throat, running nose, sneezing, dry 
coughing. Maximum rectal body temperature: 38.50 on 3rd-
4 th day of SRI. 
Serology: Negative. 
Period of increased bronchial obstruction in SRI of unknown or~g~n, 
followed by bacterial sputum infection on 7th day of SRI ( * ) , asso-
ciated with spontaneous return of FEV1 to pre-infection levels. Bacterial infection, indicated by posLtive gram stain, was confirmed 
by culture methods, yielding growth of Streptococcus pneumoniae. Anti-
biotics administered. X-thorax unchanged. 
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BIS Male IS yrs Group B-I 
MRI symptoms: Sore throat, running nose, both of mild character. 
Running nose for <36 hrs. 
Serology: Rise in CF titre to influenza A from 12 to 80. 
Distinct fall in FEV1 in the course of influenza A infection with mild 
upper respiratory symptoms (MRI). No significant changes in scores for 
dyspnoea/wheezing and cough/sputum. Spontaneous return to pre-infection 
level of FEV 1 within 1 week. 
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Case report 18 
B72 Female 18 yrs Group B-1 
MRI symptoms: Malaise 
215 
-+days 
. . 
' 
:::::;:,. 
Serology: Rise in CF titre to parainfluenza from <7 to 96. 
Fall in FEV1 associated with parainfluenza 3 infection without upper 
respiratory symptoms. Short-lasting increase in dyspnoea/wheezing, no 
change in cough/sputum. FEV1 returned to pre-infection levels within 10 days, but large variations in FEV1 were present for a period of 
about 4 weeks. 
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Case report I 9 
C8 Male 9 yrs Group C-I 
SRI symptoms: Malaise, running nose, sneezing, headache, itchy eyes. 
Maximum rectal body temperature 38.20 C on lst day of 
SRI. 
Serology: Rise in HI titre to influenza B/Hong Kong/8/72 from 60 to 
480. 
Short-lasting but serious fall in FEV 1 in SRI by influenza B. Despite decrease of FEV1 of over 50% of basel1ne value, increase in dyspnoea/ 
wheezing was denied. Spontaneous return to baseline FEV 1 values. No 
expectoration of sputum. 
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Case report 20 
C14 Male 13 yrs Group C-I 
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SRI symptoms: Malaise, running and stuffed nose, sore throat, dry 
coughing, headache, myalgia. Maximum rectal body tempe-
rature: 400 C on 2nd day of SRI. 
Serology: Rise in HI titre to influenza A/Texas/I/77(H3N2) from 
30 to 1100. 
Serious asthmatic exacerbation with FEV 1 decreasing to 520 ml in SRI by influenza A. Spontaneous return to baseline value within I week. 
Yellow-green coloured sputum expectorated from 3rd to 6th day of SRI. 
Sputum gram stain positive. No additional medication. X-thorax un-
changed. 
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....:ase report 21 
Cl4 Male 13 yrs Group C-I 
SRI symptoms: Running nose, sore throat. Maximum rectal body tempera-
ture 38.70 Con 2nd day of SRI. 
Serology: Rise in CF titre to Mycoplasma pneumoniae from <7 to 56. 
Relatively prolonged, severe asthmatic reaction to MYcoplasma pneumoniae 
infection with few upper respiratory symptoms. SRI was preceeded by 
drop in FEV1• White sputum expectorated for first 6 days of SRI. Nevertheless, antibiotics were administered. Unfortunately, laboratory 
data were not collected according to programme and chest rOntgenograms 
were not made. 
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Case report 22 
Cl7 Male 9 yrs Group C-I 
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MRI symptoms: Chest pain. }mximum rectal body temperature: 40° C on 3rd 
day of MRI. 
Serology: Rise in CF titre to influenza A from 8 to 32. 
Severe bronchopneumonia in the course of influenza A infection without 
upper respiratory symptoms in boy with extramely difficultly managable 
bronchial asthma and severe anatomic deformations in right middle and 
upper lobe. Increased bronchial obstruction associated with expectora-
tion of purulent sputum -gram stain positive, Streptococcus pneumoniae 
in culture- on 3rd and 4th day of MRI. Admission to intensive care uni~ 
where treatment with corticosteroids and antibiotics was begun. X-thorax 
see page 220. 
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X-thorax patient CI7 (case report 22). Diffuse, dense infil-
trate in right middle and lower lung fields. Patchy infiltrate 
in left coste-diaphragmatic angle. 
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Case report 23 
C4 Male 10 yrs Group C-I 
SRI symptoms: Malaise, sore throat, sore ears, dry coughing, headache. 
Maximum rectal body temperature: 37.9° Con Jst day of 
SRI. 
Serology~ Negative. 
Good control of bronchial obstruction in SRI, caused by B-haemolytic 
group A streptococci. No changes in scores for dyspnoea/wheezing and 
cough/sputum and very consistent values of FEV1. 
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Cll Male 12 yrs Group C-II 
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SRI symptoms: Running and stuffed nose, dry coughing, malaise. Maximum 
rectal body temperature: 37.7° Con 2nd day of SRI. 
Serology: Negative. 
Serious bronchial obstructive reaction associated with SRI of unknown, 
possibly coffimon cold-viral origin. Spontaneous return to pre-infection 
FEV1 values within 1 week. Purulent sputum from 2nd day of SRI onward, lasting for 6 days. Sputum gram stain positive. Antibiotics were 
administered. X-thorax unchanged. 
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SRI symptoms: Malaise, stuffed nose, sore throat, hoarseness, headache, 
myalgia, chest pain, itchy eyes. Maximum rectal body 
temperature: 39.3° C on 1st day of SRI. 
Serology: Negative. 
Poor control of asthma with exacerbation induced by dog allergen 
provocation (* ), followed be bacterial sputum infection -gram stain 
positive, Streptococc~s pneumoniae and Haemophilus inj1uenza in 
culture- associated with SRI. Spontaneous improvement of FEV1, however, 
with large variations. Antibiotics installed. X-thorax unchanged. 
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Case report 26 
C21 Male 14 yrs Group C-I 
MRI symptoms: Slight malaise 
Serology: Rise in CF titre to influenza A from <7 to 48. 
--+days 
Serious bronchial obstructiVe reaction with prolonged duration in 
influenza A infection without any other respiratory symptoms. Sponta-
neous recovery within 2 weeks. No expectoration of sputum. 
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Case report 27 
C14 Male 13 yrs Group C-I 
MRI symptoms: Malaise 
225 
---to-days 
Serology: Rise in CF titre to adenovirus from 7 to 40. 
Short-lasting, but distinct bronchial obstructive reaction in patient 
with MRI by adenovirus. No other respiratory symptoms. Spontaneous 
return to pre-infection FEV 1 values. 
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Case report 28 
CI4 Male 13 yrs Group C-I 
Symptoms of respiratory infection : None 
Serology : Rise in HI titre to influenza A/Victoria/3/75 (H3N2) virus 
from 135 to 1100. 
Short-lasting severe bronchial obstructive exacerbation in a boy whose 
asthma had been well-controlled before. Significant rise in titre to 
influenza A at the same time, possibly related to increase of asthmatic 
signs and symptoms. 
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Next control 
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SRI symptoms: Malaise, dry coughing, running nose, headache, myalgia, 
chest pain, vomiting. Maximum rectal body temperature: 
39.2° C on 2nd day of SRI. 
Serology: Rise in CF titre to parainfluenza 3 from <7 to SO. 
SRI by parainfluenza 3 in patient with severe chronic airflow obstruc-
tion. No significant changes in FEV1. Increased dyspnoea/wheezing and 
cough/sputum after 1 week with discolouration of sputum on day 7 
(* ). Sputum gram stain positive with Streptococcus pneumoniae and 
HaemophiZus infZuenzae in culture. Antibiotic treatment was given. 
X-thorax unchanged. 

APPENDIX II 




Dag~ het is leuk geweest. 
Fijn voor een moment in mijn leven 
dat reeds achter de rug is. 
Halla en tot ziens. 
Beda:nkt. 
Fred van Eseh 

